



## (51) International Patent Classification:

A61K 48/00 (2006.01) C12N 15/85 (2006.01)  
C12N 15/64 (2006.01)

## (21) International Application Number:

PCT/US2016/032153

## (22) International Filing Date:

12 May 2016 (12.05.2016)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/161,104 13 May 2015 (13.05.2015) US

(71) Applicant: SEATTLE CHILDREN' S HOSPITAL  
(DBA SEATTLE CHILDREN 'S RESEARCH INSTI-  
TUTE) [US/US]; 1900 Ninth Avenue, Seattle, WA 98101  
(US).(72) Inventors: SCHARENBERG, Andrew; 1222 NW Nor-  
cross Way, Seattle, WA 98177 (US). RAWLINGS, David;



1429 E Valley Street, Seattle, WA 98112 (US). JENSEN,  
Michael, C.; 4187 Pleasant Beach Drive NE, Bainbridge  
Island, WA 98110 (US). GWIAZDA, Kamila; 8827  
Ravenna Ave NE, Seattle, WA 98115 (US). GRIER, Alex-  
andra; 8827 Ravenna Ave NE, Seattle, WA 98115 (US).

(74) Agent: FURMAN, Eric, S.; Knobbe Martens Olson &  
Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, CA  
92614 (US).(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,  
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,  
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,  
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,  
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

## (54) Title: ENHANCING ENDONUCLEASE BASED GENE EDITING IN PRIMARY CELLS

FIG. 4B



(57) Abstract: Disclosed herein are nuclease-based systems for genome editing and methods of using the system for genome editing. Also, disclosed are approaches to enhance Cas9- mediated gene editing efficiency in primary human cells with minimal toxicity when using adeno-associated virus vectors (AAV) to express the guide RNAs necessary for CRISPR/Cas9-based genome editing in the presence of helper proteins.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (*Art. 21(3)*)
- with sequence listing part of description (*Rule 5.2(a)*)

## **ENHANCING ENDONUCLEASE BASED GENE EDITING IN PRIMARY CELLS**

### **PRIORITY AND CROSS-REFERENCE TO RELATED APPLICATIONS**

**[0001]** This application claims the benefit of priority to U.S. Provisional Application 62/161,104, filed on May 13, 2015, which is hereby incorporated by reference in its entirety.

### **REFERENCE TO SEQUENCE LISTING**

**[0002]** The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled SCRI\_094WO\_SEQLIST.txt which is 72,184 bytes in size, created on May 11, 2016 and last modified on May 11, 2016.

### **FIELD**

**[0003]** Aspects of the disclosure provided herein are generally related to endonuclease-based gene editing systems and methods. Some aspects of the disclosure provided herein are related to the CRISPR/Cas9 gene editing system.

### **BACKGROUND**

**[0004]** Endonuclease-based systems have rapidly become significant gene editing tools in biomedical research, with their application for gene disruption and/or gene targeting demonstrated in a variety of cultured cell and model organism systems.

**[0005]** Endonuclease-based systems for gene editing allow scientists to edit genomes with unprecedented precision, efficiency, and flexibility. Examples of endonuclease-based approaches for gene editing include systems comprising, without limitations, zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs), meganucleases (such as MegaTALs), and CRISPR/Cas9.

### **SUMMARY**

[0006] The present disclosure provides several methods for applying CRISPR/Cas9 in primary cells in which an mRNA is used to express Cas9, and simultaneously, mRNA is used to transiently express two adenoviral proteins, E4ORF6 and an H373A or H354 mutant version of E1B55K. The wild type E4ORF6 and E1B55K proteins relieve post-entry defects for expression from AAV vectors; however, if the wild type E1B55K or E4ORF6 proteins are used, they disable an important protein complex involved in DNA repair (known as the MRN complex), which leads to cell cycle arrest and high toxicity due to lack of repair of DNA breaks. Instead of using the wild type proteins mutants of E1B55K, which do not disable the MRN complex are utilized. Co-expression of Cas9 with E4ORF6/E1B55K mutants results in sufficient relief of the post-entry restriction on AAV expression while maintaining intact DNA repair. This allows for a substantial improvement in Cas9-mediated gene editing efficiency with minimal toxicity when an AAV vector is used to express the guide RNA's necessary for Cas9 targeting.

[0007] Some alternatives of the system provided herein, comprise endonucleases so as to provide additional tools useful in gene disruption. Several alternatives, for example, relate to systems utilizing CRISPR/Cas9 systems and methods for enhancing the efficiency of inactivation of a target gene concurrently with endonucleases. More alternatives relate to the inactivation of a target gene for therapeutic, agricultural and/or other commercially useful purposes utilizing one or more of the systems described herein. Still more alternatives relate to the production of autologous and/or non-autologous primary cells having an inactivated target gene and the use of these cells for therapeutic and/or other commercial applications.

[0008] In some alternatives, a system for editing at least one target gene in a cell is provided, the system comprising a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector; a second nucleic acid sequence encoding a Cas9 protein, a derivative or fragment thereof; a third nucleic acid sequence encoding a first adenoviral protein; and a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives of the system, the cell is a eukaryotic cell. In some alternatives of the system, the cell is a mammalian cell. In some alternatives of the system, the cell is a human cell. In some alternatives of the system, the cell is a primary cell. In some alternatives of the system, the cell is not a transformed cell. In some alternatives of



the system, the cell is a primary lymphocyte, a CD34<sup>+</sup> stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

[0009] In some alternatives of the system, the vector is a viral vector. In some alternatives of the system, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the system, the second nucleic acid encoding the Cas9 protein, a derivative or fragment thereof is an mRNA. In some alternatives of the system, the second nucleic acid sequence encoding the Cas9 protein is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the Cas9 protein, a derivative or fragment thereof is from *S. pyogenes*. In some alternatives of the system, the third nucleic acid encoding the first adenoviral protein is an mRNA. In some alternatives of the system, the mRNA is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the first adenoviral protein is E4ORF6. In some alternatives of the system, the fourth nucleic acid encoding the second adenoviral protein is an mRNA. In some alternatives of the system, the fourth nucleic acid encoding the second adenoviral protein is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the second adenoviral protein is an E1B55K mutant. In some alternatives of the system, the first, second, third and fourth nucleic acid sequences are joined to regulatory elements that are operable in a eukaryotic cell, such as a human cell. In some alternatives of the system, the first nucleic acid sequence encoding the CRISPR guide RNA is operably linked to a regulatory element. In some alternatives of the system, the nucleic acid sequence encoding the CRISPR guide RNA is operably linked to a promoter, for example, a U6 promoter. In some alternatives of the system, the first nucleic acid sequence encoding the CRISPR guide RNA is constitutively expressed.

[0010] In some alternatives, a method of editing at least one target gene in a cell is provided, the method comprising introducing into a cell a first vector that comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in said cell; introducing into said cell a second nucleic acid sequence encoding a Cas9 protein, a derivative or fragment thereof; introducing into said cell a third nucleic acid sequence encoding a first adenoviral protein; and introducing into said cell a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives of the method, the cell is a eukaryotic cell. In some alternatives

of the method, the cell is a mammalian cell. In some alternatives of the method, the cell is a human cell. In some alternatives of the method, the cell is a primary cell. In some alternatives of the method, the cell is not a transformed cell. In some alternatives of the method, the cell is a primary lymphocyte, a CD34<sup>+</sup> stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

[0011] In some alternatives of the method, the first vector comprising the first nucleic acid sequence encoding the CRISPR guide RNA is a viral vector. In some alternatives of the method, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the method, the second, third and fourth nucleic acid sequences are mRNA. In some alternatives of the method, the mRNAs are codon optimized for expression in a eukaryotic cell, such as a human. In some alternatives of the method, the Cas9 protein, a derivative or fragment thereof is from *S. pyogenes*. In some alternatives of the method, the first adenoviral protein is E4ORF6. In some alternatives of the method, the second adenoviral protein is a E1B55K mutant. In some alternatives of the method, the CRISPR guide RNA is complimentary to a target gene of interest. In some alternatives of the method, the CRISPR guide RNA is complimentary to a target gene of interest. In some alternatives of the method, the first, second, third and fourth nucleic acid sequences are transiently introduced into the cell. In some alternatives of the method, the first, second, third and fourth nucleic acid sequences are not permanently introduced into the cell. In some alternatives of the method, the introducing of the first, second, third and fourth nucleic acid sequences into the cell does not transform the cell. In some alternatives of the method, the target gene is a selected or identified gene of interest. In some alternatives of the method and/or the system, the second, third, or fourth nucleic acid sequence is provided on a vector. In some alternatives, a method of editing at least one target gene in a cell is practiced by introducing into a cell any of the alternatives of the system described herein.

[0012] In some alternatives, a method of treating, ameliorating, or inhibiting a disease and/or a condition in a subject is practiced by providing to a subject having a disease and/or a condition any of the alternatives of the system described herein.

#### BRIEF DESCRIPTION OF THE DRAWINGS

[0013] FIG. 1A shows a schematic of mRNA and AAV vector constructs used for TCR locus targeting.

[0014] FIG. 1B shows T7 assay of editing-induced insertions-deletions (indels) at TCR $\alpha$  locus.

[0015] FIG. 1C shows the effect of Cas9-T2A-mCherry mRNA dose on expression at 24h post transfection.

[0016] FIG. 1D shows the effect of increasing AAV dose on TCR $\alpha$  knockout.

[0017] FIG. 1E shows flow cytometry data related to comparison of TCR $\alpha$  knockout with single stranded (ss) versus self-complementary (sc) AAV for guide expression in T-cells.

[0018] FIG. 2A shows data related to relief of post-entry restriction of AAV-mediated gene expression.

[0019] FIG. 2B shows data related to comparison of effect of E4ORF6/E1B55K proteins on self-complementary and single-stranded AAV6-mediated gene expression

[0020] FIG. 2C shows data related to MRN inactivation and its effect of relief of post-entry restriction on AAV-mediated expression.

[0021] FIG. 3A shows the effect of E4ORF6/E1B55K mutants on AAV-driven GFP expression.

[0022] FIG. 3B shows the effect of E4ORF6/E1B55K-H373 expression on AAV transduction.

[0023] FIG. 3C shows a comparison of E1B55K, E4ORF6 mutants effects on AAV transduction.

[0024] FIG. 3D shows a comparison of E1B55K, E4ORF6 mutants effects on AAV-driven GFP expression.

[0025] FIG. 4A – FIG. 4C show data related to CRISPR-mediated gene knockout in primary human T-cells through use of adenoviral E4ORF6/E1B55K proteins.

[0026] FIG. 5A – FIG. 5C show data related to the effect of E4ORF6/E1B55K MRN mutants on indel spectra.

[0027] FIG. 6 shows the effect of E4ORF6/E1B55K proteins on non-homologous AAV insertion.

[0028] FIG. 7A – FIG. 7B show data related to implementation of CRISPR/Cas9 with mRNA/AAV delivery to achieve knockout at multiple genomic sites.

[0029] FIG. 8A – FIG. 8D show data related to implementation of Cas9 mRNA/AAV guide delivery to generate CRISPR-mediated double knockout in primary human T-cells with E4ORF6/E1B55K H373A expression.

[0030] FIG. 9 shows data related to implementation of Cas9 mRNA/AAV guide delivery to generate CRISPR-mediated knockout of more than two genes in primary human T-cells with E4ORF6/E1B55K H373A expression.

[0031] FIG. 10A – FIG. 10C show data related the effect of using E1B55K mutants (E4ORF6/E1B55K) enhance targeted CRISPR knock-in.

[0032] FIG. 11 shows data related to the effect of addition of E4ORF6/E1B55K H373A or H354 on homology directed repair (HDR) when using shorter homology arms for gene knock-in with CRISPR-Cas9 at the CCR5 locus.

[0033] FIG. 12A – FIG. 12C show data related to the effect of addition of E4ORF6/E1B55K H354 on HDR when using shorter homology arms for gene knock-in with CRISPR-Cas9 at the TCR locus .

[0034] FIG. 13A – FIG. 13B show data related to surface marker phenotype and Ca<sup>2+</sup> signaling in edited primary T-cells with E4ORF6/E1B55K H373A.

[0035] FIG. 14A – FIG. 14B show data related to cell karyotype following multiplex CRISPR editing.

[0036] FIG. 15A – FIG. 15C show data related to molecular confirmation of HDR events following CRISPR-Cas9 breaks with E4ORF6/E1B55K H373A or H354.

[0037] FIG. 16A shows alternatives of polynucleotide sequences of guide RNAs guide1 (SEQ ID NO: 15), guide2 (SEQ ID NO: 16), guide3 (SEQ ID NO: 17), and guide4 (SEQ ID NO: 5) used for generating TCR knockout using the CRISPR/Cas9 system.

[0038] FIG. 16B shows flow cytometry data comparing the efficiency of Cas9-mCherry expression from mRNA in primary T-cells from donor 1 when using guide RNAs guide1 – guide4.

[0039] FIG. 16C shows flow cytometry data comparing the efficiency of generation of TCR knockout in primary T-cells from donor 1 when using guide RNAs guide1 – guide4.

[0040] FIG. 16D shows flow cytometry data comparing Cas9-mCherry expression levels in primary T-cells from donor 1 when using different volumes of Cas9/guide sample.

[0041] FIG. 16E shows flow cytometry data comparing the efficiency of generation of TCR knockout in primary T-cells from donor 1 when using different volumes of sample containing guide RNA guide4.

[0042] FIG. 16F shows flow cytometry data comparing Cas9-mCherry expression levels in primary T-cells from donor 2 when using different volumes of Cas9/guide sample containing guide RNA guide4.

[0043] FIG. 16G shows flow cytometry data comparing the efficiency of generation of TCR knockout in primary T-cells from donor 2 when using different volumes of sample containing guide RNA guide4.

[0044] FIG. 16H shows flow cytometry data comparing the efficiency of Cas9-mCherry expression from mRNA in Jurkat T-cells when using guide RNAs guide1 – guide4.

[0045] FIG. 16I shows flow cytometry data comparing the efficiency of generation of TCR knockout in Jurkat T-cells when using guide RNAs guide1 – guide4.

[0046] FIG. 17 shows the protein sequence of an alternative of a wild type adenoviral protein E1B55K (SEQ ID NO: 1).

[0047] FIG. 18 shows the protein sequence of an alternative of a mutant adenoviral protein E1B55K with an H373A polymorphism (SEQ ID NO: 2). The mutation is shown in bold and underlined.

[0048] FIG. 19 shows the protein sequence of an alternative of a wild type adenoviral protein E4ORF6 (SEQ ID NO: 3).

[0049] FIG. 20 shows the protein sequence of an alternative of a mutant adenoviral protein E1B55K with an H354 (SEQ ID NO: 4). The mutation/insertion is shown in bold and underlined.

[0050] FIG. 21 shows flow cytometry data of generation of TCR $\alpha$  knockout with CRISPR guide RNAs guide1 (G1), guide2 (G2), guide3 (G3) and guide4 (G4).

[0051] FIG. 22 shows the protein sequence of an alternative dCas9 variant of Cas9 protein of *Streptococcus pyogenes* (SEQ ID NO: 6).

[0052] FIG. 23 shows the nucleotide sequence of an alternative Cas9 – SP variant from *Streptococcus pyogenes* (SEQ ID NO: 7).

[0053] FIG. 24 shows the nucleotide sequence of an alternative Cas9 – SPm4 variant from *Streptococcus pyogenes* (SEQ ID NO: 8).

[0054] FIG. 25 shows the nucleotide sequence of an alternative Cas9 – ST1 variant from *Streptococcus thermophilus* (SEQ ID NO: 9).

[0055] FIG. 26 shows the nucleotide sequence of an alternative Cas9 – ST1m4 variant from *Streptococcus thermophilus* (SEQ ID NO: 10).

[0056] FIG. 27 shows the nucleotide sequence of an alternative Cas9 - NM variant from *Neisseria meningitidis* (SEQ ID NO: 11).

[0057] FIG. 28 shows the nucleotide sequence of an alternative Cas9 – NMm4 variant from *Neisseria meningitidis* (SEQ ID NO: 12).

[0058] FIG. 29 shows the nucleotide sequence of an alternative Cas9 - TD variant from *Treponema denticola* (SEQ ID NO: 13).

[0059] FIG. 30 shows the nucleotide sequence of an alternative Cas9 – TDm4 variant from *Treponema denticola* (SEQ ID NO: 14).

[0060] FIG. 31 shows alternatives of polynucleotide sequences of PD1 guide RNA (SEQ ID NO: 18), TIGIT guide RNA (SEQ ID NO: 19), Lag3 guide RNA (SEQ ID NO: 20) and Tim3 guide RNA (SEQ ID NO: 21).

[0061] FIG. 32A shows the effect of TALENs on HDR for the CCR5 locus.

[0062] FIG. 32B shows the effect of TALENs on HDR for the CD40L locus.

[0063] FIG. 33 shows the nucleotide sequence of an alternative of an R240A mutant of the adenoviral protein E1B55K (SEQ ID NO: 22).

[0064] FIG. 34 shows the nucleotide sequence of an alternative of an AXA mutant of the adenoviral protein E4ORF6 (SEQ ID NO: 23).

#### DETAILED DESCRIPTION

[0065] In some alternatives, nuclease-based gene editing systems and methods are provided. Examples of nuclease-based approaches for gene editing include systems comprising nucleases such as, without limitations, ZFNs, TALENs, meganucleases (e.g., MegaTALs) and CRISPR/Cas9.

[0066] The gene-editing systems and methods provided herein can be applied to any nuclease-based gene editing approach comprising, without limitations, gene disruption and/or gene targeting. For example, aspects of the present disclosure are related to CRISPR/Cas9-based gene editing. In some alternatives, Cas9 nuclease-mediated enhancement of gene editing is provided.

[0067] An important aspect of applying CRISPR/Cas9 for gene editing is the need for a system to express the guide RNA's efficiently in a wide variety of cell types. An important system for expressing guide RNAs is based on the use of adeno-associated virus vectors (AAV). AAV vectors are able to transduce a wide range of primary cells.

[0068] However, in many cell types, there is a post-entry restriction on AAV vectors that renders AAV-mediated expression of transgenes, including guide RNAs, very inefficient, thus substantially compromising the utility of AAV vectors for this purpose. Therefore, an approach to substantially improve and expand the potential applications of the CRISPR/Cas9 system in primary cells is contemplated.

[0069] In some alternatives, Cas9-based approach enhances gene editing efficiency with minimal toxicity when adeno-associated virus vectors (AAV) are used to express the guide RNA's necessary for Cas9 targeting.

[0070] CRISPR/Cas9 and related programmable endonuclease systems have rapidly become significant gene editing tools of the biomedical research laboratory, with their application for gene disruption and/or gene targeting demonstrated in a variety of cultured cell and model organism systems. Although the flexibility with which the Cas9 nuclease can be re-programmed to target new sites is a major advantage for genome engineering in the research setting, several practical barriers limit the direct extension of research-based gene editing methods to editing of primary human cells for therapeutic purposes.

[0071] Examples of some of these practical barriers include limited opportunities to identify and enrich for cells that have incurred a desired editing event; the requirement for transient (e.g. a few days) nuclease delivery due to safety and immunogenicity issues associated with longer term and/or *in vivo* nuclease expression; and limitations in vector systems for nuclease or recombination template delivery posed by primary cells' robust

capacity to detect the presence of cytosolic DNA and consequent generation of anti-viral or pro-apoptotic signals.

[0072] Driven by the practical barriers delineated herein, therapeutic gene editing strategies utilizing zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs), and meganucleases, have gravitated towards delivery approaches that ensure transient nuclease expression, most notably mRNA transfection, and the use of viral vectors for recombination template delivery. For these same reasons, mRNA-based CRISPR component expression has recently been extended to human primary cells for the purpose of gene disruption through the use of electroporation to deliver Cas9 mRNA or protein in conjunction with either native or degradation-resistant guide RNAs.

[0073] While RNA or protein/RNA-based nuclease delivery are straightforward methods for disrupting individual genes, applications of CRISPR-based gene editing that involve gene targeting require efficient delivery of three components: Cas9, guide RNA, and a recombination template.

[0074] In some alternatives, an electroporation/transduction co-delivery method for CRISPR/Cas9 gene editing that utilizes mRNA electroporation-mediated expression of Cas9 in conjunction with variants of two adenoviral serotype 5 proteins, E4ORF6 and E1B55K is provided, that transiently enhance both primary cells' capacity for transduction by AAV and gene editing efficiency.

[0075] In some alternatives, using a cell culture/manufacturing protocol compatible with clinical translation, the application of this method for efficient gene disruption and homology-directed gene targeting in primary human T-cells is provided.

#### Definitions

[0076] In the description that follows, a number of terms are used extensively. The following definitions are provided to facilitate understanding of the present alternatives.

[0077] As used herein, "a" or "an" may mean one or more than one.

[0078] As used herein, the term "about" indicates that a value includes the inherent variation of error for the method being employed to determine a value, or the variation that exists among experiments.



[0079] As used herein, “nucleic acid” or “nucleic acid molecule” refers to polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., enantiomeric forms of naturally-occurring nucleotides), or a combination of both. Modified nucleotides can have alterations in sugar moieties and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analogous of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, and the like. The term “nucleic acid molecule” also includes so-called “peptide nucleic acids,” which comprise naturally-occurring or modified nucleic acid bases attached to a polyamide backbone. Nucleic acids can be either single stranded or double stranded. The basic components of CRISPR/Cas9 system comprise a target gene, a guide RNA, and a Cas9 endonuclease, derivative, or fragment thereof. An important aspect of applying CRISPR/Cas9 for gene editing is the need for a system to deliver the guide RNAs efficiently to a wide variety of cell types. This could for example involve delivery of an in vitro generated guide RNA as a nucleic acid (the guide RNA generated by in vitro transcription or chemical synthesis). In some alternatives the nucleic acid encoding the guide RNA is rendered nuclease resistant by incorporation of modified bases, such as 2’O-methyl bases. In some alternatives, the CRISPR/Cas9 system described herein, whereby the polynucleotide encoding the Cas9 nuclease or a derivative or functional fragment thereof (e.g., SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 14) is provided with a poly(T)

or poly(A) tail of a desired length and prepared in accordance with the teachings described herein, for example, is provided with a guide RNA that comprises one or more modified bases, such as any one or more of the modified bases described herein.

[0080] Exemplary guide RNAs useful with the alternatives described herein, which may contain one or more of the modified bases set forth herein are provided in SEQ ID NO: 5, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 21. Furthermore, an important system for expressing guide RNAs in this context is based on the use of adeno-associated virus (AAV) vectors because AAV vectors are able to transduce a wide range of primary cells. AAV vectors do not cause infection and are not known to integrate into the genome. Therefore, the use of AAV vectors has the benefits of being both safe and efficacious.

[0081] The term “complementary to” means that the complementary sequence is homologous to all or one or more portions of a reference polynucleotide sequence. For illustration, the nucleotide sequence “CAT TAG” corresponds to a reference sequence “CAT TAG” and is complementary to a reference sequence “GTAATC.”

[0082] A “promoter” is a nucleotide sequence that directs the transcription of a structural gene. In some alternatives, a promoter is located in the 5' non-coding region of a gene, proximal to the transcriptional start site of a structural gene. Sequence elements within promoters that function in the initiation of transcription are often characterized by consensus nucleotide sequences. These promoter elements include RNA polymerase binding sites, TATA sequences, CAAT sequences, differentiation-specific elements (DSEs; McGehee et al., *Mol. Endocrinol.* 7:551 (1993); incorporated by reference in its entirety herein), cyclic AMP response elements (CREs), serum response elements (SREs; Treisman, *Seminars in Cancer Biol.* 1:47 (1990); incorporated by reference in its entirety herein), glucocorticoid response elements (GREs), and binding sites for other transcription factors, such as CRE/ATF (O'Reilly et al., *J. Biol. Chem.* 267:19938 (1992)), AP2 (Ye et al., *J. Biol. Chem.* 269:25728 (1994)), SP1, cAMP response element binding protein (CREB; Loeken, *Gene Expr.* 3:253 (1993)) and octamer factors (see, in general, Watson et al., eds., *Molecular Biology of the Gene*, 4th ed. (The Benjamin/Cummings Publishing Company, Inc. 1987), and Lemaigre and Rousseau, *Biochem. J.* 303:1 (1994); all references incorporated by reference in their entireties herein). As used herein, a promoter may be constitutively active,

repressible or inducible. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter. Repressible promoters are also known. In some alternatives, a regulatory element can be an untranslated region. In some alternatives, an untranslated region is a 5' untranslated region. In some alternatives, an untranslated region is a 3' untranslated region. In some alternatives, either 5' or 3' untranslated region is used. In some alternatives, both 5' and 3' untranslated regions are used. One skilled in the art will understand the meaning of an untranslated region as used in the alternatives here.

**[0083]** A “regulatory element” is a nucleotide sequence that modulates the activity of a core promoter. For example, a regulatory element may contain a nucleotide sequence that binds with cellular factors enabling transcription exclusively or preferentially in particular cells, tissues, or organelles. These types of regulatory elements are normally associated with genes that are expressed in a “cell-specific,” “tissue-specific,” or “organelle-specific” manner. In some alternatives, a system for editing at least one target gene in a cell is provided, wherein the system comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector; said system also comprising a second nucleic acid sequence encoding a Cas9 protein, a third nucleic acid sequence encoding a first adenoviral protein, and a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives, the first, second, third and fourth nucleic acid sequences are joined to regulatory elements that are operable in a eukaryotic cell, such as a human cell.

**[0084]** A “polypeptide” is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as “peptides.” A polypeptide can be considered as a protein.

**[0085]** A “protein” is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptide components, such as carbohydrate groups. Carbohydrates and other non-peptide substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein

in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless. In some embodiments, a system for editing at least one target gene in a cell is provided, wherein the method comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complementary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector; said system also comprising a second nucleic acid sequence encoding a Cas9 protein, a third nucleic acid sequence encoding a first adenoviral protein and a fourth nucleic acid sequence encoding a second adenoviral protein.

[0086] As used herein, “transient transfection” refers to the introduction of exogenous nucleic acid(s) into a host cell by a method that does not generally result in the integration of the exogenous nucleic into the genome of the transiently transfected host cell. In some alternatives, the nucleic acid is RNA. In some alternatives, the nucleic acid is DNA. In some alternatives, when the nucleic acid is RNA, the nucleic acid does not generally integrate in the genome of the transiently transfected cell. In some alternatives, when the nucleic acid is DNA, the nucleic acid can integrate in the genome of the transiently transfected cell.

[0087] By the term “host cell” is meant a cell that is introduced with Cas9-mRNA/AAV-guide RNA according to the present alternatives, as well as, cells that are provided with the systems herein. Host cells can be prokaryotic cells or eukaryotic cells. Examples of prokaryotic host cells include, but are not limited to *E. coli*, nitrogen fixing bacteria, *Staphylococcus aureus*, *Staphylococcus albus*, *Lactobacillus acidophilus*, *Bacillus anthracis*, *Bacillus subtilis*, *Bacillus thuringiensis*, *Clostridium tetani*, *Clostridium botulinum*, *Streptococcus mutans*, *Streptococcus pneumoniae*, mycoplasmas, and cyanobacteria. Examples of eukaryotic host cells include, but are not limited to, protozoa, fungi, algae, plant, insect, amphibian, avian and mammalian cells. In some alternatives, a system for editing at least one target gene in a cell is provided, wherein the cell is a eukaryotic cell. In some alternatives, the cell is a mammalian cell. In some alternatives, the cell is a human cell. In some alternatives, the cell is a primary cell. In some alternatives, the cell is not a transformed cell. In some alternatives, the cell is a primary lymphocyte. In some alternatives, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

[0088] The term “gene expression” refers to the biosynthesis of a gene product. For example, in the case of a structural gene, gene expression involves transcription of the structural gene into mRNA and the translation of mRNA into one or more polypeptides.

[0089] The term “endonuclease” refers to enzymes that cleave the phosphodiester bond within a polynucleotide chain. The polynucleotide may be double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), RNA, double-stranded hybrids of DNA and RNA, and synthetic DNA (for example, containing bases other than A, C, G, and T). An endonuclease may cut a polynucleotide symmetrically, leaving “blunt” ends, or in positions that are not directly opposing, creating overhangs, which may be referred to as “sticky ends.” The methods and compositions described herein may be applied to cleavage sites generated by endonucleases. In some alternatives of the system, the system can further provide nucleic acids that encode an endonuclease, such as Cas9, TALEN, or MegaTAL, or a fusion protein comprising a domain of an endonuclease, for example, Cas9, TALEN, or MegaTAL, or one or more portion thereof. These examples are not meant to be limiting and other endonucleases and alternatives of the system and methods comprising other endonucleases and variants and modifications of these exemplary alternatives are possible without undue experimentation. All such variations and modifications are within the scope of the current teachings.

[0090] The term “TAL Effector Nuclease” (TALEN) refers to a nuclease comprising a TAL-effector domain fused to a nuclease domain. TAL-effector DNA binding domains, isolated from the plant pathogen *Xanthomonas* have been described (see Boch et al., (2009) Science 29 Oct. 2009 (10.1126/science.117881) and Moscou and Bogdanove, (2009) Science 29 Oct. 2009 (10.1126/science.1178817); both references incorporated by reference in their entireties herein). These DNA binding domains may be engineered to bind to a desired target and fused to a nuclease domain, such as the FokI nuclease domain, to derive a TAL effector domain-nuclease fusion protein. The methods and systems described herein may be applied to cleavage sites generated by TAL effector nucleases. In some alternatives of the systems provided herein, the systems can further comprise a TALEN nuclease or a vector or nucleic acid encoding a TALEN nuclease. In some alternatives of the methods provided herein, the method can further comprise providing a nuclease, such as a TALEN nuclease.

[0091] MegaTALs are derived from the combination of two distinct classes of DNA targeting enzymes. Meganucleases (also referred to as homing endonucleases) are single peptide chains that have the advantage of both DNA recognition and nuclease functions in the same domain. In some alternatives of the systems provided herein, the systems can further comprise a MegaTAL nuclease or a vector or nucleic acid encoding a MegaTAL nuclease. In some alternatives of the methods provided herein, the methods can further comprise providing MegaTAL nuclease or a vector or nucleic acid encoding a MegaTAL nuclease.

[0092] Cas9 (CRISPR associated protein 9) is an RNA-guided DNA endonuclease enzyme associated with the CRISPR (Clustered Regularly Interspersed Palindromic Repeats) adaptive immunity system in *Streptococcus pyogenes*, among other bacteria. *S. pyogenes* utilizes Cas9 to memorize and later interrogate and cleave foreign DNA, such as invading bacteriophage DNA or plasmid DNA. Cas9 performs this interrogation by unwinding foreign DNA and checking for if it is complementary to the 20 base pair spacer region of the guide RNA. If the DNA substrate is complementary to the guide RNA, Cas9 cleaves the invading DNA.

[0093] CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. CRISPR/Cas system has been used for gene editing (adding, disrupting or changing the sequence of specific genes) and gene regulation in species throughout the tree of life. By delivering the Cas9 protein, a derivative, or fragment thereof and appropriate guide RNAs into a cell, the organism's genome can be cut at any desired location. It can be possible to use CRISPR to build RNA-guided gene drives capable of altering the genomes of entire populations. In some alternatives, a system for editing at least one target gene in a cell is provided, wherein the method comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector, a second nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof, a third nucleic acid sequence encoding a first adenoviral protein and a fourth nucleic acid sequence encoding a second adenoviral protein. Exemplary guide RNAs useful with the alternatives described

herein, which may contain one or more modified bases, are provided in SEQ ID NO: 5, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and/or SEQ ID NO: 21.

**[0094]** In some alternatives, the use of chemically modified guide RNAs is contemplated. Chemically-modified guide RNAs have been used in CRISPR-Cas genome editing in human primary cells (Hendel, A. et al., Nat Biotechnol. 2015 Sep; 33(9):985-9). Chemical modifications of guide RNAs can include modifications that confer nuclease resistance. Nucleases can be endonucleases, or exonucleases, or both. Some chemical modification, without limitations, include 2'-fluoro, 2'-O-methyl, phosphorothioate dithiol 3'-3' end linkage, 2-amino-dA, 5-methyl-dC, C-5 propynyl-C, C-5 propynyl-U, morpholino, etc. These examples are not meant to be limiting and other chemical modifications and variants and modifications of these exemplary alternatives are also contemplated.

**[0095]** The term "exonuclease" refers to enzymes that cleave phosphodiester bonds at the end of a polynucleotide chain via a hydrolyzing reaction that breaks phosphodiester bonds at either the 3' or 5' end. The polynucleotide may be double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), RNA, double-stranded hybrids of DNA and RNA, and synthetic DNA (for example, containing bases other than A, C, G, and T). The term "5' exonuclease" refers to exonucleases that cleave the phosphodiester bond at the 5' end. The term "3' exonuclease" refers to exonucleases that cleave the phosphodiester bond at the 3' end. Exonucleases may cleave the phosphodiester bonds at the end of a polynucleotide chain at endonuclease cut sites or at ends generated by other chemical or mechanical means, such as shearing (for example by passing through fine-gauge needle, heating, sonicating, mini bead tumbling, and nebulizing), ionizing radiation, ultraviolet radiation, oxygen radicals, chemical hydrolysis and chemotherapy agents. Exonucleases may cleave the phosphodiester bonds at blunt ends or sticky ends. *E. coli* exonuclease I and exonuclease III are two commonly used 3'-exonucleases that have 3'-exonucleolytic single-strand degradation activity. Other examples of 3'-exonucleases include Nucleoside diphosphate kinases (NDKs), NDK1 (NM23-H1), NDK5, NDK7, and NDK8 (Yoon J-H, et al., Characterization of the 3' to 5' exonuclease activity found in human nucleoside diphosphate kinase 1 (NDK1) and several of its homologues. (Biochemistry 2005;44(48):15774-15786.), WRN (Ahn, B., et al., Regulation of WRN helicase activity in human base excision repair. J.

Biol. Chem. 2004, 279:53465-53474) and Three prime repair exonuclease 2 (Trex2) (Mazur, D. J., Perrino, F. W., Excision of 3' termini by the Trex1 and TREX2 3'→5' exonucleases. Characterization of the recombinant proteins. J. Biol. Chem. 2001, 276:17022-17029; both references incorporated by reference in their entireties herein). *E. coli* exonuclease VII and T7-exonuclease Gene 6 are two commonly used 5'-3' exonucleases that have 5% exonucleolytic single-strand degradation activity. The exonuclease can be originated from prokaryotes, such as *E. coli* exonucleases, or eukaryotes, such as yeast, worm, murine, or human exonucleases. In some alternatives of the systems provided herein, the systems can further comprise an exonuclease or a vector or nucleic acid encoding an exonuclease. In some alternatives, the exonuclease is Trex2. In some alternatives of the methods provided herein, the methods can further comprise providing exonuclease or a vector or nucleic acid encoding an exonuclease, such as Trex2.

[0096] The term “cleavage” refers to the breakage of the covalent backbone of a polynucleotide. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. Double stranded DNA, RNA, or DNA/RNA hybrid cleavage can result in the production of either blunt ends or staggered ends.

[0097] “Prokaryotic” cells lack a true nuclease. Examples of prokaryotic cells are bacteria (e.g., *cyanobacteria*, *Lactobacillus acidophilus*, Nitrogen-Fixing Bacteria, *Helicobacter pylori*, *Bifidobacterium*, *Staphylococcus aureus*, *Bacillus anthrax*, *Clostridium tetani*, *Streptococcus pyogenes*, *Staphylococcus pneumoniae*, *Klebsiella pneumoniae* and *Escherichia coli*) and archaea (e.g., *Crenarchaeota*, *Euryarchaeota*, and *Korarchaeota*). The Cas9 protein described herein is a protein from a prokaryotic cell.

[0098] “Eukaryotic” cells include, but are not limited to, algae cells, fungal cells (such as yeast), plant cells, animal cells, mammalian cells, and human cells (e.g., T-cells).

[0099] The term “subject” as used herein includes all members of the animal kingdom including non-human primates and humans. In some alternatives, a system for editing at least one target gene in a cell is provided, wherein the method comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is



complimentary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector, a second nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof, a third nucleic acid sequence encoding a first adenoviral protein and a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives, the cell that comprises an edited gene is delivered to a subject in need.

**[0100]** The homing endonucleases, also known as meganucleases, are sequence specific endonucleases that generate double strand breaks in genomic DNA with a high degree of specificity due to their large (e.g., >14 bp) cleavage sites. While the specificity of the homing endonucleases for their target sites allows for precise targeting of the induced DNA breaks, homing endonuclease cleavage sites are rare and the probability of finding a naturally occurring cleavage site in a targeted gene is low. In some alternatives of the systems provided herein, the systems can further comprise a meganuclease or a vector or nucleic acid encoding a meganuclease. In some alternatives of the methods provided herein, the methods can further comprise providing a meganuclease or a vector or nucleic acid encoding a meganuclease.

**[0101]** Another class of artificial endonucleases is the engineered meganucleases. Engineered homing endonucleases are generated by modifying the specificity of existing homing endonucleases. In one approach, variations are introduced in the amino acid sequence of naturally occurring homing endonucleases and then the resultant engineered homing endonucleases are screened to select functional proteins which cleave a targeted binding site. In another approach, chimeric homing endonucleases are engineered by combining the recognition sites of two different homing endonucleases to create a new recognition site composed of a half-site of each homing endonuclease. In some alternatives of the systems provided herein, the systems can further comprise an engineered meganuclease or a vector or nucleic acid encoding an engineered meganuclease.

**[0102]** Targeted DNA double-strand breaks introduced by rare-cleaving endonucleases can be harnessed for gene disruption applications in diverse cell types by engaging non-homologous end joining DNA repair pathways. However, endonucleases create chemically clean breaks that are often subject to precise repair, limiting the efficiency of targeted gene disruption. Several alternatives described herein relate to a method of improving the rate of targeted gene disruptions caused by imprecise repair of endonuclease-

induced site-specific DNA double-strand breaks. In some alternatives, systems can further comprise site specific endonucleases that are coupled with end-processing enzymes to enhance the rate of targeted gene disruption. Coupling may be, for example, physical, spatial, and/or temporal.

**[0103]** Not to be bound by any particular theory, the resolution of a double-strand DNA breaks by “error-prone” non-homologous end-joining (NHEJ) can be harnessed to create targeted disruptions and genetic knockouts, as the NHEJ process can result in insertions and deletions at the site of the break. NHEJ is mediated by several sub-pathways, each of which has distinct mutational consequences. The classical NHEJ pathway (cNHEJ) requires the KU/DNA-PKcs/Lig4/XRCC4 complex, and ligates ends back together with minimal processing. As the DNA breaks created by designer endonuclease platforms (zinc-finger nucleases (ZFNs), TAL effector nucleases (TALENs), and homing endonucleases (HEs)) all leave chemically clean, compatible overhang breaks that do not require processing prior to ligation, they are excellent substrates for precise repair by the cNHEJ pathway. In the absence or failure of the classical NHEJ pathway to resolve a break, alternative NHEJ pathways (altNHEJ) can substitute: however, these pathways are considerably more mutagenic.

**[0104]** Not to be bound by any particular theory, modification of DNA double-strand breaks by end-processing enzymes may bias repair towards an altNHEJ pathway. Further, different subsets of end-processing enzymes may enhance disruption by different mechanisms. For example, Trex2, an exonuclease that specifically hydrolyzes the phosphodiester bonds which are exposed at 3' overhangs, biases repair at break sites toward mutagenic deletion. By contrast, terminal deoxynucleotidyl transferase (TdT), a non-templative polymerase, is expected to bias repair at break sites toward mutagenic insertions by promoting the addition of nucleotide bases to alter DNA ends prior to ligation. Accordingly, one of skill in the art can use end-processing enzymes with different activities to provide for a desired engineering outcome with any of the systems or methods provided herein. Further one of skill in the art may use the synergy between different end-processing enzymes so as to achieve maximal or unique types of effects.

**[0105]** Several alternatives described herein couple DNA breaks created by endonucleases with end-processing enzymes, which can improve the rates of targeted

disruption in a variety of cell types and species, without associated toxicity to the host. This is an important advance at least because: 1) Double-strand breaks (DSBs) trigger cell cycle checkpoints to arrest division until the break has been resolved; in the case of a “persistent break” (a repetitive cycle of cleaving and precise repair), cells may arrest indefinitely, leading to apoptosis. 2) Engineering applications often utilize transient delivery of an endonuclease, providing only a short window in which enzyme concentration is sufficient to achieve breaks. 3) Persistent breaks can be a source of translocations. Coupling endonucleases to end-processing enzymes prevents the establishment of a persistent break and reduces the incidence of gross chromosomal rearrangements, thereby improving the safety of endonuclease-induced targeted disruption. 4) Multiple changes in a single round of mutagenesis can be achieved, for use for example, in multi-allelic knockouts and multiplexing, as data described herein provides evidence that coupling endonucleases to end-processing enzymes improves the mutagenic rate of two given endonucleases 5-fold at their respective targets, a 25-fold improvement can be realized in disrupting both targets simultaneously.

[0106] The system can further comprise endonucleases, end-processing enzymes, and/or fusion proteins having endonuclease and end-processing activity, for delivery to host cells. In some alternative of the system described herein, the system can further comprise a protein such as one or more polypeptides having endonuclease and/or end-processing activity may be provided directly to cells. In some alternatives, expression of endonucleases, end-processing enzymes and/or fusion proteins having endonuclease and end-processing activity in a host cell can result from delivery of one or more polynucleotides encoding one or more endonucleases, end-processing enzymes, and/or fusion proteins having endonuclease and end-processing activity to the host cell. In some alternatives, one or more polynucleotides is a DNA expression vector. In some alternatives, one or more polynucleotides is an RNA expression vector. In some alternatives, trans-splicing, polypeptide cleavage and/or polypeptide ligation can be involved in expression of one or more proteins in a cell.

[0107] The systems and methods described herein are useful for generating targeted disruptions of the coding sequences of genes and in some alternatives, creating gene knockouts. Targeted cleavage by the compositions and methods described herein can also be used to alter non-coding sequences (e.g., regulatory sequences such as promoters, enhancers,

initiators, terminators, splice sites) to alter the levels of expression of a gene product. Such methods can be used, for example, for biological research, for biotechnology applications such as crop modification, for therapeutic purposes, functional genomics, and/or target validation studies.

**[0108]** Some alternatives of the system are coupled to the activity of one or more site-specific endonucleases with one or more end-processing enzymes. In some alternatives, the endonucleases and end-processing enzymes are provided as separate proteins with the system. In some alternatives, the endonucleases and end-processing enzymes are co-expressed in a cell. If expression of the separate endonucleases and end-processing enzymes is by polynucleotide delivery, each of the endonucleases and end-processing enzymes can be encoded by separate polynucleotides, or by a single polynucleotide. In some alternatives, the endonucleases and end-processing enzymes are encoded by a single polynucleotide and expressed by a single promoter. In some alternatives, an endonuclease and end-processing enzymes are linked by a T2A sequence, which allows for two separate proteins to be produced from a single translation. In some alternatives, a different linker sequence can be used. In other alternatives a single polynucleotide encodes the endonucleases and end-processing enzymes separated by an Internal Ribosome Entry Sequence (IRES).

**[0109]** Several alternatives of the system comprises coupling the system with endonucleases selected from the group consisting of: I-Anil, I-SceI, I-CeuI, PI-PspI, PI-Sce, I-SceIV, I-CsmI, I-PanI, I-PanII, I-PanMI, I-SceII, I-PpoI, I-SceIII, I-CreI, I-LtrI, I-GpiI, I-GZeI, I-OnuI, I-HjeMI, I-TevI, I-TevII, and I-TevIII with one or more DNA end-processing enzymes selected from the group consisting of: Trex2, Trex1, Trex1 without transmembrane domain, Apollo, Artemis, DNA2, Exo1, ExoT, ExoIII, Fen1, Fan1, MreII, Rad2, Rad9, TdT (terminal deoxynucleotidyl transferase), PNKP, RecE, RecJ, RecQ, Lambda exonuclease, Sox, Vaccinia DNA polymerase, exonuclease I, exonuclease III, exonuclease VII, NDK1, NDK5, NDK7, NDK8, WRN, T7-exonuclease Gene 6, avian myeloblastosis virus integration protein (IN), Bloom, Antartic Phosphatase, Alkaline Phosphatase, Poly nucleotide Kinase (PNK), ApeI, Mung Bean nuclease, Hex1, TTRAP (TDP2), Sgs1, Sae2, CtIP, Pol mu, Pol lambda, MUS81, EME1, EME2, SLX1, SLX4 and UL-12. In some alternatives, the homing endonucleases and DNA end-processing enzymes are provided as a fusion protein. In some alternatives, the endonucleases and DNA end-processing enzymes are provided as separate

proteins. In some alternatives, the endonucleases and DNA end-processing enzymes are co-expressed in a host cell.

**[0110]** Several alternatives relate to coupling the system described herein, with DNA end-processing enzymes selected from the group consisting of: Trex2, Trex1, Trex1 without transmembrane domain, Apollo, Artemis, DNA2, Exo1, ExoT, ExoIII, Fen1, Fan1, MreII, Rad2, Rad9, TdT (terminal deoxynucleotidyl transferase), PNKP, RecE, RecJ, RecQ, Lambda exonuclease, Sox, Vaccinia DNA polymerase, exonuclease I, exonuclease III, exonuclease VII, NDK1, NDK5, NDK7, NDK8, WRN, T7-exonuclease Gene 6, avian myeloblastosis virus integration protein (IN), Bloom, Antarctic Phosphatase, Alkaline Phosphatase, Poly nucleotide Kinase (PNK), Apel, Mung Bean nuclease, Hex1, TTRAP (TDP2), Sgs1, Sae2, CtIP, Pol mu, Pol lambda, MUS81, EME1, EME2, SLX1, SLX4 and UL-12. In some alternatives of the system, the end-processing enzymes are provided as separate proteins. In some alternatives of the system, the end-processing enzymes are co-expressed in a host cell.

**[0111]** In several alternatives, the activity of one or more site-specific homing endonucleases selected from the group consisting of: I-Anil, I-SceI, I-CeuI, PI-PspI, PI-Sce, I-SceIV, I-CsmI, I-PanI, I-PanII, I-PanMI, I-SceII, I-PpoI, I-SceIII, I-CreI, I-LtrI, I-GpiI, I-GZeI, I-OnuI, I-HjeMI, I-TevI, I-TevII, and I-TevIII is coupled with the activity of one or more DNA end-processing enzymes selected from the group consisting of: Artemis, Trex1, Flap endonuclease, terminal deoxynucleotide transferase, Trex2, Vaccinia DNA polymerase, Mre11, exonuclease I, exonuclease III, NDK1, NDK5, NDK7, NDK8, and WRN. In some alternatives, the homing endonucleases and DNA end-processing enzymes are provided as a fusion protein. In some alternatives, the endonucleases and DNA end-processing enzymes are provided as separate proteins. In some alternatives, the endonucleases and DNA end-processing enzymes are co-expressed in a host cell.

**[0112]** Several alternatives of the system further comprise a heterologous fusion protein, which comprises an endonuclease domain and an end-processing domain or one or more portions thereof. Several alternatives relate to a heterologous fusion construct, which encodes a fusion protein having endonuclease and end-processing activity. The present alternatives also relate to systems and methods that further comprise the heterologous fusion construct, as well as, methods for producing a fusion protein having endonuclease and end-

processing activity and compositions thereof. In one alternative, the endonuclease domain is coupled to the end-processing domain by recombinant means (e.g., the fusion protein is generated by translation of a nucleic acid in which a polynucleotide encoding all or one or more portions of an endonuclease is joined in-frame with a polynucleotide encoding all or one or more portions of an end-processing enzyme). In other alternatives, the endonuclease domain and end-processing domain of a fusion protein are linked chemically. This chemical linkage can be carried out, for example, by using bifunctional linker molecules, such as, BS3 (Bis[sulfosuccinimidyl] suberate).

**[0113]** Some alternatives of the system further comprise a protein comprising an endonuclease domain and exonuclease domain in which it is provided as a protein or a vector or nucleic acid encoding the protein comprising an endonuclease domain and exonuclease domain as a fusion protein. In some alternatives, the fusion protein comprises at least a fragment or variant of a homing endonuclease and at least a fragment or variant of an exonuclease, for example a 3' exonuclease, which are associated with one another by genetic or chemical conjugation to one another. In several alternatives, the 3' exonuclease is a Trex2 monomer, dimer, or a variant thereof. In other alternatives, the fusion protein comprises at least a fragment or variant of a zinc finger endonuclease and at least a fragment or variant of a 5' exonuclease, which are associated with one another, by genetic fusion or chemical conjugation to one another. The endonuclease and exonuclease, once part of the fusion protein, may be referred to as a "portion", "region," "domain" or "moiety" of the endo/exonuclease fusion protein. In some alternatives, the exonuclease domain comprises Trex or one or more portions thereof.

**[0114]** An endonuclease/end-processing enzyme fusion protein may optionally include a linker peptide between the endonuclease and end-processing enzyme domains to provide greater physical separation between the moieties and thus maximize the accessibility of the endonuclease portion, for instance, for binding to its target sequence. The linker peptide may consist of amino acids selected to make it more flexible or more rigid depending on the relevant function. The linker sequence can be cleavable by a protease or cleavable chemically to yield separate endonuclease and end-processing enzyme moieties. Examples of enzymatic cleavage sites in the linker include sites for cleavage by a proteolytic enzyme, such as enterokinase, Factor Xa, trypsin, collagenase, and thrombin. In some alternatives, the

protease is one, which is produced naturally by the host or it is exogenously introduced. Alternatively, the cleavage site in the linker may be a site capable of being cleaved upon exposure to a selected chemical, e.g., cyanogen bromide, hydroxylamine, or low pH. The optional linker sequence may serve a purpose other than the provision of a cleavage site. The linker sequence should allow effective positioning of the endonuclease moiety with respect to the end-processing enzyme moiety so that the endonuclease domain can recognize and cleave its target sequence and the end-processing domain can modify the DNA ends exposed at the cleavage site. The linker may also be a simple amino acid sequence of a sufficient length to prevent any steric hindrance between the endonuclease domain and the end-processing domain. In addition, the linker sequence may provide for post-translational modification including, but not limited to, e.g., phosphorylation sites, biotinylation sites, sulfation sites,  $\gamma$ -carboxylation sites, and the like. In some alternatives, the system can further comprise a fusion with an endonuclease/end-processing protein.

**[0115]** In some alternatives, the linker sequence comprises from 4 to 30 amino acids, more preferably from 8 to 22 amino acids. That is, the linker sequence can be any number of amino acids from 4 to 30, such as at least or equal to 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids or a length that is within a range defined by any two of the aforementioned lengths. In some alternatives, the linker sequence is flexible so as not hold the biologically active peptide in a single undesired conformation. The linker may be predominantly comprised of amino acids with small side chains, such as glycine, alanine, and serine, so as to provide for flexibility. In some alternatives about 80 or 90 percent or greater of the linker sequence comprises glycine, alanine, or serine residues, particularly glycine and serine residues. In several alternatives, a G4S linker peptide separates the end-processing and endonuclease domains of the fusion protein. In other alternatives, a T2A linker sequence allows for two separate proteins to be produced from a single translation. Suitable linker sequences can be readily identified empirically. Additionally, suitable size and sequences of linker sequences also can be determined by conventional computer modeling techniques.

**[0116]** Expression of a fusion protein in a cell can result from delivery of the fusion protein to the cell or by delivery of a polynucleotide encoding the fusion protein to a cell, wherein the polynucleotide is transcribed, and the transcript is translated, to generate the

fusion protein. Trans-splicing, polypeptide cleavage and polypeptide ligation can also be involved in expression of a protein in a cell. Methods for polynucleotide and polypeptide delivery to cells are well known in the art.

[0117] A variety of DNA molecules encoding the endonucleases described herein, end-processing enzymes and fusion proteins may be constructed for providing the selected proteins or peptides to a cell. The DNA molecules encoding the endonucleases, end-processing enzyme, and fusion proteins may be modified to contain different codons to optimize expression in a selected host cell, as is known in the art.

[0118] A variety of RNA molecules encoding the endonucleases described herein, end-processing enzymes and fusion proteins may be constructed for providing the selected proteins or peptides to a cell. The RNA molecules encoding the endonucleases, end-processing enzyme, and fusion proteins may be modified to contain different codons to optimize expression in a selected host cell, as is known in the art. In some alternatives, the RNA can comprise a poly(A) tail of 50, 100, 150, 200, 250, 300, 350, 400, 450, 500 covalently linked adenosine residues, or an amount of residues within a range defined by any two of the aforementioned values.

[0119] Several alternatives of the system further comprise a vector or nucleic acid for the simultaneous expression of a site-specific endonuclease and an end-processing enzyme to improve the efficiency of targeted gene disruption by up to ~70 fold, essentially fixing a mutagenic outcome in 100% of a population of cells containing the target site in less than 72 hours.

[0120] In some alternatives of the system, an additional vector or nucleic acid is provided for effective amounts of endonucleases and end-processing enzymes or an effective amount of a fusion protein for delivery to a cell either directly by contacting the cell with the protein(s) or by transient expression from an expression construct. In such alternatives of the system, in which the system is delivered to a cell, cell division reduces the concentration of the nucleases to sub-active levels within a few cell divisions.

[0121] Several alternatives of the systems and methods provided herein, further provide a fusion protein for conferring site specificity on a DNA end-processing enzyme by physically tethering an end-processing enzyme domain to a site specific DNA binding domain. In some alternatives, the end-processing enzyme domain is tethered to a DNA



binding domain through a linker peptide. The composition and structure of the linker peptide is not especially limited and in some alternatives the linker may be chemically or enzymatically cleavable. The linker peptide may be flexible or rigid and may comprise from about 4 to 30 amino acids. In other alternatives, the end-processing enzyme domain is chemically fused to a DNA binding domain. Not wishing to be bound by a particular theory, imparting site specificity to an end-processing enzyme through tethering the end-processing enzyme to a site specific DNA binding domain decreases toxicity associated with indiscriminate end-processing activity, such as exonuclease activity, and reduces the effective amount of end-processing enzyme required for efficient modification of the exposed double stranded DNA break caused by endonuclease activity compared to untethered end-processing enzyme. In some alternatives, the end-processing enzyme is tethered to a homing endonuclease. In other alternatives, the end-processing enzyme is tethered to zinc finger endonuclease. In some alternatives, an end-processing enzyme domain is tethered to a zinc finger DNA binding domain which binds to a DNA sequence adjacent to the cleavage site of a homing endonuclease or zinc finger endonuclease.

**[0122]** Several alternatives of the system and methods relate to coupling the activity of the CRISPR/Cas9 system with one or more site-specific endonucleases with Trex2, in order to promote gene knockout efficiently when coupled with the systems provided herein. Trex2 may be provided as a monomer or dimer. The Trex2 enzyme specifically hydrolyzes the phosphodiester bonds, which are exposed at 3' overhangs. While homing endonucleases can generate 3' overhangs, which are susceptible to Trex2 exonuclease activity, the zinc finger nucleases, which utilize the Fok1 cleavage domain, generate double strand DNA breaks with 5' overhangs. The homing endonucleases and zinc finger nucleases generate mutations at their cleavage sites at a baseline rate. Co-expression of Trex2 with homing endonucleases increased the mutation rate ~70 fold. Co-expression of Trex2 with zinc finger endonucleases was also observed to effect on the rate of mutation. Some alternatives of the methods relate to providing the system described herein, with co-expression of an exonuclease, Trex2.

**[0123]** As used herein, an Ad5 adenoviral protein, and Ad5 viral protein or an Ad5 protein refers to a protein that is encoded by adenovirus serotype 5. Non-limiting examples include E4ORF6 and E1B55K. The protein sequence of an alternative of the wild

type E1B55K protein is shown in FIG. 17 (SEQ ID NO: 1). The protein sequence of an alternative of the wild type E4ORF6 protein is shown in FIG. 19 (SEQ ID NO: 3). In some alternatives, a mutant form of an Ad5 protein is used. Non-limiting examples include the H373A mutant of E1B55K and the H354 mutant of E1B55K. In some alternatives, Ad5 refers to a combination of two or more Ad5 viral proteins. In some alternatives, Ad5 refers to a combination two or more wild type Ad5 viral proteins. In some alternatives, Ad5 refers to a combination two or more Ad5 viral proteins at least one of which is a wild type form. In some alternatives, Ad5 refers to a combination two or more Ad5 viral proteins at least one of which is a mutant form. In some alternatives, Ad5<sup>wt</sup> refers to one or more wild type Ad5 viral proteins. In some alternatives, Ad5<sup>MRN-</sup> refers to one or more mutant Ad5 viral proteins that do not disable the MRN complex. In some alternatives, at least one Ad5 viral protein is used in combination with or not in combination with a nuclease. In some alternatives, the nuclease is an endonuclease. In some alternatives, the endonuclease is Cas9, a derivative, or fragment thereof. In some alternatives, the nuclease is an exonuclease. In some alternatives, the exonuclease is Trex2. In some alternatives, at least one Ad5 viral protein is used in combination with more than one a nuclease. In some alternatives, at least one Ad5 viral protein is used in combination with Cas9, a derivative, or fragment thereof and Trex2.

#### Expression Vectors

[0124] Expression constructs can be readily designed using methods known in the art. Examples of nucleic acid expression vectors include, but are not limited to: recombinant viruses, lentiviruses, adenoviruses, plasmids, bacterial artificial chromosomes, yeast artificial chromosomes, human artificial chromosomes, minicircle DNA, episomes, cDNA, RNA, and PCR products. In some alternatives, nucleic acid expression vectors encode a single peptide (e.g., an endonuclease, an end-processing enzyme, or a fusion protein having endonuclease and end-processing activity). In some alternatives, nucleic acid expression vectors encode one or more endonucleases and one or more end-processing enzymes in a single, polycistronic expression cassette. In some alternatives of the system, one or more endonucleases and one or more end-processing enzymes are provided, wherein they are linked to each other by a 2A peptide sequence or an “autocleavage” or self-cleavage sequence. In some alternatives, the nucleic acid expression vectors are DNA expression

vectors. In some alternatives, the nucleic acid expression vectors are RNA expression vectors. In some alternatives, the expression vectors are viral vectors. In some alternatives of the systems provided herein, the viral vector is an Adeno-associated virus (AAV) vector.

[0125] In some alternatives, a nucleic acid expression vector further comprises one or more selection markers that facilitate identification or selection of host cells that have received and express the endonuclease(s), end-processing enzyme(s), and/or fusion protein(s) having endonuclease and end-processing activity along with the selection marker. Examples of selection markers include, but are not limited to, genes encoding fluorescent proteins, e.g., EGFP, DS-Red, YFP, and CFP; genes encoding proteins conferring resistance to a selection agent, e.g., PuroR gene, ZeoR gene, HygroR gene, neoR gene, and the blasticidin resistance gene. In some cases, the selection marker comprises a fluorescent reporter and a selection marker.

[0126] In some alternatives, a DNA expression vector comprises a promoter capable of driving expression of one or more endonuclease(s), end-processing enzyme(s), and/or fusion protein(s) having endonuclease and end-processing activity. Examples of promoters include, but are not limited to, retroviral LTR elements; constitutive promoters such as CMV, HSV1-TK, SV40, EF-1 $\alpha$ ,  $\beta$ -actin; inducible promoters, such as those containing Tet-operator elements; and tissue specific promoters. Suitable bacterial and eukaryotic promoters are well known in the art and described, e.g., in Sambrook et al., *Molecular Cloning, A Laboratory Manual* (2nd ed. 2001); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (2010), the references are incorporated by reference in their entireties herein. Non-limiting examples of plant promoters include promoter sequences derived from *A. thaliana* ubiquitin-3 (ubi-3).

[0127] In some alternatives, a nucleic acid encoding one or more endonucleases, end-processing enzymes, and/or fusion proteins having endonuclease and end-processing activity or exonuclease activity are cloned into a vector for transformation into eukaryotic cells along with the vectors and nucleic acid of the systems provided herein. In some alternatives, nucleic acids encoding different endonucleases and end-processing enzymes are cloned into the same vector. In such cases, the nucleic acids encoding different endonucleases and end-processing enzymes may optionally be separated by T2A, self-

cleavage sequences, protease cleavage sites, or IRES sequences. Vectors can be prokaryotic vectors, e.g., plasmids, or shuttle vectors, insect vectors, or eukaryotic vectors, including plant vectors described herein. Expression of the nucleases and fusion proteins may be under the control of a constitutive promoter or an inducible promoter. In some alternatives, the vector comprises a nucleic acid sequence that encodes Cas9, a derivative, or fragment thereof. In some alternatives, the vector comprises a nucleic acid sequence that encodes Trex. In some alternatives, the genes and/or nucleic acids in the vector are codon optimized for expression in a mammalian cell, such as a human cell. In some alternatives, the vector is an mRNA. In some alternatives, the vector is an mRNA encoding a Cas9 protein, a derivative, or fragment thereof. In some alternatives, the nucleic acid encoding Cas9 protein, a derivative, or fragment thereof is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives, the Cas9 protein, a derivative, or fragment thereof is from *S. pyogenes* or is a consensus sequence made from other Cas9 proteins from other organisms.

[0128] Introduction of polypeptides having endonuclease and/or end-processing activity and/or polynucleotides encoding polypeptides having endonuclease and/or end-processing activity into host cells may use any suitable methods for nucleic acid or protein delivery as described herein or as would be known to one of ordinary skill in the art. The polypeptides and polynucleotides described herein can be delivered into cultured cells *in vitro*, as well as *in situ* into tissues and whole organisms. Introduction of the polypeptides and polynucleotides of the present alternatives into a host cell can be accomplished chemically, biologically, or mechanically. This may include, but is not limited to, electroporation, sonoporation, use of a gene gun, lipotransfection, calcium phosphate transfection, use of dendrimers, microinjection, polybrene, protoplast fusion, the use of viral vectors including adenoviral, AAV, and retroviral vectors, and group II ribozymes.

#### Immune Response against AAV Vectors

[0129] Adeno-associated viral (AAV) vectors are widely used for gene therapy-based treatment genetic diseases. However, generation of immune responses against the AAV vector can undermine the therapeutic efficacy of the vector. Similarly, generation of immune responses against the AAV vector used in CRISPR/Cas9-based (or one or more other nucleases-based) genome editing can undermine the efficacy of gene targeting.

[0130] In some alternatives, it is contemplated that the AAV vectors used for CRISPR/Cas9-based (and/or one or more other nucleases-based) genome editing will possess reduced immunogenicity. In some alternatives, it is contemplated that the AAV vectors used for CRISPR/Cas9-based (and/or one or more other nucleases-based) genome editing will possess no immunogenicity. In some alternatives, because of the reduced immunogenicity, the likelihood of development of resistance against the AAV vector will be minimal. In some alternatives, because of the lack of immunogenicity, the likelihood of development of resistance against the AAV vector will be non-existent.

### Organisms

[0131] The alternatives described herein are applicable to any eukaryotic organism in which it is desired to edit a gene. Examples of eukaryotic organisms include, but are not limited to, algae, plants, animals (e.g., mammals such as mice, rats, primates, pigs, cows, sheep, rabbits, dogs, cats, or horses etc.), fish, and insects. In some alternatives, isolated cells from the organism are genetically modified as described herein. In some alternatives, the modified cells develop into reproductively mature organisms. Eukaryotic (e.g., algae, yeast, plant, fungal, piscine, avian, and mammalian cells) cells can be used. Cells from organisms containing one or more additional genetic modifications can also be used.

[0132] Examples of mammalian cells include any cell or cell line of the organism of interest, for example oocytes, somatic cells, K562 cells, CHO (Chinese hamster ovary) cells, HEP-G2 cells, BaF-3 cells, Schneider cells, COS cells (monkey kidney cells expressing SV40 T-antigen), CV-1 cells, HuTu80 cells, NTERA2 cells, NB4 cells, HL-60 cells and HeLa cells, 293 cells and myeloma cells like SP2 or NS0. Peripheral blood mononucleocytes (PBMCs) or T-cells can also be used, as can embryonic and adult stem cells. For example, stem cells that can be used include embryonic stem cells (ES), induced pluripotent stem cells (iPSC), mesenchymal stem cells, hematopoietic stem cells, muscle stem cells, skin stem cells, adipose derived stem cells, and neuronal stem cells. In some alternatives, a system for editing at least one target gene in a cell is provided, wherein the system comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector, wherein said system further comprises a second nucleic acid

sequence encoding a Cas9 protein, a derivative, or fragment thereof, a third nucleic acid sequence encoding a first adenoviral protein and a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives, the cell is a eukaryotic cell. In some alternatives, the cell is a mammalian cell, such as a human cell. In some alternatives, the cell is a primary cell. In some alternatives the cell is not a transformed cell. In some alternatives, the cell is a primary lymphocyte, a CD34<sup>+</sup> stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

[0133] Examples of target plants and plant cells include, but are not limited to, monocotyledonous and dicotyledonous plants, such as crops including grain crops (e.g., wheat, maize, rice, millet, barley), fruit crops (e.g., tomato, apple, pear, strawberry, orange), forage crops (e.g., alfalfa), root vegetable crops (e.g., carrot, potato, sugar beets, yam), leafy vegetable crops (e.g., lettuce, spinach); flowering plants (e.g., petunia, rose, chrysanthemum), conifers and pine trees (e.g., pine fir, spruce); plants used in phytoremediation (e.g., heavy metal accumulating plants); oil crops (e.g., sunflower, rape seed) and plants used for experimental purposes (e.g., Arabidopsis). Thus, the disclosed methods and compositions have use over a broad range of plants, including, but not limited to, species from the genera Asparagus, Avena, Brassica, Citrus, Citrullus, Capsicum, Cucurbita, Daucus, Erigeron, Glycine, Gossypium, Hordeum, Lactuca, Lolium, Lycopersicon, Malus, Manihot, Nicotiana, Orychophragmus, Oryza, Persea, Phaseolus, Pisum, Pyrus, Prunus, Raphanus, Secale, Solanum, Sorghum, Triticum, Vitis, Vigna, and Zea. The term plant cells include isolated plant cells as well as whole plants or one or more portions of whole plants such as seeds, callus, leaves, roots, etc. The present disclosure also encompasses seeds of the plants described herein. The present disclosure further encompasses the progeny, clones, cell lines, or cells of the plants described.

#### Generating Homozygously Modified Organisms

[0134] Cells in which systems are provided with one or more vectors or nucleic acids encoding endonucleases for co-expression with one or more fusion proteins comprising endonuclease and end-processing activity are expressed and are assayed for site specific cleavage. Such modified cells can be identified using any suitable method known to the

skilled artisan, including sequencing, PCR analysis, southern blotting, and the like. In some alternatives, an amplicon spanning the endonuclease target site is generated by PCR.

#### Pharmaceutical Compositions and Administration

[0135] Cells manufactured by the systems or methods provided herein can be administered directly to a patient for targeted cleavage of a DNA sequence and for therapeutic or prophylactic applications, for example, for treating, inhibiting, or ameliorating cancer, ischemia, diabetic retinopathy, macular degeneration, rheumatoid arthritis, psoriasis, HIV infection, sickle cell anemia, Alzheimer's disease, muscular dystrophy, neurodegenerative diseases, vascular disease, cystic fibrosis, stroke, hyper IGE syndrome, or hemophilia. In some alternatives, cells are manufactured by the systems provided herein. In some alternatives, a method of editing at least one target gene in a cell is provided, wherein the method comprises introducing into a cell a first vector that comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in said cell, introducing into said cell a second nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof; introducing into said cell a third nucleic acid sequence encoding a first adenoviral protein; and introducing into said cell a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives, a cell is provided, wherein the cell is manufactured by the said methods. In some alternatives, a composition is provided, wherein the composition comprises the cell. In some alternatives, the compositions described herein, can be used in methods of treating, preventing, ameliorating, or inhibiting a disease (e.g., cancer, ischemia, diabetic retinopathy, macular degeneration, rheumatoid arthritis, psoriasis, HIV infection, sickle cell anemia, Alzheimer's disease, muscular dystrophy, neurodegenerative diseases, vascular disease, cystic fibrosis, stroke, hyper IGE syndrome, hemophilia) or ameliorating a disease condition or symptom associated with a disease, such as, cancer, ischemia, diabetic retinopathy, macular degeneration, rheumatoid arthritis, psoriasis, HIV infection, sickle cell anemia, Alzheimer's disease, muscular dystrophy, neurodegenerative diseases, vascular disease, cystic fibrosis, stroke, hyper IGE syndrome, or hemophilia. In some alternatives, the cells or compositions are administered to treat, prevent, ameliorate, or inhibit an autosomal dominant disease, such as achondroplasia, pseudoachondroplasia, the multiple epiphyseal

dysplasias, chondrodysplasias, osteogenesis imperfecta, Marfan syndrome, polydactyly, hereditary motor sensory neuropathies I and II (Charcot-Marie-Tooth disease), myotonic dystrophy, and neurofibromatosis or ameliorate a disease condition or symptom associated with an autosomal dominant disease, such as achondroplasia, pseudoachondroplasia, the multiple epiphyseal dysplasias, chondrodysplasias, osteogenesis imperfecta, Marfan syndrome, polydactyly, hereditary motor sensory neuropathies I and II (Charcot-Marie-Tooth disease), myotonic dystrophy, and/or neurofibromatosis. In some alternatives, the cells or compositions provided herein, are administered to treat, prevent, ameliorate, or inhibit a disease caused by misregulation of genes. In some alternatives, the cells or compositions provided herein, are administered to treat, prevent, ameliorate, or inhibit a cancer, such as BCL-2, Bcl-XI, and FLIP, or ameliorate a disease condition or symptom associated with a cancer, such as BCL-2, Bcl-XI, and FLIP.

[0136] The compositions comprising the cells are administered in any suitable manner, and in some alternatives with pharmaceutically acceptable carriers. Suitable methods of administering such proteins or polynucleotides are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.

[0137] Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions that are available (see, e.g., Remington's Pharmaceutical Sciences).

[0138] Formulations suitable for parenteral administration, such as, for example, by intravenous, intramuscular, intradermal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The disclosed compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally. The formulations of compounds can be



presented in unit-dose or multi-dose sealed containers, such as ampules and vials. Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

[0139] In some alternatives, one or more of parenteral, subcutaneous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal routes of administration are contemplated. In some embodiments, the composition to be administered can be formulated for delivery via one or more of the above noted routes.

#### Additional Alternatives

[0140] RNA-guided endonuclease (RGEN) technology has great promise for enabling efficient editing of a target genomic locus. In some alternatives, the application of *S. pyogenes* Cas9 for gene editing in primary human cells such as primary human T-cells using mRNA-mediated delivery of a first generation spCas9 and adeno-associated virus (AAV) to drive guide RNA expression has been evaluated. In some alternatives, spCas9-mediated editing using mRNA-mediated delivery of a first generation spCas9 and adeno-associated virus (AAV) to drive guide RNA expression achieves targeted gene disruption rates at the TCR $\alpha$  locus of up to 30%. In some alternatives, the evaluation of the dose response of editing efficiency at different Cas9 mRNA doses and over a range of AAV MOI provided evidence that editing efficiency is limited primarily by AAV-driven guide RNA expression. In some alternatives, the evaluation of several approaches to achieve higher editing efficiencies led to the development of approaches that achieve up to 90% TCR $\alpha$  disruption at reduced AAV MOI in selected cell populations. In some alternatives, the results provide evidence that a Cas9-mRNA/AAV-guide approach can be applied to effectively disrupt multiple individual genes in primary human T-cells, and resulted in an innovative method through which CRISPR/Cas9 technology has enhanced efficiency.

[0141] The basic components of CRISPR/Cas9 system comprise a target gene, a protospacer adjacent motif (PAM), a guide RNA, Cas9 endonuclease. An important aspect of applying CRISPR/Cas9 for gene editing is the need for a system to deliver the guide RNAs efficiently to a wide variety of cell types. This could, for example, involve delivery of an in vitro generated guide RNA as a nucleic acid (the guide RNA generated by in vitro transcription or chemical synthesis). In some alternatives the nucleic acid could be rendered nuclease resistant by incorporation of modified bases. An important system for expressing guide RNAs is based on the use of adeno-associated virus (AAV) vectors because AAV vectors are able to transduce a wide range of primary cells. AAV vectors do not cause infection and are not known to integrate into the genome. Therefore, the use of AAV vectors has the benefits of being both safe and efficacious.

[0142] In some alternatives, an AAV vector is used to deliver one or more components of the CRISPR/Cas9 system for gene editing. In some alternatives, an AAV vector is used to deliver one or more components of CRISPR/Cas9 system for gene editing in primary cells. In some alternatives, an AAV vector is used to deliver a CRISPR guide RNA for gene editing. In some alternatives, an AAV vector is used to deliver a CRISPR guide RNA for gene editing in primary cells. In some alternatives, a primary cell, is a cell directly derived from a host donor, which is not transformed or cancerous and which cannot be propagated indefinitely outside the host.

[0143] In many cell types, there is a post-entry or post-delivery restriction on AAV vectors. This renders AAV-mediated expression of transgenes, including guide RNAs, very inefficient, thus substantially compromising the utility of AAV vectors for this purpose. Certain adenoviral proteins facilitate expression and replication of AAV and AAV vectors. In particular, in some alternatives, E4ORF6 and E1B55K are used as helper proteins in AAV vector production and/or as helper proteins in replication of AAV vector encoding guide RNA.

[0144] Previous work has shown that wild type E1B55K or wild type E4ORF6 proteins can disable an important protein complex involved in DNA repair (known as the MRN complex). This leads to cell cycle arrest and high toxicity due to lack of repair of DNA breaks. On the other hand, it has been realized that neither the H373A mutant of E1B55K nor the H354 mutant of E1B55K disable the MRN complex. This leaves the DNA

repair machinery intact and provides increased safety and efficacy when using the mutant form of ad proteins for AAV replication in cells. Thus, in some alternatives, the wild type E1B55K is used in combination with the H373A mutant of E1B55K protein. In some alternatives, the wild type E4ORF6 is used in combination with the H354 mutant of E1B55K protein. In some alternatives, the use of wild type E4ORF6 in combination with the H373A mutant of E1B55K protein does not disable the MRN complex. In some alternatives, the use of wild type E4ORF6 in combination with the H354 mutant of E1B55K protein does not disable the MRN complex. In some alternatives, the use of wild type E4ORF6 in combination with the H373A mutant of E1B55K protein does not lead to cell cycle arrest. In some alternatives, the use of wild type E4ORF6 in combination with the H354 mutant of E1B55K protein does not lead to cell cycle arrest. In some alternatives, the use of wild type E4ORF6 in combination with the H373A mutant of E1B55K protein does not lead to toxicity due to lack of repair of DNA breaks. In some alternatives, the use of wild type E4ORF6 in combination with the H354 mutant of E1B55K protein does not lead to toxicity due to lack of repair of DNA breaks.

[0145] In some alternatives, the use of mutant adenoviral proteins for AAV transduction resulted in lower transduction efficiency of primary cells, as compared to wild type adenoviral proteins. However, the use of mutant adenoviral proteins resulted in dramatic enhancement of CRISPR/Cas9-based gene editing. In some alternatives, this is likely due to enhancing gRNA expression from the AAV vector. In some alternatives, this is likely due to modulation of the DNA repair environment of the cell to promote mutagenic repair of double strand breaks created by CRISPR. In some alternatives, this is likely due to both enhancing gRNA expression from the AAV vector as well as modulation of the DNA repair environment of the cell to promote mutagenic repair of double strand breaks created by CRISPR.

[0146] In some alternatives, expression of E4ORF6 and mutant E1B55K-H373A results in sufficient relief of the post-entry restriction on AAV expression while maintaining intact DNA repair. In some alternatives, expression of E4ORF6 and mutant E1B55K-H354 results in sufficient relief of the post-entry restriction on AAV expression while maintaining intact DNA repair. In some alternatives, expression of E4ORF6 and E1B55K-H373A allows for a substantial improvement in gene editing efficiency. In some alternatives, expression of

E4ORF6 and E1B55K-H354 allows for a substantial improvement in gene editing efficiency. In some alternatives, expression of E4ORF6 and E1B55K-H373A allows for a substantial improvement in CRISPR/Cas9-mediated gene editing efficiency. In some alternatives, expression of E4ORF6 and E1B55K-H354 allows for a substantial improvement in CRISPR/Cas9-mediated gene editing efficiency. In some alternatives, expression of E4ORF6 and E1B55K-H373A allows a substantial improvement in gene editing efficiency in primary cells. In some alternatives, expression of E4ORF6 and E1B55K-H354 allows a substantial improvement in gene editing efficiency in primary cells. In some alternatives, expression of E4ORF6 and E1B55K-H373A allows for a substantial improvement in CRISPR/Cas9-mediated gene editing efficiency in primary cells. In some alternatives, expression of E4ORF6 and E1B55K-H354 allows for a substantial improvement in CRISPR/Cas9-mediated gene editing efficiency in primary cells.

[0147] In some alternatives, a system of introducing CRISPR/Cas9 in primary cells using an AAV-mRNA split system approach is provided. In some alternatives of the split system, Cas9, a derivative, or fragment thereof and adenoviral proteins are expressed from mRNA and expressed transiently, and gRNA is expressed constantly and expressed from AAV. In some alternatives, the split system increased the efficiency of gene editing in primary human cells.

[0148] Some alternatives relate to a method of introducing CRISPR guide RNA in primary cells using an AAV vector. More alternatives relate to a method of introducing Cas9, a derivative, or fragment thereof in primary cells encoded by an mRNA. In some alternatives, a method of introducing Cas9, a derivative, or fragment thereof in primary cells encoded as a fusion protein by an mRNA is provided. In some alternatives, Cas9 is fused with a fluorophore at the C terminus. In some alternatives, Cas9, a derivative, or fragment thereof is fused with a fluorophore at the N terminus. In some alternatives, Cas9, a derivative, or fragment thereof is fused with a fluorophore and the Cas9, a derivative, or fragment thereof and fluorophore are separated by a self-cleavage sequence, such as a T2A sequence. In some alternatives, Cas9, a derivative, or fragment thereof is fused to an NLS. In some alternatives, the NLS is fused at the N terminus of Cas9, a derivative, or fragment thereof. In some alternatives, the NLS is fused at the C terminus of Cas9, a derivative, or fragment thereof. In some alternatives, the NLS is fused at both the N and the C terminus of

Cas9, a derivative, or fragment thereof. In some alternatives, Cas9, a derivative, or fragment thereof is tagged with an mCherry fluorophore.

[0149] In some alternatives, the mRNA comprises a poly A tail. In some alternatives, the poly A tail confers stability to the mRNA. In some alternatives, the length of the poly A tail is greater than or equal to 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or 500 base pairs or a length that is within a range defined by any two of the aforementioned lengths. In some alternatives, the mRNA is encoded by a vector. In some alternatives, the mRNA is expressed from the vector by *in vitro* transcription. In some alternatives, the mRNA encodes a nuclease, helicase and/or an adenoviral protein. In some alternatives, the mRNA encodes Cas9, a derivative, or fragment thereof. In some alternatives, the mRNA encodes MegaTAL or TALEN. In some alternatives, the mRNA encodes E4ORF6. In some alternatives, the mRNA encodes E1B55K. In some alternatives, the mRNA encodes H373A E1B55K. In some alternatives, the mRNA encodes H354 E1B55K. In some alternatives, the mRNA encodes Trep2.

[0150] In some alternatives, the expression of adenoviral proteins is desired along with the Cas9 protein. mRNAs with poly A tails that are greater than or equal to 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or 500 base pairs or a length that is within a range defined by any two of the aforementioned lengths, wherein said mRNAs encode Cas9, a derivative, or fragment thereof, TALEN, or MegaTAL, can be efficiently co-expressed in primary human cells. In some alternatives, said mRNA is used to express Cas9, a derivative, or fragment thereof. In some alternatives, said mRNA is used to express wild type adenoviral proteins. In some alternatives, said mRNA is used to express mutant adenoviral proteins. In some alternatives, AAV is used to express guide RNA. Some alternatives relate to methods of introducing adenoviral proteins in primary cells encoded by an mRNA. In some alternatives, mRNA is used to introduce the wild type adenoviral protein E4ORF6. In some alternatives, mRNA is used to introduce the mutant adenoviral protein H373A E1B55K. In some alternatives, mRNA is used to introduce the mutant adenoviral protein H354 E1B55K. In some alternatives, separate mRNAs are used to introduce both wild type E4ORF6 and the mutant H373A E1B55K. In some alternatives, separate mRNAs are used to introduce both wild type E4ORF6 and the mutant H354 E1B55K. In some alternatives, the mRNAs are on a vector. In some alternatives, AAV with guide RNA and

mRNA encoding Cas9, a derivative, or fragment thereof, and E4ORF6 and mutant H373A E1B55K or AAV with guide RNA and mRNA encoding Cas9, E4ORF6 and mutant H354 E1B55K are simultaneously introduced. In some alternatives, AAV with guide RNA and mRNA encoding Cas9, a derivative, or fragment thereof, and E4ORF6 and mutant H373A E1B55K or AAV with guide RNA and mRNA encoding Cas9, E4ORF6 and mutant H354 E1B55K are sequentially introduced. In some alternatives, AAV with guide RNA and mRNA encoding Cas9, a derivative, or fragment thereof, and E4ORF6 and mutant H373A E1B55K or AAV with guide RNA and mRNA encoding Cas9, E4ORF6 and H354 E1B55K are present in a cell at the same time. In some alternatives, mRNA is used to transiently express wild type adenoviral proteins. In some alternatives, mRNA is used to transiently express mutant adenoviral proteins. In some alternatives, mRNA is used to simultaneously albeit transiently to express Cas9, a derivative, or fragment thereof, wild type adenoviral proteins and mutant adenoviral protein. In some alternatives, guide RNA is prone to degradation. In some alternatives, therefore AAV is used to constantly express guide RNA. In some alternatives, AAV with guide RNA and mRNA encoding Cas9, a derivative, or fragment thereof, and E4ORF6 and mutant H373A E1B55K or AAV with guide RNA and mRNA encoding Cas9, and E4ORF6 and H354 E1B55K are present transiently. In some alternatives, AAV with guide RNA and mRNA encoding Cas9, a derivative, or fragment thereof, E4ORF6 and mutant H373A E1B55K or AAV with guide RNA and mRNA encoding Cas9, E4ORF6 and H354 E1B55K are not present permanently.

**[0151]** In some alternatives, co-expressing Cas9, a derivative, or fragment thereof with E4ORF6/E1B55K-H373A results in sufficient relief of post-entry restriction on AAV expression while maintaining intact DNA repair. This allows substantial improvement in Cas9-mediated gene editing efficiency with minimal toxicity when an AAV vector is simultaneously used to express the guide RNAs necessary for Cas9 targeting, thus yielding results counterintuitive to what one might have expected from the use of AAV vectors and substantially improving and expanding the potential applications of the CRISPR/Cas9 system in primary cells.

**[0152]** In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout in primary cells is provided. In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout in primary T-cells is

provided. In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout in Jurkat T-cells is provided. In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout in primary cells using a combined mRNA/AAV approach is provided. In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout in primary T-cells using a combined mRNA/AAV approach is provided. In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout in Jurkat T-cells using a combined mRNA/AAV approach is provided. In some alternatives, the use of mutant adenoviral proteins to enhance CRISPR-mediated gene knockout is provided. In some alternatives, the use of mutant adenoviral proteins to enhance CRISPR-mediated gene knockout in primary cells is provided. In some alternatives, the use of mutant adenoviral proteins to enhance CRISPR-mediated gene knockout in primary T-cells is provided. In some alternatives, the use of mutant adenoviral proteins to enhance CRISPR-mediated gene knockout in Jurkat T-cells is provided.

**[0153]** In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout and enhanced homologous recombination in primary T-cells is described. In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout and enhanced homologous recombination in primary T-cells using a combined mRNA/AAV approach is described. In some alternatives, the use of mutant adenoviral proteins to enhance CRISPR-mediated gene knockout and enhanced homologous recombination is provided. In some alternatives, the mutant adenoviral proteins enhance CRISPR-mediated gene knockout and enhance homologous recombination in primary T-cells.

**[0154]** The application of this technology is not limited to primary human cells. In some alternatives, a system for targeting of non-human sequences, for example pathogenic organisms, is provided. In some alternatives, a method for targeting of non-human sequences, for example pathogenic organisms, is provided. In some alternatives, a system for targeting diseases is provided. In some alternatives, a method for targeting diseases is provided. In some alternatives, the disease can be an infectious disease caused by a pathogenic organism. In some alternatives, the disease can be a non-infectious disease.

**[0155]** Double strand DNA break repair through the NHEJ pathway is often not mutagenic. The majority of endonuclease-induced breaks repaired by the NHEJ pathway

involve precise re-ligation, resulting in the restoration of the original DNA sequence. HDR, in contrast to NHEJ, requires a repair template and imprecise repair through this pathway can result in mutations at the break site, such as DNA base deletions and insertions, as well as, translocations and telomere fusion.

[0156] In some alternatives, the use of Cas9-mRNA/AAV-guide system results in increased NHEJ rates. Thus, in some alternatives of the Cas9-mRNA/AAV-guide system, a repair template is introduced into the cell. In some alternatives the repair template is RNA. In some alternatives, the repair template is DNA. In some alternatives, the Cas9-mRNA/AAV-guide system is driven towards HDR to achieve greater mutation rate. In some alternatives, the mRNA-AAV system is implemented with another nuclease without providing a repair template. In some alternatives, the mRNA-AAV system implemented with another nuclease without providing a repair template allows for NHEJ. In some alternatives, the system further comprises a nuclease, wherein the nuclease is MegaTAL.

#### Additional Preferred Alternatives

[0157] In some alternatives, a system for editing at least one target gene in a cell, comprising a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector, wherein said system further comprises a second nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof; a third nucleic acid sequence encoding a first adenoviral protein, and a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives of the system, the cell is a eukaryotic cell. In some alternatives of the system, the cell is a mammalian cell. In some alternatives, the cell is a human cell. In some alternatives of the system, the cell is a primary cell. In some alternatives, the cell is not a transformed cell. In some alternatives of the system, the cell is a primary lymphocyte, a CD34<sup>+</sup> stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell. In some alternatives of the system, the vector is a viral vector. In some alternatives of the system, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the system, the second nucleic acid encoding the Cas9 protein, a derivative, or fragment thereof is an mRNA. In some alternatives of the system, the second nucleic acid sequence encoding the Cas9 protein, a



derivative, or fragment thereof is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the Cas9 protein, a derivative, or fragment thereof is from *S. pyogenes*. In some alternatives of the system, the third nucleic acid encoding the first adenoviral protein is an mRNA. In some alternatives of the system, the mRNA is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the first adenoviral protein is E4ORF6. In some alternatives of the system, the fourth nucleic acid encoding the second adenoviral protein is an mRNA. In some alternatives of the system, the fourth nucleic acid encoding the second adenoviral protein is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the second adenoviral protein is an E1B55K mutant. In some alternatives of the system, the second adenoviral protein comprises the amino acid sequence set forth in SEQ ID NO: 2. In some alternatives of the system, the second adenoviral protein comprises the amino acid sequence set forth in SEQ ID NO: 4. In some alternatives of the system, the first, second, third and fourth nucleic acid sequences are joined to regulatory elements that are operable in a eukaryotic cell, such as a human cell. In some alternatives of the system, the first nucleic acid sequence encoding the CRISPR guide RNA is operably linked to a regulatory element. In some alternatives of the system, the nucleic acid sequence encoding the CRISPR guide RNA is operably linked to a U6 promoter. In some alternatives of the system, the nucleic acid sequence encoding the CRISPR guide RNA is constitutively expressed.

[0158] In some alternatives, a method of editing at least one target gene in a cell, comprises introducing into a cell a first vector that comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in said cell; introducing into said cell a second nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof; introducing into said cell a third nucleic acid sequence encoding a first adenoviral protein; and introducing into said cell a fourth nucleic acid sequence encoding a second adenoviral protein.

[0159] In some alternatives of the method, the cell is a eukaryotic cell. In some alternatives of the method, the cell is a mammalian cell. In some alternatives of the method, the cell is a human cell. In some alternatives of the method, the cell is a primary cell. In some alternatives of the method, the cell is not a transformed cell. In some alternatives of the

method, the cell is a primary lymphocyte, a CD34<sup>+</sup> stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell. In some alternatives of the method, the first vector comprising the first nucleic acid sequence encoding the CRISPR guide RNA is a viral vector. In some alternatives of the method, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the method, the second, third and fourth nucleic acid sequences are mRNA. In some alternatives of the method, the mRNAs are codon optimized for expression in a eukaryotic cell, such as a human. In some alternatives of the method, the Cas9 protein, a derivative, or fragment thereof is from *S. pyogenes*. In some alternatives of the method, the first adenoviral protein is E4ORF6. In some alternatives of the method, the second adenoviral protein is an E1B55K mutant. In some alternatives of the method, the second adenoviral protein comprises the amino acid sequence set forth in SEQ ID NO: 2. In some alternatives of the method, the second adenoviral protein comprises the amino acid sequence set forth in SEQ ID NO: 4.

[0160] In some alternatives of the system, the CRISPR guide RNA is any and all guide RNAs that are complimentary to a gene of interest. In some alternatives of the system, the CRISPR guide RNA is complimentary to a target gene on interest. Some non-limiting examples of target genes of interest include TCR $\alpha$ , TCR $\beta$ , PD-1, Tim3, Lag3, TIGIT or HBB.

[0161] In some alternatives of the system, the CRISPR guide RNA sequence targeting TCR comprises a sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 5. These sequences are described in FIG. 16A. In some alternatives of the system, polynucleotide sequence alternatives of PD1 guide target comprises a sequence set forth in SEQ ID NO: 18, TIGIT guide target comprises a sequence set forth in SEQ ID NO: 19, Lag3 guide target comprises a sequence set forth in SEQ ID NO: 20 and Tim3 guide target comprises a sequence set forth in SEQ ID NO: 21. These sequences are provided in FIG. 31.

[0162] In some alternatives of the method, the first, second, third and fourth nucleic acid sequences are not permanently introduced into the cell. In some alternatives of the method, introducing the first, second, third and fourth nucleic acid sequences into the cell does not transform the cell. In some alternatives of the method and/or the system, the second, third, or fourth nucleic acid sequence is provided on a vector. In some alternatives, a method

of editing at least one target gene in a cell, the method comprising introducing into the cell any of the alternatives of the system described herein.

[0163] In some alternatives, a method of treating, ameliorating, or inhibiting a disease and/or a condition in a subject, the method comprising providing to the subject having a disease and/or a condition and in need thereof, any of the alternatives of the system described herein. Some non-limiting examples of diseases and/or conditions can be sickle cell disease, hypercholesterolemia, cancer, autoimmune disease, inherited disorder of metabolism, immunodeficiency or genetic disease such as any disease due to a functional deficit in a gene product due to an alteration in the genome of the cell relative to a reference human genome.

#### More Alternatives

[0164] In more alternatives, a system for editing at least one target gene in a cell is provided, the system comprising a nucleic acid encoding Cas9 protein, at least one nucleic acid encoding at least protein, which alone or together with other proteins modifies the substrate specificity of at least one ubiquitin ligase enzyme or enzyme complex in the cell, and a vector that comprises at least one nucleic acid sequence encoding a CRISPR guide RNA, wherein the one or more CRISPR guide RNAs is/are complimentary to at least one target gene in a cell and in some alternatives of the system a vector that comprises a nucleic acid template for homologous gene targeting.

[0165] In some alternatives of the system, the Cas9 protein, a derivative, or fragment thereof and the ubiquitin ligase substrate specificity modifying proteins are encoded on the same nucleic acid. In some alternatives of the system, the Cas9 protein, a derivative, or fragment thereof and the ubiquitin ligase substrate specificity modifying proteins are encoded on two or more nucleic acids. In some alternatives of the system, the cell is a eukaryotic cell. In some alternatives of the system, the cell is a mammalian cell. In some alternatives of the system, the cell is a human cell. In some alternatives of the system, the cell is a primary cell. In some alternatives of the system, the cell is not a transformed cell. In some alternatives of the system, the cell is a primary lymphocyte, a CD34<sup>+</sup> stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell. In some alternatives of the system, the vector encoding the guide RNA(s) is a viral vector. In

some alternatives of the system, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives, the viral vector is a lentiviral vector.

[0166] In some alternatives of the system, the nucleic acid encoding the Cas9 protein, a derivative, or fragment thereof is an mRNA the second nucleic acid encoding the Cas9 protein, a derivative, or fragment thereof is an mRNA. In some alternatives of the system, the nucleic acid sequence encoding the Cas9 protein is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the Cas9 protein, a derivative, or fragment thereof is from *S. pyogenes*.

[0167] In some alternatives of the system, the nucleic acid or nucleic acids encoding any of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins are mRNA. In some alternatives of the system, the one or more mRNA's encoding ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins are codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, one of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins is the adenoviral protein E4ORF6 of any adenoviral serotype. In some alternatives of the system, one of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins is E1B55K of any adenovirus serotype.

[0168] In some alternatives of the system, one of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins is an E1B55K mutant, said mutant having an one or more amino acid changes or additions relative to the wild type E1B55K protein, which cause an alteration in the mutant protein's ability to modify cellular ubiquitin ligase substrate specificity relative the wild type E1B55K protein.

[0169] In some alternatives of the system, one of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins comprises the amino acid sequence set forth in SEQ ID NO: 2.

[0170] In some alternatives of the system, one of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins comprises the amino acid sequence set forth in SEQ ID NO: 4.

[0171] In some alternatives of the system, the nucleic acid sequences are joined to regulatory elements that are operable in a eukaryotic cell, such as a human cell. In some alternatives of the system, the nucleic acid sequence encoding the CRISPR guide RNA is

operably linked to a regulatory element. In some alternatives of the system, the nucleic acid sequence encoding the CRISPR guide RNA is operably linked to a U6 promoter. In some alternatives of the system, the nucleic acid sequence encoding the CRISPR guide RNA is constitutively expressed. In some alternatives, the nucleic acid sequence encoding the CRISPR guide RNA is operably linked to the U6 promoter and constitutively expressed.

[0172] In some alternatives, a method of editing at least one target gene in a cell is provided, the method comprising introducing into the cell a nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof; introducing into said cell at least one nucleic acid sequence encoding a ubiquitin ligase enzyme/enzyme complex substrate specificity modifying protein; introducing into said cell a vector that comprises at least one nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in said cell; and in some alternative of the method, introducing into said cell a vector that comprises a nucleic acid template for homologous gene targeting.

[0173] In some alternatives of the method, the cell is a eukaryotic cell. In some alternatives of the method, the cell is a mammalian cell. In some alternatives of the method, the cell is a human cell. In some alternatives of the method, the cell is a primary cell. In some alternatives of the method, the cell is not a transformed cell. In some alternatives of the method, the cell is a primary lymphocyte, a CD34<sup>+</sup> stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell. In some alternatives of the method, the vector comprising the first nucleic acid sequence encoding the endonuclease is a viral vector. In some alternatives, Cas9 is encoded in a viral vector. In some alternatives, a guide RNA is encoded in a viral vector. In some alternatives, a Cas9 and a guide RNA are encoded together in a viral vector. In some alternatives, a Cas9 and a guide RNA encoded together in a viral vector is used in combination with one or more Ad5 protein encoded by mRNA.

[0174] In some alternatives of the method, the vector comprising the nucleic acid sequence encoding the one or more CRISPR guide RNAs is a viral vector. In some alternatives of the method, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the method, the viral vector is a lentiviral vector. In some alternatives of the method, the nucleic acids encoding Cas9, a derivative, or fragment thereof and/or the ubiquitin ligase substrate specificity modifying proteins are mRNA. In some alternatives of

the method, the mRNAs are codon optimized for expression in a eukaryotic cell, such as a human.

[0175] In some alternatives of the method, the Cas9 protein, a derivative, or fragment thereof is from *S. pyogenes*. In some alternatives of the method, the ubiquitin ligase substrate specificity modifying proteins is E4ORF6 of any adenoviral serotype. In some alternatives of the method, the ubiquitin ligase substrate specificity modifying proteins is E1B55K of any adenoviral serotype. In some alternatives of the method, the second adenoviral protein comprises the amino acid sequence set forth in SEQ ID NO: 2. In some alternatives of the method, the second adenoviral protein comprises the amino acid sequence set forth in SEQ ID NO: 4.

[0176] In some alternatives of the system, the CRISPR guide RNA is any and all guide RNAs that are complimentary to a gene of interest. In some alternatives of the system, the CRISPR guide RNA is complimentary to a target gene of interest. Some non-limiting examples of target genes of interest include TCR $\alpha$ , TCR $\beta$ , PD-1, Tim3, Lag3, TIGIT or HBB.

[0177] In some alternatives of the system, alternatives of the CRISPR guide RNA sequence targeting TCR comprise a sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 5. These sequences are shown in FIG. 16A. In some alternatives of the system, a polynucleotide sequence comprises alternatives of PD1 guide target (SEQ ID NO: 18), TIGIT guide target (SEQ ID NO: 19), Lag3 guide target (SEQ ID NO: 20) or Tim3 guide target (SEQ ID NO: 21). These sequences are provided in FIG. 31.

[0178] In some alternatives of the method, the nucleic acid sequences are transiently introduced into the cell. In some alternatives of the method, the nucleic acid sequences are not permanently introduced into the cell. In some alternatives of the method, introducing the nucleic acid sequences into the cell does not permanently transform the cell.

[0179] Any of the alternatives of the system or the method described herein, wherein said second, third, or fourth nucleic acid sequence is provided on a vector.

[0180] In some alternatives, a method of editing at least one target gene in a cell, the method comprising introducing into the cell any of the alternatives of the system described herein.

**[0181]** In some alternatives, a method of treating, ameliorating, or inhibiting a disease and/or a condition in a subject, the method comprising providing to the subject having a disease and/or a condition and in need thereof, any of the alternatives of the system described herein. Some non-limiting examples of diseases and/or conditions can be sickle cell disease, hypercholesterolemia, cancer, autoimmune disease, inherited disorder of metabolism, immunodeficiency or genetic disease such as any disease due to a functional deficit in a gene product due to an alteration in the genome of the cell relative to a reference human genome.

**[0182]** In some alternatives, a system for editing at least one target gene in a cell is provided, the system comprising a nucleic acid encoding an endonuclease protein that targets at least one sequence in a cell, and at least one nucleic acid encoding at least one protein, which alone or together with other proteins modifies the substrate specificity of at least one ubiquitin ligase enzyme or enzyme complex in the cell, and, optionally, a vector that comprises a nucleic template for homologous gene targeting. In some alternatives of the system, the nuclease protein and the ubiquitin ligase substrate specificity modifying proteins are encoded on the same nucleic acid. In some alternatives of the system, the nuclease protein and the ubiquitin ligase substrate specificity modifying proteins are encoded on two or more nucleic acids. In some alternatives of the system, the nucleic template for homologous gene targeting is a DNA. In some alternatives of the system, the nucleic template for homologous gene targeting is an RNA. In some alternatives of the system, the cell is a eukaryotic cell. In some alternatives of the system, the cell is a mammalian cell. In some alternatives of the system, the cell is a human cell. In some alternatives of the system, the cell is a primary cell. In some alternatives of the system, the cell is not a transformed cell. In some alternatives of the system, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell. In some alternatives of the system, the vector is a viral vector. In some alternatives of the system, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the system, the viral vector is a lentiviral vector.

**[0183]** In some alternatives of the system, the nucleic acid encoding the Cas9 nuclease, a derivative, or fragment thereof is an mRNA. In some alternatives of the system, the nucleic acid sequence encoding the nuclease is codon optimized for expression in a

eukaryotic cell, such as a human cell. In some alternatives of the system, the nucleic acid or nucleic acids encoding any of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins are mRNA. In some alternatives of the system, the one or more mRNAs encoding ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins are codon optimized for expression in a eukaryotic cell, such as a human cell.

[0184] In some alternatives of the system, the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins is the adenoviral protein E4ORF6 of any adenoviral serotype. In some alternatives of the system, the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins is E1B55K of any adenovirus serotype. In some alternatives of the system, the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins is an E1B55K mutant, said mutant having an one or more amino acid changes relative to the wild type E1B55K protein which cause an alteration in the mutant protein's ability to modify cellular ubiquitin ligase substrate specificity relative the wild type E1B55K protein. In some alternatives of the system, the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins comprises the amino acid sequence set forth in SEQ ID NO: 2. In some alternatives of the system, the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins comprises the amino acid sequence set forth in SEQ ID NO: 4. In some alternatives of the system, the ubiquitin ligase substrate specificity modifying proteins are one or more viral proteins.

[0185] In some alternatives of the system, the nucleic acid sequence encoding the endonuclease RNA is operably linked to a regulatory element. In some alternatives of the system, the nucleic acid sequence encoding the endonuclease RNA is operably linked to a U6 promoter. In some alternatives of the system, the nucleic acid sequence encoding the endonuclease RNA is constitutively expressed. In some alternatives, the nucleic acid sequence encoding the endonuclease RNA is operably linked to the U6 promoter and constitutively expressed.

[0186] In some alternatives, a method of editing at least one target gene in a cell is provided, the method comprising introducing into a cell a nucleic acid sequence encoding an endonuclease, introducing into said cell at least one nucleic acid sequence encoding a ubiquitin ligase enzyme/enzyme complex substrate specificity modifying protein; and



optionally introducing into said cell a vector that comprises a nucleic acid template capable of homologous gene targeting of at least one genomic sequence in the cell. In some alternatives of the method, the nucleic template for homologous gene targeting is a DNA. In some alternatives of the method, the nucleic template for homologous gene targeting is an RNA.

[0187] In some alternatives of the method, the cell is a eukaryotic cell. In some alternatives, a method the cell is a mammalian cell. In some alternatives of the method, the cell is a human cell. In some alternatives of the method, the cell is a primary cell. In some alternatives of the method, the cell is not a transformed cell. In some alternatives of the method, the cell is a primary lymphocyte, a CD34<sup>+</sup> stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell. In some alternatives of the method, the vector comprising the first nucleic acid sequence encoding the endonuclease is a viral vector. In some alternatives, Cas9, a derivative, or fragment thereof is encoded in a viral vector. In some alternatives, a guide RNA is encoded in a viral vector. In some alternatives, a Cas9, a derivative, or fragment thereof and a guide RNA are encoded together in a viral vector. In some alternatives, a Cas9, a derivative, or fragment thereof and a guide RNA encoded together in a viral vector is used in combination with one or more Ad5 protein encoded by mRNA. In some alternatives of the method, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the method, the viral vector is a lentiviral vector. In some alternatives of the method, the nucleic acids encoding the nuclease and/or the ubiquitin ligase substrate specificity modifying proteins are mRNA. In some alternatives of the method, the mRNAs are codon optimized for expression in a eukaryotic cell, such as a human. In some alternatives of the method, the endonuclease protein is a meganuclease, a TALEN, a zinc finger nuclease, or a MegaTAL. In some alternatives of the method, one of the ubiquitin ligase substrate specificity modifying proteins is E4ORF6 of any adenoviral serotype. In some alternatives of the method, one of the ubiquitin ligase substrate specificity modifying proteins is E1B55K of any adenoviral serotype. In some alternatives of the method, one of the ubiquitin ligase substrate specificity modifying proteins comprises the amino acid sequence set forth in SEQ ID NO: 2. In some alternatives of the method, one of the ubiquitin ligase substrate specificity modifying proteins comprises the amino acid sequence set forth in SEQ ID NO: 4. In some alternatives of the system, the

nuclease targets a gene of interest. Some non-limiting examples of target genes of interest include TCR $\alpha$ , TCR $\beta$ , PD-1, Tim3, Lag3, TIGIT or HBB.

[0188] In some alternatives of the method, the nucleic acid sequences are transiently introduced into the cell. In some alternatives of the method, the nucleic acid sequences are not permanently introduced into the cell. In some alternatives of the method, introducing the nucleic acid sequences into the cell does not transform the cell. In some alternatives of the system, the target gene intended for homologous gene targeting is a gene of interest. Some non-limiting examples of target genes of interest include TCR $\alpha$ , TCR $\beta$ , PD-1, Tim3, Lag3, TIGIT or HBB. In some alternatives of any of the system or any of the method described herein, the nucleic acid sequences are provided on a vector. In some alternatives, a method of editing at least one target gene in a cell is provided, the method comprising introducing into the cell any of the alternatives of the system described herein.

[0189] In some alternatives, a method of treating, ameliorating, or inhibiting a disease and/or a condition in a subject, the method comprises providing to the subject having a disease and/or a condition and in need thereof, any of the alternatives of the system described herein. Some non-limiting examples of diseases and/or conditions can be sickle cell disease, hypercholesterolemia, cancer, autoimmune disease, inherited disorder of metabolism, immunodeficiency or genetic disease such as any disease due to a functional deficit in a gene product due to an alteration in the genome of the cell relative to a reference human genome.

[0190] While the foregoing written description enables one of ordinary skill to make and use what is considered presently to be the best mode thereof, those of ordinary skill will understand and appreciate the existence of variations, combinations, and equivalents of the specific embodiment, method, and examples herein. The present alternatives should therefore not be limited by the herein described embodiment, method, and examples, but by all alternatives and methods within the scope and spirit of the present alternatives. The following examples are presented for illustrative purposes and should not be construed as being limiting.

#### Further Alternatives

[0191] Alternative of Cas9 described herein can be used in any and all of the alternatives of the system and/or method described herein. Some alternatives of Cas9 are disclosed in the following references which are hereby incorporated by reference in their entirety (Gilbert et al, Cell, Jul 18, 154(2): 442–451, 2013; Hilton et al, Nat Biotechnol. Apr 6. doi: 10.1038/nbt.3199, 2015; Qi et al, Cell, Feb 28; 152(5): 1173–1183, 2013; Esvelt et al, Nature Methods 10, 1116–1121, 2013; Zetsche et al, Nature Biotechnology, 33, 139–142, 2015; all references incorporated by reference in their entirety herein). The ability of Cas9 to co-localizing RNA, DNA and protein to a target region of a genome offers unprecedented control over cellular organization, regulation and behavior using the Cas9 system (Mali et al).

[0192] The CRISPR-associated catalytically inactive variant of *S. pyogenes* Cas9 (dCas9 or nuclease null Cas9) can be used for RNA-guided DNA targeting (Gilbert et al; incorporated by reference in its entirety herein). Fusion of dCas9 to effector domains of regulatory proteins (for example, a transcriptional activator (hereinafter, activator domain) or a transcriptional repressor (hereinafter, repressor domain) enables stable and efficient transcriptional regulation in human and yeast cells (Gilbert et al; incorporated by reference in its entirety herein). The site-specific delivery of dCas9 is determined solely by a guide RNA (Gilbert et al). CRISPR interference (CRISPRi)-mediated transcriptional repression, which entails coupling dCas9 to a transcriptional repressor domain, can robustly and specifically silence gene expression in eukaryotic cells (Gilbert et al; incorporated by reference in its entirety herein) and *Escherichia coli* (Qi et al; incorporated by reference in its entirety herein).

[0193] Thus, in some alternatives, a catalytically inactive Cas9 (dCas9) is used which does not cause a double stranded DNA break. In some alternatives, a dCas9 is fused to an activator domain. In some alternatives, a dCas9 is fused to a repressor domain. In some alternatives, a dCas9-activator domain is encoded by an mRNA. In some alternatives, a dCas9-repressor domain is encoded by an mRNA. In some alternatives, an mRNA encoding dCas9-activator domain is used in combination an AAV vector encoding a guide RNA. In some alternatives, an mRNA encoding dCas9-repressor domain is used in combination an AAV vector encoding a guide RNA. In some alternatives, an mRNA encoding dCas9-activator domain is used in combination an mRNA encoding an Ad5 protein

and an AAV vector encoding a guide RNA. In some alternatives, an mRNA encoding dCas9-repressor domain is used in combination an mRNA encoding an Ad5 protein and an AAV vector encoding a guide RNA. In some alternatives, a dCas9-activator domain activates transcription. In some alternatives, a dCas9-repressor domain represses transcription. In some alternatives, one or more Ad5 proteins further increases activation of transcription by a dCas9-activator domain fusion. In some alternatives, one or more Ad5 proteins further increases repression of transcription by dCas9-repressor domain fusion.

[0194] Creating a fusion of dCas9 with a catalytic core of a human acetyltransferase led to acetylation of histone H3, resulting in robust transcriptional activation of target genes from promoters and both proximal and distal enhancers (Hilton et al; incorporated by reference in its entirety herein). Thus, in some alternatives, dCas9 is fused to a functional catalytic domain of a histone modifying enzyme. In some alternatives, dCas9 is fused to a functional catalytic domain, for example, a catalytic core of a histone acetyltransferase. In some alternatives, dCas9 is fused to a functional catalytic domain of a histone deacetylase. In some alternatives, dCas9 is fused to a functional catalytic domain of a histone methyl transferase. In some alternatives, dCas9 fused to a functional catalytic domain of a histone modifying enzyme can activate transcription. In some alternatives, dCas9 fused to a functional catalytic domain of a histone modifying enzyme can repress transcription.

[0195] A set of fully orthogonal Cas9 proteins mediated simultaneous and independently targeted gene regulation and editing in bacteria and in human cells (Esvelt et al). In some alternatives, the Cas9 variants recognize different variants of PAM (Kleinstiver et al). A PAM is a DNA sequence immediately following a DNA sequence targeted by Cas9. Thus, in some alternatives, Cas9 is from *S. pyogenes*. In some alternatives, an *S. pyogenes* Cas9 variant can recognize an NGG protospacer PAM. In some alternatives, an *S. pyogenes* Cas9 variant can recognize a PAM that is not NGG. In some alternatives, Cas9 variants can be from *Staphylococcus aureus*. In some alternatives, Cas9 variants can be from *Streptococcus thermophiles*. In some alternatives, Cas9 variants can be from *Neisseria meningitidis*. In some alternatives, Cas9 variants can be is from *Treponema denticola*. In some alternatives, the sequence of Cas9 can be a Cas9 consensus sequence derived from two or more of the organisms provided herein, for example, *Staphylococcus aureus* and *Streptococcus thermophiles*. In some alternatives, the sequence of Cas9 can be from any of

the organisms provided herein and codon optimized for expression in any of the other organisms provided herein.

[0196] Examples of desirable alternatives of Cas9 include Cas9 from *S. pyogenes* and variants thereof. In some alternatives, Cas9 can be from *S. pyogenes*. In some alternatives, Cas9 can be a variant of Cas9 from *S. pyogenes*. In some alternatives, Cas9 can be an ortholog of Cas9 from *S. pyogenes*. In some alternatives, Cas9 can be a variant of an ortholog of Cas9 from *S. pyogenes*. In some alternatives, Cas9 is catalytically inactive. In some alternatives, a dCas9 is inactive because of mutations. In some alternatives, a dCas9 is inactive because of mutations D10A and H841A in the protein sequence.

[0197] A modular Cas9 architecture for inducible genome editing and transcription modulation was reported in which Cas9 was split into an N terminal piece and a C terminal piece, each catalytically active and fused to a dimerization domain. The two dimerization domains of each of the two Cas9 pieces were brought together by a small molecule (for example, a drug) to generate a functional Cas9 capable of generating a double strand break (Zetsche et al; incorporated by reference in its entirety herein). Thus, in some alternatives, an N terminal fragment of Cas9 is used. In some alternatives, a C terminal fragment of Cas9 is used. In some alternatives, an N terminal fragment of Cas9 is used in combination a C terminal fragment of Cas9. In some alternatives, an N terminal fragment of Cas9 is fused to a dimerization domain. In some alternatives, a C terminal fragment of Cas9 is fused to a dimerization domain. In some alternatives, the dimerization domains dimerize. In some alternatives, the dimerization domains do not dimerize. In some alternatives, the dimerization domains dimerize in the presence of a small molecule, for example, a drug. In some alternatives, the dimerization domains do not dimerize in the presence of a small molecule, for example, a drug. In some alternatives, the dimerization domains dimerize in the absence of a small molecule, for example, a drug. In some alternatives, the dimerization domains do not dimerize in the absence of a small molecule, for example, a drug. In some alternatives, dimerization of the dimerization domains brings the N and C terminal fragments of Cas9 into close proximity. In some alternatives, a double stranded DNA break is created at a target genomic locus when the two Cas9 fragments are brought into close proximity. Examples of desirable alternatives of N terminal fragments of Cas9 can be Cas9 fragments extending from amino acids 1-203, 1-256, 1-311, 1-535, 1-573, 1-714, 1-1004, 1-1055, 1-

1115, 1-1153 or 1-1246. Examples of desirable alternatives of C terminal fragments of Cas9 can be Cas9 fragments extending from amino acids 204-1368, 257-1368, 312-1368, 536-1368, 574-1368, 715-1368, 1005-1368, 1056-1368, 1116-1368, 1154-1368 or 1247-1368.

Endonuclease-based gene editing in primary human T-cells

[0198] Many future therapeutic applications of RNA-guided endonucleases are likely to require their use to promote gene targeting, thus necessitating development of methods that provide for delivery of three components - endonuclease, guide RNAs and recombination templates - to primary cells rendered proficient for homology-directed repair to achieve gene disruption and/or gene targeting for recombination.

[0199] For example, many future therapeutic applications of CRISPR/Cas9 and related RNA-guided endonucleases are likely to require their use to promote gene targeting, thus necessitating development of methods that provide for delivery of three components - Cas9, guide RNAs and recombination templates - to primary cells rendered proficient for homology-directed repair. Thus, in some alternatives, a CRISPR gene editing in primary human T-cells using mRNA/AAV co-delivery is contemplated.

[0200] In some alternatives, a high efficiency CRISPR/Cas9-mediated gene editing in primary human T-cells using mutant adenoviral E4ORF6/E1B55K “helper” proteins are provided.

[0201] In some alternatives, an electroporation/transduction co-delivery method that utilizes mRNA to express Cas9 in conjunction with mutant adenoviral E4ORF6 and E1B55K helper proteins is provided. In some alternatives, the mutant adenoviral E4ORF6 and E1B55K helper proteins serve to transiently enhance both the target cells’ permissiveness to AAV transduction and its gene editing efficiency.

[0202] In some alternatives, the system and/or method provided herein can be applied for efficient gene disruption at one or more loci and/or simultaneously at multiple loci in cells in general is contemplated. In some alternatives, the system and/or method provided herein can be applied for efficient homologous gene targeting at one or more loci and/or simultaneously at multiple loci in cells in general is contemplated. In some alternatives, the system and/or method provided herein can be applied for efficient gene

disruption and homologous gene targeting at one or more loci and/or simultaneously at multiple loci in cells in general is contemplated.

[0203] In some alternatives, the system and/or method provided herein can be applied for efficient gene disruption at one or more loci and/or simultaneously at multiple loci in primary cells is contemplated. In some alternatives, the system and/or method provided herein can be applied for efficient homologous gene targeting at one or more loci and/or simultaneously at multiple loci in primary cells is contemplated. In some alternatives, the system and/or method provided herein can be applied for efficient gene disruption and homologous gene targeting at one or more loci and/or simultaneously at multiple loci in primary cells is contemplated.

[0204] In some alternatives, the system and/or method provided herein can be applied for efficient gene disruption at one or more loci and/or simultaneously at multiple loci in primary T-cells is contemplated. In some alternatives, the system and/or method provided herein can be applied for efficient homologous gene targeting at one or more loci and/or simultaneously at multiple loci in primary T-cells is contemplated. In some alternatives, the system and/or method provided herein can be applied for efficient gene disruption and homologous gene targeting at one or more loci and/or simultaneously at multiple loci in primary T-cells is contemplated.

[0205] In some alternatives, the system and/or method provided herein can be applied for both efficient gene disruption and/or homologous gene targeting at one or more loci and/or simultaneously at multiple loci in human cells in general, illustrating its broad potential for application in translational gene editing. For example, in some alternatives, this method can be applied for both efficient gene disruption and/or homologous gene targeting at multiple loci in primary human T-cells, illustrating its broad potential for application in translational gene editing.

#### Preferred Alternatives

[0206] In some alternatives, a system for editing at least one target gene in a cell, the system comprising a first nucleic acid sequence, or a set of nucleic acid sequences, encoding one or more CRISPR guide RNA, wherein the one or more CRISPR guide RNA is complimentary to the at least one target gene in a cell and, wherein the first nucleic acid

sequence, or the set of nucleic acid sequences, may be comprised in one or more vectors, but not required to be comprised in one or more vectors; a Cas9 protein or a second nucleic acid sequence encoding a Cas9 protein; a third nucleic acid sequence encoding a first adenoviral protein; and a fourth nucleic acid sequence encoding a second adenoviral protein.

[0207] In some alternatives of the system, the cell is a eukaryotic cell. In some alternatives of the system, the cell is a mammalian cell. In some alternatives of the system, the cell is a human cell. In some alternatives of the system, the cell is a primary cell. In some alternatives of the system, the cell is not a transformed cell. In some alternatives of the system, the cell is a primary lymphocyte, a CD34<sup>+</sup> stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

[0208] In some alternatives of the system, the vector is a viral vector. In some alternatives of the system, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the system, the AAV vector is a self-complementary vector. In some alternatives of the system, the AAV vector is a single stranded vector. In some alternatives of the system, the AAV vector is a combination of a self-complementary vector and a single stranded vector.

[0209] In some alternatives of the system, the second nucleic acid encoding the Cas9 protein is an mRNA. In some alternatives of the system, the second nucleic acid sequence encoding the Cas9 protein is codon optimized for expression in a eukaryotic cell, such as a human cell.

[0210] In some alternatives of the system, the Cas9 protein is from *S. pyogenes*.

[0211] In some alternatives of the system, the third nucleic acid encoding the first adenoviral protein is an mRNA. In some alternatives of the system, the third nucleic acid encoding the first adenoviral protein is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the first adenoviral protein is from an AAV of serotype 5.

[0212] In some alternatives of the system, the first adenoviral protein is a wild type E4ORF6. In some alternatives of the system, the sequence of the wild type E4ORF6 is set forth in SEQ ID NO: 3. In some alternatives of the system, the first adenoviral protein is a mutant E4ORF6. In some alternatives of the system, the mutant E4ORF6 protein is an AXA mutant. In some alternatives of the system, the AXA mutant is set forth in SEQ ID NO: 23.



[0213] In some alternatives of the system, the fourth nucleic acid encoding the second adenoviral protein is an mRNA. In some alternatives of the system, the fourth nucleic acid encoding the second adenoviral protein is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the second adenoviral protein is from an AAV of serotype 5.

[0214] In some alternatives of the system, the second adenoviral protein is a wild type E1B55K. In some alternatives of the system, the sequence of the wild type E1B55K is set forth in SEQ ID NO: 1. In some alternatives of the system, the second adenoviral protein is a mutant E1B55K. In some alternatives of the system, the mutant E1B55K is an H373A mutant. In some alternatives of the system, the sequence of the H373A mutant is set forth in SEQ ID NO: 2. In some alternatives of the system, the mutant E1B55K is an H354 mutant. In some alternatives of the system, the sequence of the H354 mutant is set forth in SEQ ID NO: 4. In some alternatives of the system, the mutant E1B55K is an R240A mutant. In some alternatives of the system, the sequence of R240A mutant is set forth in SEQ ID NO: 22.

[0215] In some alternatives of the system, the first, second, third and fourth nucleic acid sequences are operably linked to regulatory elements that are operable in a eukaryotic cell, such as a human cell.

[0216] In some alternatives of the system, the first nucleic acid sequence encoding one or more CRISPR guide RNA is operably linked to a regulatory element. In some alternatives of the system, the first nucleic acid sequence encoding one or more CRISPR guide RNA is operably linked to a U6 promoter. In some alternatives of the system, when the first nucleic acid sequence encodes more than one CRISPR guide RNA, each guide RNA is operably linked to a separate regulatory element.

[0217] In some alternatives of the system, the first nucleic acid sequence encoding the CRISPR guide RNA is constitutively expressed. In some alternatives of the system, the first nucleic acid sequence encoding the CRISPR guide RNA is transiently expressed.

[0218] In some alternatives of the system, the CRISPR guide RNA sequences for the TCR $\alpha$  gene are set forth in SEQ ID NO: 5, SEQ ID NO: 15, SEQ ID NO: 16 and/or SEQ ID NO: 17.

[0219] In some alternatives of the system, the CRISPR guide RNA sequence for the PD1 gene is set forth in SEQ ID NO: 18, for the TIGIT gene is set forth in SEQ ID NO: 19, for the Lag3 gene is set forth in SEQ ID NO: 20, and for the Tim3 gene is set forth in SEQ ID NO: 21.

[0220] In some alternatives of the system, the system can be used for gene knockout, gene knock-in, or both.

[0221] In some alternatives of the system, the first nucleic acid sequence, or the set of nucleic acid sequences, and the Cas9 protein or the second nucleic acid sequence encoding the Cas9 protein, are collectively replaced by a fifth nucleic sequence and a sixth nucleic acid sequence, wherein the fifth and sixth nucleic acid sequences comprise mRNAs encoding a left component and a right component of a TALEN nuclease, respectively.

[0222] In some alternatives, a method for editing at least one target gene in a cell, the method comprising introducing into a cell a first nucleic acid sequence, or a set of nucleic acid sequences, encoding one or more CRISPR guide RNA, wherein the one or more CRISPR guide RNA is complimentary to at least one target gene in the cell; introducing into the cell a Cas9 protein or a second nucleic acid sequence encoding a Cas9 protein; introducing into the cell a third nucleic acid sequence encoding a first adenoviral protein; and introducing into the cell a fourth nucleic acid sequence encoding a second adenoviral protein.

[0223] In some alternatives of the method, the cell is a eukaryotic cell. In some alternatives of the method, the cell is a mammalian cell. In some alternatives of the method, the cell is a human cell. In some alternatives of the method, the cell is a primary cell. In some alternatives of the method, the cell is not a transformed cell. In some alternatives of the method, the cell is a primary lymphocyte, a CD34<sup>+</sup> stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

[0224] In some alternatives of the method, the vector comprising the first nucleic acid sequence, or a set of nucleic acid sequences, encoding the one or more CRISPR guide RNAs, may be comprised in one or more vectors, but not required to be comprised in one or more vectors. In some alternatives of the method, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the method, the AAV vector is a self-complementary vector. In some alternatives of the method, the AAV vector is a single

stranded vector. In some alternatives of the method, the AAV vector is a combination of a self-complementary vector and a single stranded vector.

[0225] In some alternatives of the method, the second, third and fourth nucleic acid sequences are mRNA. In some alternatives of the method, the mRNAs are codon optimized for expression in a eukaryotic cell, such as a human.

[0226] In some alternatives of the method, the Cas9 protein is from *S. pyogenes*.

[0227] In some alternatives of the method, the first adenoviral protein is from an AAV of serotype 5. In some alternatives of the method, the first adenoviral protein is a wild type E4ORF6. In some alternatives of the method, the sequence of the wild type E4ORF6 is set forth in SEQ ID NO: 3.

[0228] In some alternatives of the method, the first adenoviral protein is a mutant E4ORF6. In some alternatives of the method, the mutant E4ORF6 protein is an AXA mutant. In some alternatives of the method, the sequence of the AXA mutant is set forth in SEQ ID NO: 23.

[0229] In some alternatives of the method, the second adenoviral protein is from an AAV of serotype 5. In some alternatives of the method, the second adenoviral protein is a wild type E1B55K. In some alternatives of the method, the sequence of the wild type E1B55K is set forth in SEQ ID NO: 1. In some alternatives of the method, the second adenoviral protein is a mutant E1B55K. In some alternatives of the method, the mutant E1B55K is an H373A mutant. In some alternatives of the method, the sequence of the H373A mutant is set forth in SEQ ID NO: 2. In some alternatives of the method, the mutant E1B55K is an H354 mutant. In some alternatives of the method, the sequence of the H354 mutant is set forth in SEQ ID NO: 4. In some alternatives of the method, the mutant E1B55K is an R240A mutant. In some alternatives of the method, the sequence of R240A mutant is set forth in SEQ ID NO: 22. In some alternatives of the method, wherein any one of the E4ORF6 variants can be used in combination with any one the E1B55K variants.

[0230] In some alternatives of the method, the number of genes that are simultaneously knocked out is 2 – 10. In some alternatives of the method, the number of genes that are simultaneously knocked out is 2 – 5. In some alternatives of the method, the dose of mRNA is 0.01 µg to 1 µg. In some alternatives of the method, there is a 1.5 fold to 9 fold increase in the rate of mutations.

[0231] In some alternatives of the method, the CRISPR guide RNA sequences for the TCR $\alpha$  gene are set forth in SEQ ID NO: 5, SEQ ID NO: 15, SEQ ID NO: 16 and/or SEQ ID NO: 17.

[0232] In some alternatives of the method, the CRISPR guide RNA sequence for the PD1 gene is set forth in SEQ ID NO: 18, for the TIGIT gene is set forth in SEQ ID NO: 19, for the Lag3 gene is set forth in SEQ ID NO: 20, and for the Tim3 gene is set forth in SEQ ID NO: 21.

[0233] In some alternatives of the method, the first, second, third and fourth nucleic acid sequences are transiently introduced into the cell. In some alternatives of the method, the first, second, third and fourth nucleic acid sequences are not permanently introduced into the cell. In some alternatives of the method, introducing the first, second, third and fourth nucleic acid sequences into the cell do not transform the cell.

[0234] In some alternatives of the system, the target gene is a gene of interest. In some alternatives of the method, the target gene is a gene of interest.

[0235] In some alternatives of the system and/or method provided herein, the third nucleic acid sequence and fourth nucleic acid sequence are comprised in the AAV vector.

[0236] In some alternatives of the method, the second nucleic acid sequence is introduced into the cell first followed by the AAV vector comprising the first nucleic acid sequence, the second nucleic acid sequence, and the third nucleic acid sequence.

[0237] In some alternatives of the method, the AAV vector comprising the first nucleic acid sequence, the second nucleic acid sequence, and the third nucleic acid sequence is introduced into the cell first followed by second nucleic acid sequence.

[0238] In some alternatives of the method, the second nucleic acid sequence and the AAV vector comprising the first nucleic acid sequence, the second nucleic acid sequence, and the third nucleic acid sequence are co-delivered and introduced into the cell at the same time.

[0239] In some alternatives of the method, the system can be used for gene knockout, gene knock-in, or both.

[0240] In some alternatives of the method, the first nucleic acid sequence, or the set of nucleic acid sequences, and the Cas9 protein or the second nucleic acid sequence

encoding the Cas9 protein, are collectively replaced by a fifth nucleic acid sequence and a sixth nucleic acid sequence, wherein the fifth and sixth nucleic acid sequences comprise mRNAs encoding a left component and a right component of a TALEN nuclease, respectively.

[0241] In some alternatives, a method for editing at least one target gene in a cell, comprising introducing into a cell any of the alternatives of the system provided herein.

[0242] In some alternatives, a method for treating, ameliorating, and/or inhibiting a disease and/or a condition in a subject, the method comprising providing to a subject having a disease and/or a condition any of the alternatives of the system provided herein.

[0243] In some alternatives, a system for editing at least one target gene in a cell and a method of using the system for genome editing are contemplated. In some alternatives, the target gene is a gene of interest, which is edited by can be either gene disruption. In some alternatives, the cell is a primary T-cell.

[0244] In some alternatives, the system comprises a first nucleic acid sequence encoding one or more guide RNA and a second nucleic acid sequence encoding an endonuclease protein. In some alternatives, the endonuclease can be any of the endonucleases disclosed herein and/or alternative variants and modifications of that are within the scope of the current disclosure. In some alternatives, the second nucleic acid is an mRNA and encodes any of the endonuclease protein. In some alternatives, the second nucleic acid sequence encoding the endonuclease protein is codon optimized for expression in a eukaryotic cell. In some alternatives, the one or more guide RNA is complimentary to the at least one target gene in a cell. In some alternatives, the one or more guide RNA is provided in a vector. In some alternatives, the vector can be a viral vector. In some alternatives, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives, the AAV vector can be a self-complementary vector, or a single stranded vector, or a combination of a self-complementary vector and a single stranded vector.

[0245] As many cell types possess a post-entry restriction on AAV vectors that renders AAV-mediated expression of transgenes, including guide RNAs, very inefficient, proteins that suppress the post-entry restriction on AAV vectors are provided on additional nucleic acid sequences. Thus, in some alternatives, the system comprises a third nucleic acid sequence encoding a first adenoviral protein and a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives, the third nucleic acid and the fourth nucleic

acid are mRNAs, which are codon optimized for expression in a eukaryotic cell. In some alternatives, the nucleic acid sequences can either be introduced into the cell sequentially and in any order or be introduced into the cell simultaneously.

[0246] In some alternatives, the first and second adenoviral proteins are from an AAV of serotype 5. In some alternatives, the first adenoviral protein is a wild type E4ORF6, or an AXA mutant of E4ORF6. In some alternatives, the second adenoviral protein is a wild type E1B55K, or an H373A mutant of E1B55K, or an H354 mutant of E1B55K, or an R240A mutant of E1B55K. While the mutant proteins are not as efficient as wild type proteins at suppressing at post-entry restriction on AAV vectors, they are relatively more efficient at enhancing gene targeting.

[0247] In some alternatives, the first, second, third and fourth nucleic acid sequences are operably linked to regulatory elements that are operable in a eukaryotic cell. In some alternatives, the first nucleic acid sequence can encode one or more guide RNA and each guide RNA is operably linked to a separate regulatory element. In some alternatives, the first nucleic acid sequence encoding the guide RNA is transiently expressed in the cell. In some alternatives, the one or more guide RNA sequences are complementary to the TCR $\alpha$  gene, the PD1 gene, the TIGIT gene, the Lag3 gene, and/or the Tim3 gene. In some alternatives, the system also comprises nucleic acid sequences regions that bear homology to the gene of interest.

[0248] In some alternatives, the system comprising the above-mentioned components is introduced into the primary T cell. These nucleic acid sequence regions that bear homology to the gene of interest direct the endonuclease-based system to be targeted to a specific gene. Targeting to the specific gene can result in a gene knockout, a gene knock-in, or both.

[0249] Depending on the nature of gene targeting approach (knockout or knock-in) the result can be determined by flow cytometry, or sequencing or both. For example, if the system is used for knocking out a gene of interest that encodes a cell surface-expressed protein, flow cytometry can be used to check for suppressed and/or lack of cell surface expression of the protein. Or, if the system is used for knocking out a gene of interest that encodes an intracellularly-expressed protein, flow cytometry can be used to check for suppressed and/or lack of intracellular expression of the protein. Or, if the system is used for

knock-in, for example, knock-in of a dominant epitope of an antigen into a gene of interest that encodes a cell surface-expressed protein, flow cytometry can be used to check for cell surface expression of the dominant epitope. Or, if the system is used for knock-in, for example, knock-in of a dominant epitope of an antigen into a gene of interest that encodes an intracellularly-expressed protein, flow cytometry can be used to check for intracellular expression of the dominant epitope. In any of the above cases, the DNA sequencing of genomic DNA can also be used to confirm the desired gene targeting event. In some alternatives, the number of genes that can be simultaneously targeted for knockout, knock-in or both can be 2 – 5.

**[0250]** In some alternatives, the T-cells in which the gene of interest has been targeted are enriched by cell sorting or other cell enrichments methods. If the enriched cells are intended to be used for treating, ameliorating, and/or inhibiting a disease and/or a condition in a subject, the enriched cells are administered to the subject. For example, in some alternatives, the subject may have a disease and/or a condition because the T-cells in the subject are “exhausted,” and therefore, are not effective at clearing one or more antigens from the disease and/or condition.

**[0251]** By targeting one or more “exhaustion” markers (e.g., PD1, TIGIT, Lag3 and Tim3), the “exhausted” condition of T-cells can be reversed. In some alternatives, the targeted T-cells are administered to the subject (e.g., via the intravenous route). Follow-up testing is performed on the subject to assess the status of the targeted T-cells and their effect on the disease and/or condition. For example, in some alternatives, blood is drawn from the subject at various intervals following administration of the targeted T-cells. In some alternatives, testing is performed to determine whether the administered T-cells are activated, for example, by assessing their secretion of the cytokine (e.g., IL-2, TNF $\alpha$ ). In some alternatives, testing is also performed to determine the effect of administration of the targeted T-cells on the disease and/or condition.

**[0252]** Any of the systems and/or methods provided herein in regard to humans can also be provided to one or more companion animals or animals domesticated for commercial interest. A companion animal, without limitations, can be dog, cat, guinea pig, mouse, rat, rabbit or hamster. An animal domesticated for commercial interest, without limitations, can be goat, sheep, cow, pig, monkey or elephant.

[0253] Detailed below are some non-limiting examples with references to figures illustrating how CRISPR gene editing can be implemented. These examples are not meant to be limiting and other endonucleases and alternatives of the system and methods comprising other endonucleases and variants and modifications of these exemplary alternatives are possible without undue experimentation. All such variations and modifications are within the scope of the current teachings.

Example 1: An mRNA/AAV delivery method effects Cas9-mediated gene disruption in primary human T-cells

[0254] In some alternatives, CRISPR gene editing in primary human T-cells using mRNA/AAV co-delivery is provided.

[0255] AAV6 capsid-based AAV vectors are able to achieve sufficient transduction efficiencies of human primary T-cells and CD34+ cells to serve as templates for TALEN and other nuclease-catalyzed homologous recombination. Thus, it was hypothesized that AAV vectors might serve as safe and effective vectors for transient expression of guide RNAs as well as delivery of recombination templates for Cas9-induced gene targeting.

[0256] In some alternatives, cell used can be, without limitations, a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

[0257] In some alternatives, the duration of transient expression of guide RNAs can be 1 min to 1 week or within a range defined by any two of the aforementioned values.

[0258] In some alternatives, the size of the recombination template can range from 0.05 kb to 1 kb. In some alternatives, the length of the homology arm can be 0.05, 0.075, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95 or 1 kb or within a range defined by any two of the aforementioned values.

[0259] Through this series of experiments and our previous experience with other nuclease platforms, it was observed that performing the mRNA electroporation step first appeared to work most reliably. Thus, in some alternatives, mRNA electroporation followed by AAV transduction was adopted as our standard approach. In some preferred alternatives, mRNA electroporation is performed before AAV transduction.



[0260] In some alternatives, to evaluate the potential of an mRNA/AAV delivery method in which spCas9 was expressed through mRNA electroporation, and an AAV vector was used to provide guide RNA expression, an AAV construct was generated which included both a U6 promoter driven guide RNA cassette and an MND promoter driven GFP cassette - the latter provides for tracking of AAV transduction efficiency.

[0261] **FIG. 1A**, top panel, shows a schematic of mCherry and Cas9-T2A-mCherry constructs that were cloned in different in-house backbones to generate mRNA. **FIG. 1A**, middle and bottom panels, show schematic of guide position(s) within the TCR genomic locus. Self-complementary and single-stranded AAV vector backbones were used for expression of guides.

[0262] In some alternatives, one or more nucleases can be delivered using a single or a plurality of mRNAs. In some alternatives, 1 to 5 nucleases can be delivered using a single mRNA or a plurality of mRNAs. In some alternatives, 1, 2, 3, 4 or 5 nucleases can be delivered using a single mRNA or a plurality of mRNAs.

[0263] In some alternatives, delivery of nuclease(s), guide RNA(s), helper protein(s), template with homologous region(s), and any additional component(s) as may be required by AAV is contemplated. In some alternatives, delivery of any one of nuclease(s), guide RNA(s), helper protein(s), template with homologous region(s), and any additional component(s) as may be required by mRNA and the rest by AAV is contemplated. In some alternatives, delivery of any two of nuclease(s), guide RNA(s), helper protein(s), template with homologous region(s), and any additional component(s) as may be required by mRNA and the rest by AAV is contemplated. In some alternatives, delivery of any three of nuclease(s), guide RNA(s), helper protein(s), template with homologous region(s), and any additional component(s) as may be required by mRNA and the rest by AAV is contemplated. In some alternatives, delivery of any four of nuclease(s), guide RNA(s), helper protein(s), template with homologous region(s), and any additional component(s) as may be required by mRNA and the rest by AAV is contemplated. In some alternatives, delivery of nuclease(s), guide RNA(s), helper protein(s) and template with homologous region(s) by mRNA is contemplated.

[0264] In some alternatives, one or more reporters can be delivered using a single mRNA or a plurality of mRNAs. In some alternatives, 1 to 5 reporters can be delivered

using a single mRNA or a plurality of mRNAs. In some alternatives, 1, 2, 3, 4 or 5 reporters can be delivered using a single mRNA or a plurality of mRNAs.

[0265] In some alternatives, one or more reporters can be delivered using AAV transduction. In some alternatives, 1 to 5 reporters can be delivered using AAV transduction. In some alternatives, 1, 2, 3, 4 or 5 reporters can be delivered AAV transduction.

[0266] In some alternatives, one or more nucleases and one or more reporters can be delivered using a single mRNA or a plurality of mRNAs. In some alternatives, 1 to 5 nucleases and 1 to 5 reporters can be delivered using a single mRNA or a plurality of mRNAs. In some alternatives, 1, 2, 3, 4 or 5 nucleases and 1, 2, 3, 4 or 5 reporters can be delivered using a single mRNA or a plurality of mRNAs.

[0267] In some alternatives, mRNA electroporation of Cas9 (as a Cas9-T2A-mCherry fusion) was tested both before and after AAV transduction for guide delivery, and moderately efficient Cas9 cleavage was achieved within the constant region of the TCR $\alpha$  gene using several protocols with two different guides.

[0268] In some alternatives, one or more guide RNAs can be delivered using AAV transduction. In some alternatives, 1 to 5 guide RNAs can be delivered using AAV transduction. In some alternatives, 1, 2, 3, 4 or 5 guide RNAs can be delivered AAV transduction.

[0269] In some alternatives, the use of chemically modified guide RNAs is contemplated. In some alternatives, chemically modified guide RNAs can be provided as separate RNAs. Thus, in some alternatives when one or more guide RNAs are designed against one or more target genes of interest, each guide RNA is provided as a separate chemically-modified guide RNA. For example, when the use of 10 guide RNAs is contemplated against 10 separate target genes of interest, each guide RNA is a chemically-modified guide RNA and each guide RNA is separate and distinct RNA molecule from the other guide RNAs. In some alternatives, the 10 different guide RNAs can be introduced into a cell either sequentially in any order or simultaneously.

[0270] In some alternatives, when the use of Cas9 protein pre-complexed with guide RNAs in conjunction with adenoviral proteins is contemplated, the guide RNAs are provided as chemically modified guide RNAs, wherein when one or more guide RNAs are

designed against one or more target genes of interest, each guide RNA is provided as a separate chemically-modified guide RNA.

[0271] Thus, in some alternatives, mRNA electroporation can be performed before AAV transduction. In some alternatives, mRNA electroporation can be performed after AAV transduction. In some alternatives, mRNA and AAV can be co-delivered.

[0272] In some alternatives, for optimization of Cas9 mRNA transfection in primary human T-cells, CD4<sup>+</sup> T-cells were transfected with varying concentrations of Cas9-T2A-mcherry mRNA using the Neon electroporation system and cultured at 30°C for the initial 24 hrs, after which they were transferred to 37°C. Flow cytometry analysis of T-cells 24 hrs after electroporation with the indicated amounts of Cas9-T2A-mCherry mRNA (FIG. 1C). Percentages of mCherry positive cells are indicated in **FIG. 1C**.

[0273] In some alternatives, analysis of AAV-guide doses in primary human T-cells was performed by transfecting CD4<sup>+</sup> T-cells with 1µg of Cas9-T2A-mcherry mRNA. Two hours post-electroporation, cells were transduced with AAV expressing TCRα guide at MOI 600 and 6000 (corresponding to culture volume of 1% and 10%, respectively). Cells were cultured at 30°C for the initial 24 hrs, after which cells were transferred to 37°C and kept there for the duration of the experiment. Cells were analyzed by flow cytometry for loss of surface CD3 expression as an index of TCRα gene knockout on day 7 post EP/transduction (**FIG. 1D**).

[0274] In some alternatives, using the mRNA/AAV transduction protocol, a range of Cas9 mRNA and AAV-guide doses were evaluated (**FIG. 1C** and **FIG. 1D**) to determine ranges that maximize Cas9 cleavage efficiency and minimize toxicity. In some alternatives, while mRNA dose appeared to saturate (1 µg in our standard electroporation conditions). In some alternatives, the mRNA dose can range from 0.05 to 3 µg. In some alternatives, the mRNA dose can be 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75 or 3 µg or within a range defined by any two of the aforementioned doses.

[0275] In some alternatives, a dose-dependent increase in knockout with AAV up to the maximum tolerated MOI was observed. In some alternatives, the AAV dose can range from 60 to 60,000. In some alternatives, the AAV dose can range from 60, 125, 250, 500,

1,000, 2,000, 4,000, 8,000, 16,000, 30,000 or 60,000 or within a range defined by any two of the aforementioned doses.

[0276] In some alternatives, for T7 endonuclease I assay (T7EI) for cleavage following Cas9/AAV.sgRNA delivery into primary human T-cells, primary CD4<sup>+</sup> T-cells were electroporated with Cas9 mRNA followed by AAV.sgRNA transduction 2 hours later. Ten days following electroporation/transduction, genomic DNA was isolated from the cells, and T7 endonuclease assay was performed (**FIG. 1B**). Arrow indicates the expected position of DNA bands cleaved by T7EI (**FIG. 1B**).

[0277] In some alternatives, Cas9 cleavage was detected as indel formation demonstrated by T7 assay of amplicons surrounding the predicted target site in TCR $\alpha$  (**FIG. 1B**). In some alternatives, loss of surface TCR/CD3 complex expression by flow cytometry (TCR/CD3 complex expression requires expression of a functional TCR $\alpha$  chain (**FIG. 1D**).

[0278] In some alternatives, T7 Endonuclease I assay yielded similar levels of cutting efficiency for both TCR $\alpha$  and CCR5 loci.

[0279] In some alternatives, both single stranded and self-complementary AAV vectors were compared (**FIG. 1E**). sgTCR $\alpha$  in **FIG. 1E** indicates single guide TCR $\alpha$ . In some alternatives, flow cytometric comparison was performed of TCR $\alpha$  knockout with scAAV and ssAAV-GFP by electroporating primary T-cells with mRNA encoding for control mCherry or Cas9-T2A-mCherry proteins, rested for 3 hours, and transduced with AAV driving guide RNA expression. Cells were cultured at 30°C for the initial 24 hours, after which cells were transferred to 37°C. Cells were analyzed using flow cytometry for mCherry and GFP expression 24 and 96 hours following electroporation/transduction, and surface CD3 expression was analyzed at 7 days post electroporation/transduction.

[0280] In some alternatives, no significant differences was observed between self-complementary and single stranded AAV in the efficiency of Cas9 target cleavage as assessed by loss of surface CD3 (**FIG. 1E**). Thus, in some alternatives, Cas9-mRNA and guide-AAV mediated efficient TCR knockout in primary cells and both self-complementary and single stranded guide RNA yielded similar levels of CD3 knockout.

[0281] Thus, in some alternatives the AAV vector can be single stranded. In some alternatives the AAV vector can be self-complementary. In some alternatives the AAV vector can be both single stranded and self-complementary.

Example 2: Adenoviral serotype 5 E4ORF6 and E1B55K helper proteins enhance permissiveness of primary human T-cells to AAV transduction

[0282] In some alternatives, enhanced AAV-mediated gene expression in primary human T-cells using adenoviral E4ORF6/E1B55K proteins to relieve post-entry AAV restriction mechanisms is provided.

[0283] The dependence of Cas9 cleavage efficiency on AAV dose observed in our initial analyses suggested to us that efficiency of AAV transduction is a key limiting factor for application of the mRNA/AAV method in T-cells. AAV transduction in many human cell types is known to be subject to restriction at the cell entry stage by surface receptor expression binding properties of the capsid, and post-entry based on multiple mechanisms. In cultured transformed cells, plasmid-based expression of E4ORF6 and E1B55K proteins from multiple adenoviral serotypes is effective at relieving post-entry restrictions on AAV expression, among them genome concatamerization by DNA damage response proteins, activation of cell cycle DNA damage checkpoints, and pro-apoptotic DNA damage signaling.

[0284] Thus, in some alternatives, E4ORF6 and E1B55K proteins can be from multiple adenoviral serotypes. In some alternatives, the adenoviral serotypes can be Ad1, Ad2, Ad3, Ad4, Ad5, Ad6 or Ad7. Additional alternative serotypes are also contemplated and are within the scope of the current disclosure. In some alternatives, E4ORF6 and E1B55K proteins can be from the same adenoviral serotype. In some alternatives, E4ORF6 can be from one adenoviral serotype and E1B55K from a different serotype.

[0285] As DNA plasmid-based expression is toxic to primary T-cells, in some alternatives, it was evaluated whether electroporation of adenoviral serotype 5 E4ORF6/E1B55K mRNAs could achieve a transient relief of post-entry restriction of AAV-based expression in primary T-cells (**FIG. 2**).

[0286] In some alternatives, for assessing AAV-mediated GFP expression following relief of post-entry AAV restriction by E4ORF6/E1B55K, primary CD4<sup>+</sup> T-cells

were electroporated with mRNA encoding adenoviral serotype 5 E4ORF6/E1B55K (0.33 $\mu$ g each), rested for 2-4 hours, then transduced with AAV driving GFP expression. Cells were placed in culture for the indicated periods of time (**FIG. 2A**, left panel), following which the cells were collected and analyzed for GFP expression by flow cytometry. Expansion of cell populations following the indicated exposure to E4ORF6/E1B55K mRNA transfection and AAV transduction, following the same protocol as described in the left panel (**FIG. 2A**, right panel).

[0287] In some alternatives, following mRNA-based co-expression of E4ORF6/E1B55K in primary T-cells (but not either protein alone; data not shown), a 4 log increase in GFP mean fluorescence intensity (MFI), and an 8 fold increase in GFP expression, driven from an AAV vector encoding a promoter/GFP cassette (**FIG. 2A**, left panel), without compromising the rate of cell expansion (**FIG. 2A**, right panel) was obtained.

[0288] In some alternatives, the increase in MFI of GFP (or one or more other reporters) can range from 2 log to 8 log. In some alternatives, the increase in MFI of GFP (or one or more other reporters) can be 2 log, 3 log, 4 log, 5 log, 6 log, 7 log or 8 log or within a range defined by any two of the aforementioned values.

[0289] In some alternative, the increased GFP (or one or more other reporters) expression can range from 2 fold to 16 fold. In some alternative, the increased GFP (or one or more other reporters) expression can be 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 11 fold, 12 fold, 13 fold, 14 fold, 15 fold or 16 fold or within a range defined by any two of the aforementioned values.

[0290] In some alternatives, comparison of effect of E4ORF6/E1B55K proteins on self-complementary and single-stranded AAV6-mediated gene expression was performed by electroporating primary CD4<sup>+</sup> T-cells with mRNA encoding E4ORF6/E1B55K proteins (0.33 $\mu$ g each), rested for 2-4 hours, and transduced with either single-stranded or self-complementary AAV6 driving GFP expression (MOI of both viruses:  $2 \times 10^4$ ) (**FIG. 2B**). Cells were placed in culture for the indicated periods of time, following which the cells were collected and analyzed for GFP expression by flow cytometry (**FIG. 2B**).

[0291] In some alternatives, the same enhancing effect was observed irrespective of whether a self-complementary or single stranded AAV was used (**FIG. 2B**), suggesting

that E4ORF6/E1B55K complexes possess a robust capacity to relieve post-entry restrictions on AAV expression in primary human T-cells that is unrelated to initiation of second strand DNA synthesis. Thus, in some alternatives, the AAV vector can be single stranded. In some alternatives, the AAV vector can be self-complementary. In some alternatives, the AAV vector can be both single stranded and self-complementary.

Example 3: MRN complex is a dominant post-entry restriction mechanism on AAV transduction of primary human T-cells

[0292] In some alternatives, the effect of E4ORF6/E1b55K mutants on AAV-driven GFP expression was evaluated.

[0293] The ability of E4ORF6/E1B55K proteins to enhance AAV expression in cultured cell models has been reported to depend on their capacity to target the Mre11/Rad51/NBS1 DNA repair complex (MRN) for degradation, thus allowing incoming AAV genomes to escape intra-nuclear detection and silencing.

[0294] In some alternatives, to determine if this same mechanism applied to primary human T-cells, a comparison of AAV-driven gene expression alone or following transient expression of wild type E4ORF6/E1B55K proteins or E4ORF6/E1B55K-H373A and E4ORF6/E1B55K-H354 mutants (**FIG. 2C**) was performed. Both of these mutants have largely lost the capacity for inducing degradation of MRN, whilst fully preserving other functions of wild type E4ORF6/E1B55K.

[0295] In some alternatives, primary CD4<sup>+</sup> T-cells were electroporated with mRNA encoding Cas9-2A-mCherry (1 µg) along with E4ORF6/E1B55K (wild type) proteins or the indicated E1B55K mutants at the indicated RNA doses, rested for 2-4 hours, and transduced with ssAAV driving both TCRα guide and GFP expression (**FIG. 2C**). E4ORF6 mRNA dose was the same as each E1B55K RNA dose for each indicated point (**FIG. 2C**). Cells were placed in culture for 2 days, following which the cells were collected and analyzed for GFP MFI by flow cytometry. See also **FIG. 3** demonstrating a 2-3 fold increase in GFP expression catalyzed by the E4ORF6/E1B55K H373A mutant complex that is not visible on the same scale as GFP expression catalyzed by the wild type E4ORF6/E1B55K complex.

[0296] In some alternatives, as assessed by GFP MFI, E1B55K mutants were markedly less efficient at relieving post-entry restrictions on AAV expression than wild type E4ORF6/E1B55K, in a dose-dependent manner. Thus, in some alternatives, E1B55K MRN degradation mutants demonstrate requirement for MRN inactivation for complete relief of post-entry restriction on AAV-mediated expression (**FIG. 2C**).

[0297] In some alternatives, replicate experiments were performed in which primary CD4+ or CD3+ human T-cells were electroporated with mRNA encoding Cas9-2A-mCherry proteins (1 $\mu$ g) and either wild type or the indicated E4ORF6/E1B55K mutants (0.03 $\mu$ g each), rested for 2-4 hours, and transduced with AAV driving guide expression and GFP. Cells were placed in culture for the indicated periods of time, following which the cells were collected and analyzed for GFP expression and mean fluorescence intensity (MFI) by flow cytometry and quantified. **FIG. 3A** and **FIG. 3B** represent n=5-6 independent experiments.

[0298] In some alternatives, replicate experiments using the E1B55K-H373A mutant, analyzed at a smaller scale, demonstrated that E4ORF6/E1B55K-H373A expression was able to support a level of GFP expression significantly greater (1.58 $\pm$ 0.09-fold at 96 hours) than that observed in the absence of E4ORF6/E1B55K expression, consistent with its possessing a residual capacity to relieve post-entry transduction or expression restrictions (**FIG. 3A** and **FIG. 3B**).

[0299] In some alternatives, the role of other known E4ORF6/E1B55K functional capabilities in relieving post-entry restriction of AAV transduction in T-cells was evaluated using two additional mutants - E1B55K R240A (SEQ ID NO: 22; **FIG. 33**), which disrupts the ability of E1B55K to catalyze degradation of p53, and E4ORF6 AXA (SEQ ID NO: 23; **FIG. 34**), which binds inefficiently to E1B55K and results in generally hypofunctional E4ORF6/E1B55K complexes. In some alternatives, the E4ORF6 AXA mutant has two polymorphisms – R243A and L245A (SEQ ID NO: 23; **FIG. 34**).

[0300] These mutants exhibit full (R240A) or partial (AXA) capacities to degrade the MRN complex, and consistent with a key role for MRN in post-entry restriction of AAV expression in T-cells, these mutants retained full (R240A) or partial (AXA; data not shown) capacities to enhance GFP expression following AAV transduction of T-cells (**FIG. 3C** and



**FIG. 3D).** In some alternatives, expression of AXA/E1B55K was only able to enhance GFP expression from AAV vectors at high doses of mRNA electroporation (0.33 $\mu$ g), and not 10-fold lower, as shown in **FIG. 3**.

[0301] Thus, in some alternatives, the use of various combinations of wild type and mutant forms of E4ORF6 and E1B55K proteins are contemplated. For example, in some alternatives, any one of the different forms of the E4ORF6 protein (e.g., wild type or AXA mutant) can be used in combination with any one of the different forms of E1B55K protein (e.g., wild type, H373A mutant, H354 mutant, R240A mutant). In some alternatives, the various combinations of wild type and mutant forms of E4ORF6 and E1B55K can be delivered as separate mRNAs. In some alternatives, the various combinations of wild type and mutant forms of E4ORF6 and E1B55K can be delivered as a single mRNAs.

Example 4: H373A and H354 mutant E4ORF6/E1B55K expression enhance CRISPR-mediated knockout in primary human T-cells

[0302] In some alternatives, enhancement of CRISPR-mediated gene knockout in primary human T-cells through use of adenoviral E4ORF6/E1B55K proteins was assessed.

[0303] Based on the capacity of E4ORF6/E1B55K proteins to enhance AAV-driven GFP expression in the analyses herein, it was hypothesized that their transient expression would similarly enhance the level and/or duration of guide RNA expression from a polIII-driven U6 promoter/guide RNA cassette incorporated into an AAV genome, and thus potentially enhance Cas9-mediated gene disruption efficiency by the mRNA/AAV system.

[0304] In some alternatives, this hypothesis was tested by expressing wild type E4ORF6/E1B55K proteins using the mRNA/AAV co-delivery protocol by including their respective mRNAs with Cas9 in the electroporation step, followed by transduction of the cells with an AAV vector encoding both a TCR $\alpha$  guide RNA and a promoter/GFP expression cassette. Thus, the effect of E4ORF6/E1B55K mutants on AAV-driven GFP expression was assessed.

[0305] In some alternatives, the expression of wild type E4ORF6/E1B55K proteins markedly increased GFP expression from the TCR $\alpha$  guide/GFP AAV, as expected from the analyses in **FIG. 2**.

[0306] In some alternatives, despite the marked increase in AAV-based expression, only a moderately increased level of TCR $\alpha$  knock-out (**FIG. 4A**) was observed, and only at lower AAV vector doses (**FIG. 4B**, top panel).

[0307] In some alternatives, an apparent toxicity was observed that had not been observed in the absence of Cas9 expression (manifesting as a loss, rather than stable level, of CD3<sup>+</sup> cells over time. In some alternatives, primary CD4<sup>+</sup> or CD3<sup>+</sup> human T-cells were electroporated with mRNA encoding Cas9-T2A-mCherry proteins (1 $\mu$ g) and E4ORF6/E1B55K wildtype proteins or the indicated mutants, at high or low doses, as indicated (0.33 $\mu$ g or 0.03 $\mu$ g), rested for 2-4 hours, and transduced with AAV driving TCR $\alpha$  guide expression. Cells were placed in culture, and analyzed for TCR $\alpha$ /CD3 expression by flow cytometry at the indicated time-points (**FIG. 5A**).

[0308] In some alternatives, in order to gain information on the influence of specific biochemical activities attributed to E4ORF6/E1B55K complexes on gene editing outcome, H373A, H354, R240A, and AXA mutants were also expressed, and TCR $\alpha$  knockout efficiency among the various contexts was compared (**FIG. 4**).

[0309] In some alternatives, data related to a representative experiment indicating primary CD4<sup>+</sup> T-cells electroporated with mRNA encoding Cas9-T2A-mCherry, (1 $\mu$ g), E4ORF6/E1B55K (wild type), or the indicated mutants (at 0.33 $\mu$ g or 0.03 $\mu$ g each), rested for 2-4 hours, and transduced with AAV driving TCR $\alpha$  guide expression are shown (**FIG. 4A**). Cells were placed in culture, following which the cells were collected and analyzed for CD3 expression by flow cytometry at the indicated time-points following EP/transduction. **FIG. 4A**, top panel, shows quantification of CD3 knockout. **FIG. 4A**, bottom panel, shows representative flow plots from a subset of the experiment at seven days post EP/transduction.

[0310] In some alternatives, E1B55K mutants enhance gene knockout achieved using mRNA/AAV delivery of CRISPR components. While expression of E4ORF6 with E1B55K-H373A and H354 mutants produced the expected much smaller effects on GFP expression (i.e., **FIG. 2C**), unexpectedly, substantial increases in TCR $\alpha$  knockout efficiency were also observed that were not accompanied by toxicity or loss of CD3<sup>+</sup> cells (**FIG. 4A** and **FIG. 5A**).

[0311] In some alternatives, despite their inability to fully relieve post-transduction restrictions on AAV gene expression, these E1B55K mutants retained residual activities that were sufficient to markedly enhance the overall efficiency of gene knockout achievable with the mRNA/AAV delivery approach. In some alternatives, this is supported by the results obtained when the E4ORF6/E1B55K R240A mutant was expressed. In some alternatives, potentiated toxicity was obtained relative to what was obtained with the wild type E4ORF6/E1B55K, along with marked reductions in efficiency of CD3 knockout (**FIG. 4A** and **FIG. 4C**). In some alternatives, p53 inactivation, for which R240A is deficient but which is preserved in the H373A and H354 mutants, contributed to the knockout potentiating properties of H373A and H354.

[0312] In some alternatives, T-cells edited using mRNA/AAV delivery exhibit normal expansion kinetics as determined by electroporating primary CD4<sup>+</sup> T- with mRNA encoding Cas9-T2A-mCherry (1µg) proteins along with wild type E4ORF6/E1B55K proteins or the indicated E1B55K mutants, resting for 2-4 hours, and transducing with AAV driving TCRα guide expression. Cells were placed in culture for the indicated periods of time, during which aliquots of the cells were collected and counted for quantification of cell expansion. **FIG. 4C**, left panel, shows low dose (0.03µg) of E4ORF6/E1B55K mutants electroporated with high dose of AAV (MOI ~ 6000). **FIG. 4C**, right panel shows electroporation and transduction of both low and high dose (0.33µg) E4ORF6/E1B55K-R240A RNA, and low and high dose AAV.

[0313] In some alternatives, the H373A and H354 mutants exhibited considerable potency in their effects on Cas9-mediated gene disruption, with dose/response testing of the H373A mutant demonstrating that it maintained a nearly full effect at enhancing TCRα knockout at mRNA doses down to < 0.04 µg (**FIG. 5B**). In some alternatives, the mRNA dose can be 0.01 µg to 1 µg. In some alternatives, the mRNA dose can be 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1 µg or within a range defined by any two of the aforementioned doses.

[0314] In some alternatives, representative flow plots of primary CD4<sup>+</sup> human T-cells that were electroporated with mRNA encoding Cas9-T2A-mCherry proteins (1µg) and E4ORF6/E1B55K H373A, at the indicated doses, rested for 2-4 hours, and transduced

with AAV driving TCR $\alpha$  guide expression are shown in **FIG. 5B**. Cells were placed in culture for one week, following which the cells were collected and analyzed for TCR $\alpha$ /CD3 expression by flow cytometry (**FIG. 5B**).

[0315] In some alternatives, the effect of E4ORF6/E1B55K MRN-inactivation deficient mutants on CRISPR-mediated knockout was assessed (**FIG. 4B**). In some alternatives, quantification of n=3-4 independent experiments at two different AAV MOIs was performed. In some alternatives, data using primary human CD4<sup>+</sup> or CD3<sup>+</sup> T-cells indicating that both E1B55K H373A and H354 mutants significantly increase CRISPR-mediated TCR $\alpha$  knockout, quantified by CD3 staining at seven days post EP/transduction (**FIG. 4B**). Thus, in some alternatives, E4Orf6/E1B55K mutants enhance TCR knockout.

[0316] In some alternatives, the effect of E4ORF6/E1B55K MRN mutants on indel spectra was assessed. Primary CD4<sup>+</sup> human T-cells were electroporated with mRNA encoding Cas9-T2A-mCherry proteins (1 $\mu$ g) and E4ORF6/E1B55K H373A or H354 (0.03 $\mu$ g), rested for 2-4 hours, and transduced with AAV driving TCR $\alpha$  guide expression. Cells were placed in culture for one week, following which cells were collected, genomic DNA was isolated, the region surrounding TCR $\alpha$  was amplified using PCR, cloned into a vector, and analyzed using Sanger sequencing (**FIG. 5C**).

[0317] In some alternatives, amplicon sequencing of the indel spectra generated by Cas9-mediated gene disruption in the context of both H373A and H354 mutant E4ORF6/E1B55K complexes demonstrated the expected higher rate of mutations as well as an increased proportion of larger deletions, up to 150bp, spanning the predicted Cas9 cleavage site (**FIG. 5C**). In some alternatives, the rate of mutations increased 1.5 fold to 10 fold. In some alternatives, the rate of mutations increased 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 fold or within a range defined by any two of the aforementioned values.

Example 5: E4ORF6/E1B55K H373A and H354 mutants enhance CRISPR/Cas9-mediated homologous recombination in primary human T-cells

[0318] Given their biochemical activities and capacity to enhance gene disruption efficiency achievable with the mRNA/AAV co-delivery method, it was hypothesized that the

E4ORF6/E1B55K H373A and H354 mutants would have similarly enhancing effects on homology-directed gene targeting rates. To test this hypothesis, Cas9 mRNA was electroporated along with E4ORF6 and wild type E1B55K, H373A or H354 mutant mRNAs into primary human T-cells, followed by transduction of the cells with separate AAV vectors to provide guide RNA expression and recombination template delivery, respectively (**FIG. 10**).

[0319] In some alternatives, one or more guide RNAs can be provided in separate AAV vectors. In some alternatives, one or more templates for homologous recombination can be provided in separate AAV vectors. In some alternatives, one or more guide RNAs and one or more templates for homologous recombination can be provided in the same AAV vector. In some alternatives, one or more guide RNAs and template for homologous recombination for a particular target gene can be provided in separate AAV vectors. In some alternatives, one or more guide RNAs and template for homologous recombination for a particular target gene can be provided in the same AAV vector.

[0320] Primary CD4<sup>+</sup> or CD3<sup>+</sup> T-cells were electroporated using the MaxCyte GT or the Neon systems with mRNA encoding Cas9-2A-mCherry proteins (1 $\mu$ g) along with wild type E4ORF6/E1B55K proteins or the indicated E1B55K mutants (0.03 $\mu$ g each), rested for 2-4 hours, and transduced with separate AAVs driving CCR5 guide expression and a targeting template for the CCR5 locus (**FIG. 15**). Cells were placed in culture, following which the cells were collected and analyzed for BFP expression by flow cytometry. Shown are representative flow plots from the indicated manipulations at three weeks post EP/transduction, from n=5-6 independent experiments (**FIG. 10A**).

[0321] In some alternatives, quantification of n=5-6 independent experiments of the fold change in knock-in frequency (BFP<sup>+</sup> cells) over baseline (Cas9 + guide + donor) at three weeks post EP/transduction were performed (**FIG. 10B**).

[0322] In these experiments, Cas9 alone plus the two AAVs allowed for integration of a promoter-BFP cassette into the CCR5 locus at an efficiency of 17.6 $\pm$ 4.0%. In some alternatives, consistent with the results observed herein with the various E4ORF6/E1B55K complexes, substantial potentiation of early BFP expression by the wild

type E4ORF6/E1B55K complexes relative to either the H373A or H354 mutants or without any Ad5 protein was observed (**FIG. 6**, top panel).

[0323] In some alternatives, the fold change in HDR was significantly increased using either E4ORF6/E1B55K-H354 or H373A with CRISPR/Cas9 (**FIG. 10B**). In some alternatives, similar to the effects of each of these mutant complexes on gene knockout, expression of either mutant complex generated significantly higher efficiency of recombination-based genome editing (**FIG. 10A and FIG. 10B**), increasing HDR by 1.8-fold ( $31.2 \pm 5.7\%$  BFP+ with H373A, and  $30.8 \pm 1.8$  with H354).

[0324] In some alternatives, the rate of HDR can be increased using either E4ORF6/E1B55K-H354 or H373A with CRISPR/Cas9 by 1.5 to 3.5 fold as compared to when using wild type E4ORF6/E1B55K proteins. In some alternatives, the rate of HDR can be increased by 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25 or 3.5 fold or within a range defined by any two of the aforementioned values.

[0325] Thus, in some alternatives, enhanced targeted knock-in can be achieved using E1B55K mutant proteins. In some alternatives, E4ORF6/E1B55K mutants can enhance targeted CRISPR knock-in. In some alternatives, E4ORF6/E1B55K H373A and H354 mutants enhance CRISPR-mediated recombination achieved with mRNA/AAV co-delivery

[0326] In order to determine whether T-cells edited via mRNA/AAV CRISPR-mediated recombination exhibited normal expansion kinetics, primary T-cells were electroporated with mRNA encoding control or Cas9-2A-mCherry proteins ( $1\mu\text{g}$ ) along with wild type E4ORF6/E1B55K and the E1B55K mutants ( $0.03\mu\text{g}$  each), rested for 2-4 hours, and transduced with AAV driving CCR5 guide expression as well as AAV CCR5 BFP template. Cells were placed in culture for the indicated periods of time, following which the cells were collected and counted for quantification of cell expansion (**FIG. 10C**)

[0327] Importantly, expression of E4ORF6/E1B55K complexes (whether wild type or mutant) did not affect the rates of expansion of T-cells that had undergone homology-directed gene targeting (**FIG. 10C**).

Example 6: E4ORF6/E1B55K mutant proteins do not enhance non-homologous AAV insertion

[0328] In some alternatives, primary CD3<sup>+</sup> or CD4<sup>+</sup> T-cells were electroporated with mRNA encoding Cas9-2A-mCherry proteins (1 $\mu$ g) along with wild type E4ORF6/E1B55K proteins or the indicated E1B55K mutants (0.03 $\mu$ g each), rested for 2-4 hours, and transduced with AAV driving CCR5 guide expression and AAV containing a promoter-GFP cassette without flanking homology arms. Cells were placed in culture for the indicated periods of time, following which the cells were collected and analyzed for GFP expression by flow cytometry. GFP fluorescence detected at 96 hours reflects expression primarily from episomal AAV genomes. GFP fluorescence detected at three weeks represents expression from both residual episomal or integrated AAV genomes. n=5-6 independent experiments (**FIG. 6**).

[0329] In some alternatives, representative flow plots of primary T-cells demonstrating low rate of insertion events at Cas9-induced double strand break by AAV lacking homology arms are shown in **FIG. 6**.

[0330] Importantly, expression of E4ORF6/E1B55K complexes (whether wild type or mutant) did not affect the rates of non-homologous AAV integration, as assessed by the rate of long term fluorophore expression following co-delivery of Cas9 with AAVs expressing the same guide and a promoter/fluorophore cassette lacking CCR5 homology arms (**FIG. 6**, top panel).

[0331] Thus, in some alternatives, E4ORF6/E1B55K wild type proteins mildly increase non-specific AAV integration at target site for CRISPR knockout whereas mutant proteins do not.

#### Example 7: E4OrF6/E1B55K mutants enhance CRISP single knockouts for other loci than TCR

[0332] In some alternatives, the influence of E4ORF6/E1B55K H373A and H354 mutant complexes on the efficiency of CRISPR/Cas9 gene disruption at other genomic targets was evaluated. In some alternatives, guide RNAs were generated and validated targeting four translationally relevant human surface protein targets: the T-cell inhibitory checkpoint proteins PD-1, TIGIT, LAG-3, and Tim3. The guide RNAs targeting these proteins are represented by SEQ ID NO: 18 (**FIG. 31**) for PD1, SEQ ID NO: 19 (**FIG. 31**)

for TIGIT, SEQ ID NO: 20 (**FIG. 31**) for LAG-3, and SEQ ID NO: 21 (**FIG. 31**) for Tim3. In some alternatives, one or more of these guide RNAs were incorporated into U6-guide expression cassettes in AAV vector backbones upstream of the MND-GFP cassette to provide for tracking of transduction/expression, and packaged into AAV vectors.

[0333] Primary human CD3<sup>+</sup> T-cells were electroporated using the MaxCyte GT system with mRNA encoding Cas9-2A-mCherry proteins (1 $\mu$ g) along with E4ORF6/E1B55K-H373A proteins (0.03 $\mu$ g each), rested for 2-4 hours, and transduced with AAV driving guide expression against the indicated surface proteins. Cells were placed in culture and allowed to expand; 9-12 days following initial stimulation, cells were re-stimulated using Dynal CD3/CD28 beads for 48 hours, following which the cells were collected and analyzed for expression of the indicated surface proteins by flow cytometry and assessed for knockout by amplicon sequencing. Representative flow cytometry plots indicating that T-cells edited using mRNA/AAV co-delivery exhibit loss of targeted surface checkpoint proteins. Data represent n=3-5 independent editing experiments. The representative flow cytometry data are presented in **FIG. 7A**.

[0334] In some alternatives, analysis of knockout by flow cytometry is assessed by percent loss of induction of surface protein expression. Data represent n=3-5 independent editing experiments (**FIG. 7B**). Quantification and summary data from flow cytometry analysis of gene knockout and sequencing analysis of amplicons from genomic target sites are shown in **FIG. 7B**.

[0335] Thus, in some alternatives, knockout efficiency can be assessed by sequencing analysis of amplicons from genomic target sites. In some alternatives, knockout efficiency can be assessed by flow cytometry (if the protein encoded by the targeted gene is expressed on the surface). Thus, in some alternatives, knockout efficiency can be assessed by sequencing analysis of amplicons from genomic target sites as well as surface expression by flow cytometry (if the protein encoded by the targeted gene is expressed on the surface).

[0336] In some alternatives, the use of these AAV vectors with the E4ORF6/E1B55K H373A mutant in a scaled up expansion/manufacturing protocol based on the MaxCyte GT electroporation system resulted in generation of human T-cell populations with approximate respective targeted gene disruption efficiencies of 71.6 $\pm$ 2.7%, 59.1 $\pm$ 14.8%, 59.2 $\pm$ 8.5%, and 66.1 $\pm$ 14.3% of indels at the intended cleavage site of PD-1, TIGIT, LAG-3,



and Tim3, respectively, as derived from sequence analysis (PD-1, TIGIT, Tim3) or flow cytometry (LAG-3).

[0337] Thus, in some alternatives, implementation of CRISPR/Cas9 with mRNA/AAV delivery is able to achieve efficient knockout at multiple genomic sites.

[0338] An important secondary observation that emerged from these experiments was that the influence of E4ORF6/E1B55K H373A mutant complexes on gene disruption efficiency was particularly prominent when the activity of a particular guide RNA was relatively low. For example, the knockout rates at the PD-1 and TIGIT loci doubled with the chosen guide RNAs in the presence of E4ORF6/E1B55K H373A as compared to the knockout rates in the absence of E4ORF6/E1B55K expression, which were only  $36.4 \pm 10.9\%$  and  $40.4 \pm 3.6\%$ , respectively. In some alternatives, the rates were assessed by sequencing.

[0339] Thus, in some alternatives a particularly salient feature of E4ORF6/E1B55K H373A expression is that it can ‘rescue’ poor guide RNA activity. In other words, in some alternatives, E4ORF6/E1B55K H373A expression can potentiate the activity of poor guide RNAs. In some alternatives, the effect of highly active guide RNAs is not as effectively potentiated by E4ORF6/E1B55K protein expression.

[0340] In some alternatives, a poor guide RNA is only 5% to 30% efficient. In some alternatives, a poor guide RNA is only 5, 10, 15, 20, 25 or 30% efficient or within a range defined by any two of the aforementioned values. In some alternatives, E4ORF6/E1B55K H373A expression potentiates the activity of a poor guide RNA by 5% to 150%. In some alternatives, E4ORF6/E1B55K H373A expression potentiates the activity of a poor guide RNA by 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150% or within a range defined by any two of the aforementioned values.

Example 8: H373A mutant E4ORF6/E1B55K expression enhance CRISPR-mediated multiplex knockout of two genes in primary human T-cells

[0341] Based on our analyses herein, it was hypothesized that efficient levels of multiplex knockout could be successfully achieved, using a single AAV vector to deliver multiple guides. In some alternatives, a single AAV vector can be used to deliver one or more guides. In some alternatives, a single AAV vector can be used to deliver 1 to 5 guides.

In some alternatives, a single AAV vector can be used to deliver 1, 2, 3, 4 or 5 guides. In some alternatives, one AAV vector is used to deliver a single guide. In some alternatives, separate AAV vectors are used to deliver separate guides.

**[0342]** In some alternatives, primary human CD3<sup>+</sup> T-cells were electroporated using the MaxCyte GT system with mRNA encoding Cas9-2A-mCherry proteins (1 $\mu$ g) along with E4ORF6/E1B55K-H373A proteins (0.03 $\mu$ g each), rested for 2-4 hours, and transduced with AAVs driving guide expression against Tim3 and TCR $\alpha$ , as well as GFP expression to track transduction efficiency. Cells were placed in culture and allowed to expand; 7 days following EP/transduction, cells were assessed for TCR $\alpha$  knockout by CD3 stain. Three weeks following initial stimulation, cells were re-stimulated using PMA/ionomycin for 3-4 hours and allowed to recover for 48 hours, following which the cells were collected and analyzed for expression of Tim3 by flow cytometry (**FIG. 8**).

**[0343]** In some alternatives, using the same architecture as the single AAV guide vectors, a dual-guide Tim3/TCR $\alpha$  vector was constructed, with both guides driven by individual U6 promoters. A schematic of the multiplex AAV vector expressing guide RNAs against Tim3 and TCR $\alpha$ , with individual U6 promoters is shown in **FIG. 8A**. In some alternatives, TCR $\alpha$  and Tim3 knockout was analyzed following MaxCyte electroporation with Cas9 or E4ORF6/E1B55K-H373A and AAV transduction with either the single Tim3 guide AAV or the AAV containing dual Tim3/TCR $\alpha$  guides.

**[0344]** A representative flow cytometry analysis of TCR $\alpha$  knockout by CD3 staining, seven days after EP/transduction, is shown in **FIG. 8B**. A representative flow cytometry analysis of TCR $\alpha$  knockout and Tim3 knockout, three weeks after initial stimulation, is shown in **FIG. 8C**. In some alternatives, to upregulate Tim3 surface expression independently of TCR, cells were stimulated using PMA/ionomycin (10ng/mL and 1 $\mu$ g/mL, respectively), for 3-4 hours and rested for 48 hours.

**[0345]** In some alternatives, upregulation of Tim3 with and without PMA/ionomycin stimulation was assessed by comparing control cells (AAV treatment only) with and without PMA/ionomycin treatment, and stimulated cells with Tim3 knockout compared to stimulated cells missing both Tim3 and TCR $\alpha$ . There were no differences between cells proficient and deficient in TCR $\alpha$  signaling, suggesting that PMA/ionomycin

stimulation is independent of this pathway. In shaded grey are unstained cells is shown in **FIG. 8D**.

[0346] In some alternatives, successful knockout of both targeted genes using a single AAV, along with an increased efficiency of knockout when E4ORF6/E1B55K-H373A were co-transfected with Cas9 was obtained.

[0347] In some alternatives, on significant differences in knockout efficiency between the single Tim3 guide AAV and the dual Tim3 guide/TCR $\alpha$  guide AAV were observed. In addition, in some alternatives, the majority of Tim3<sup>+</sup> cells were also CD3<sup>+</sup> cells (thus TCR $\alpha$ <sup>+</sup>), consistent with the expected outcome that any cell sufficiently well-transduced to drive guide expression to cleave one target gene also experienced a high level of guide expression for the other target gene.

[0348] Thus, in some alternatives, Cas9 mRNA/AAV guide delivery is able to achieve efficient CRISPR-mediated multiplex knockout in primary human T-cells with E4ORF6/E1B55K H373A expression. In some alternatives, E4OrF6/E1B55K mutants enhance CRISPR-mediated multiplex knockout of more than one gene. In some alternatives, E4OrF6/E1B55K mutants enhance CRISPR-mediated multiplex knockout of two genes.

Example 9: H373A mutant E4ORF6/E1B55K expression enhance CRISPR-mediated multiplex knockout of five genes in primary human T-cells

[0349] In some alternatives, a multiplex knockout of five genes was performed. In some alternatives, cells were cultured for 3 weeks and allowed to expand prior to analysis. Unstimulated cells did not have significant expression of cell surface proteins. One million cells per condition were stimulated with PMA (10ng/mL) and ionomycin (1  $\mu$ g/mL) to up-regulate surface checkpoint protein expression. PMA/ionomycin was left in the media for three hours, following which the cells were washed 4 times with PBS, and left to recover in full media for 48 hours and stained, for the indicated cell surface proteins (CD3, PD1, Tim3, Lag3, and TIGIT) as a measure of gene knockout.

[0350] Data are presented in **FIG. 9**. Top panel shows data for cells that received Cas9 RNA and AAV guide construct only. Bottom panel shows data for cells that received Cas9 RNA, AAV guide construct, and E4ORF6/E1B55K-H373A RNA during the electroporation.

[0351] In some alternatives, simultaneous multiplex deletion of five genes was achieved. Thus, in some alternatives, the method of the present disclosure can be used to delete at least two genes. In some alternatives, the method of the present disclosure can be used to delete at least five genes. In some alternatives, the method of the present disclosure can be used to delete 1 to 10 genes. In some alternatives, the method of the present disclosure can be used to delete 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 genes. In some alternatives, the method of the present disclosure can be used to delete at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten genes.

[0352] In some alternatives, one or more guide RNAs targeting one or more genes can be delivered using AAV transduction. In some alternatives, 1 to 5 guide RNAs targeting 1 to 10 genes can be delivered using AAV transduction. In some alternatives, 1, 2, 3, 4 or 5 guide RNAs can be delivered targeting 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 genes using AAV transduction.

Example 10: Addition of E4ORF6/E1B55K H373A rescues HDR when shorter homology arms are used for gene knock-in with CRISPR-Cas9 at the CCR5 locus

[0353] In some alternatives, the effect of addition of the Ad5 proteins (the two E1B55K mutants, H373A or H354, both with E4ORF6) on the lower levels of HDR knock-in that are caused by using templates with shorter homology arms with CRISPR/Cas9 was evaluated.

[0354] In some alternatives, quantification of n=2-5 experiments of primary human T-cells treated with Cas9 RNA, AAV expressing a guide against the CCR5 gene, AAV donors containing a GFP knock-in construct with different homology arm lengths (0.8kb, 0.5kb, and 0.25kb), and RNA expressing the E4ORF6/E1B55K H354 or H373A mutant proteins are shown in **FIG. 11**. Fold change in HR is calculated based on change from baseline, defined here as CRISPR-Cas9 with AAV donor containing the 0.8kb homology arm, at three weeks following electroporation and transduction.

[0355] In some alternatives, the length of the homology arm can range from 0.05 kb to 1 kb. In some alternatives, the length of the homology arm can be 0.05, 0.075, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95 or 1 kb or within a range defined by any two of the aforementioned lengths.

[0356] In some alternatives, as shown in **FIG. 11**, the addition of E4ORF6/E1B55K H373A proteins significantly rescues the low rate of HDR due to the use of shorter homology arms. Data are presented for the CCR5 locus.

[0357] In some alternatives, the addition of the Ad5 proteins (the two E1B55K mutants, H373A or H354, both with E4ORF6), can rescue lower levels of HDR knock-in that are caused by using templates with shorter homology arms with CRISPR/Cas9. In some alternatives, the fold change in HDR can range from 50% to 150%. In some alternatives, the fold change in HDR can be 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145 or 150% or within a range defined by any two of the aforementioned values.

Example 11: Addition of E4ORF6/E1B55K H373A rescues HDR when shorter homology arms are used for gene knock-in with CRISPR-Cas9 at the TCR locus

[0358] In some alternatives, effect of addition of E4ORF6/E1B55K H354 on homology directed repair (HDR) when using shorter homology arms for gene knock-in with CRISPR-Cas9 was assessed for the TCR locus.

[0359] In some alternatives,  $1 \times 10^6$  T-cells were stimulated with CD3/CD28 beads for 48 hours, and electroporated with the combinations of RNAs encoding the proteins indicated on the legend to the graph (**FIG. 12A**). Cas9 mRNA was 1.0  $\mu\text{g}$ . Ad5 proteins were 0.1  $\mu\text{g}$  each (0.1  $\mu\text{g}$  of E4ORF6, and 0.1  $\mu\text{g}$  of E1B55K H354 mutant). AAV's encoding the repair templates and guides were iodixanol concentrated viral preps, used at 10 % of culture volume.

[0360] In some alternatives, H354 mutant increased knock-in at the TCR locus (**FIG. 12A**). In the bar graph of **FIG. 12B**, NHEJ rates are shown in red, HR rates are shown in blue. In some alternatives, the use of the H354 mutant substantially increased the percentage of breaks resolved through a homology-directed repair assay.

[0361] In some alternatives, the observed HDR observed had occurred as early by day 4 post-electroporation (**FIG. 12C**). In some alternatives, the H354 mutant biases toward increased HDR without significantly increasing NHEJ. In some alternatives, the H354 mutant biases toward increased HDR without significantly increasing NHEJ when a template is present.

Example 12: Edited primary T-cells with E4ORF6/E1B55K H373A exhibit normal surface marker phenotype

[0362] In some alternatives, whether expression of the E4ORF6/E1B55K H373A mutant was detrimentally influencing T-cell phenotype or signaling properties over the course of the editing process was assessed for which expression of a panel of surface markers and measured PHA-induced calcium signaling at two weeks post-editing was evaluated.

[0363] In some alternatives, representative flow plots (**FIG. 13A**) of primary CD4<sup>+</sup> T-cells that were electroporated with mRNA encoding Cas9-2A-mCherry proteins (1 $\mu$ g) along with E4ORF6/E1B55K H373A proteins (0.03 $\mu$ g each) and transduced with AAV driving TCR $\alpha$  guide expression as shown (**FIG. 13A**). Cells were placed in culture and assessed for surface protein markers 16-20 days following EP/transduction by flow cytometry. n=2 independent experiments (**FIG. 13A**).

[0364] Flow cytometric assessment of cell surface markers that define naïve and memory T-cell populations in T-cells edited using mRNA/AAV co-delivery exhibited normal surface marker phenotype and no differences were between edited versus unedited populations (**FIG. 13A**).

Example 13: T-cells rendered TCR-deficient via mRNA/AAV co-delivery deficient in TCR signaling

[0365] In some alternatives, primary CD4<sup>+</sup> T-cells were electroporated with mRNA encoding Cas9-T2A-mCherry proteins (1 $\mu$ g) along with E4ORF6/E1B55K H373A (0.03 $\mu$ g each), rested for 2 hours, and transduced with AAV driving TCR $\alpha$  guide expression. Nine days following EP/transduction, CD3<sup>-</sup> cells were purified using CD3 microbeads (Miltenyi Biotech) and placed back in culture. Cells were allowed to expand for ten days, following which they were collected, re-suspended in Hanks calcium signaling buffer, incubated with 100 $\mu$ M Indo calcium dye for 30min, and analyzed for anti-CD3-stimulated calcium signaling by flow cytometry. 200 $\mu$ g/mL PHA was used to stimulate the cells. Five million cells per condition were used (**FIG. 13B**).

[0366] In some alternatives, edited T-cells exhibited a loss of surface TCR following TCR $\alpha$  gene editing showing a loss of capacity to mobilize Ca<sup>2+</sup> in response to stimulation with PHA relative to cells retaining surface TCR (**FIG. 13B**). Thus, in some alternatives, TCR knockout T-cells using E4ORF6/E1B55K mutants were deficient in Ca<sup>2+</sup> signaling.

Example 14: Cells exhibit normal karyotype following multiplex CRISPR editing

[0367] As translocations are a potential consequence of simultaneous induction of multiple double strand breaks, in some alternatives, karyotyping was performed as an unbiased approach to detecting cell engineering-associated translocations, and did not observe any gross abnormalities in any of twenty metaphase spreads from each condition (**FIG. 14**).

[0368] In some alternatives, G-banding analysis following GTW staining indicated normal phenotype in cells that have undergone CRISPR/Cas9 editing with E4ORF6/E1B55K-H373A (**FIG. 14**). Cells were stimulated using PMA/ionomycin for 3-4 hours, and left to recover for 72 hours. All samples achieved metaphase spreads. Twenty metaphase spreads were created and analyzed using G-banding karyotype analysis per sample. In some alternatives, no abnormalities were detected in any sample (**FIG. 14**).

[0369] In some alternatives, representative image (**FIG. 14A**) shows normal karyotype in cells treated with Cas9 (1 $\mu$ g) with AAV expressing guides against Tim3 and TCR $\alpha$ . Knockout frequencies can be seen in **FIG. 8B** and **FIG. 8C**.

[0370] Representative image (**FIG. 14A**) shows normal karyotype in cells treated with Cas9 (1 $\mu$ g) with AAV expressing guides against Tim3 and TCR $\alpha$ , and E4ORF6/E1B55K-H373A (0.03 $\mu$ g) RNAs. Knockout frequencies can be seen in **FIG. 8B** and **FIG. 8C**.

[0371] For karyotype analysis, in some alternatives,  $\sim 20 \times 10^6$  cells per sample were submitted for analysis following PMA/ionomycin stimulation, and metaphase spreads were successfully obtained from each sample. Data from karyotyping results are shown in **TABLE 1**.

TABLE 1

Sample	Band Level	Metaphase Cells Analyzed	Abnormalities Detected (Y/N)?
Untreated	400-450	20	N
AAV.sgTim3.GFP	300-450	20	N
AAV.sgTim3.sg.TCR $\alpha$ .GFP	300-400	20	N
Cas9 alone	300-550	20	N
Cas9 + AAV.sgTim3.GFP	300-450	20	N
Cas9 + AAV.sgTim3.sg.TCR $\alpha$ .GFP	450-650	20	N
Cas9 + E4ORF6/E1B55K-H373A + AAV.sgTim3.GFP	300-400	20	N
Cas9 + E4ORF6/E1B55K-H373A + AAV.sgTim3.sg.TCR $\alpha$ .GFP	300-450	20	N

[0372] In some alternatives, no discernable abnormalities were detected in any of the twenty spreads analyzed, at the band resolutions indicated, suggesting a translocation rate of less than 5% indicating that cells with double gene knockout do not commonly have gross rearrangements/karyotypic abnormalities.

Example 15: Molecular confirmation of precise HDR events following CRISPR-Cas9 breaks with E4ORF6/E1B55K H373A or H354.

[0373] The molecular nature of the HDR events was assessed by sequencing through the junctions to confirm seamless HDR (**FIG. 15**). A schematic of donor template, with homology arms and BFP insert. Primer binding sites are indicated, and resulting amplicon (1.3kb) is shown in **FIG. 15A**. A representative agarose gel indicating results of PCR from primers is shown in **FIG. 15A**. Results are from n=3 independent PCR experiments, from cells obtained from data shown in **FIG. 10**. PCR products from **FIG. 15B** were purified, cloned into vectors, and sequenced. Representative amplicons are shown indicating precise junctions at both the upstream (1) and downstream (2) regions of the 3'



homology arm, as indicated in **FIG. 15A**. No clones were obtained that had non-precise junctions, nor were any clones obtained that included AAV-based ITR sequence

[0374] Thus, in some alternatives, targeted integrations are indeed seamless integrations as determined by the precise HDR events following CRISPR-Cas9 breaks with E4ORF6/E1B55K H373A or H354.

Example 16: Comparison of different guide RNA alternatives for generating TCR knockout

[0375] In some alternatives, the CRISPR-Cas9 system was used for generating TCR knockout. Human TCR  $\alpha$   $\delta$  locus corresponds to chr14 NG\_001332.2. Location within the TCR $\alpha$  gene corresponds to 1,071,537 – 1,071,809.

[0376] In some alternatives, guide RNAs guide1 (SEQ ID NO: 15; **FIG. 16A**), guide2 (SEQ ID NO: 16; **FIG. 16A**), guide3 (SEQ ID NO: 17; **FIG. 16A**), and guide4 (SEQ ID NO: 5; **FIG. 16A**) were used.

[0377] In some alternatives, primary T-cells were transfected with Cas9-mCherry mRNA followed by transduction with AAV guides. Data from four different experiments are shown in **FIG. 16B – FIG. 16I**.

[0378] In some alternatives, comparison of the efficiency of generation of TCR knockout in primary T-cells from donor 1 when using guide RNAs guide1 – guide4. Cas9-mCherry expression at 24 hrs was comparable in primary T-cells from donor 1 irrespective of the guide RNA sequence alternative used (**FIG. 16B**). Same MOI was used for all AAV guide RNAs. Controls are shown in **FIG. 16B**, top panel.

[0379] In some alternatives, comparison of the efficiency of generation of TCR knockout in primary T-cells from donor 1 when using guide RNAs guide1 – guide4 showed that guide4 (**FIG. 16A**) yielded the highest knockout efficiency (90%) (**FIG. 16C**). Flow cytometry analysis was performed using anti-CD3-Alexa488 antibody at 168 hrs. Controls are shown in **FIG. 16C**, top panel. **FIG. 21** also shows data that guide4 generated the highest TCR $\alpha$  knockout.

[0380] In some alternatives, comparison of Cas9-mCherry expression levels at 24 hrs in primary T-cells from donor 1 when using different volumes of Cas9/guide sample showed a slightly higher percentage of cells expressing Cas9-mCherry at 20  $\mu$ L volume

(96.4%) as compared to 10  $\mu$ L (87.2%) or 15  $\mu$ L (85.1%) (**FIG. 16D**). Controls are shown in **FIG. 16D**, top panel.

[0381] In some alternatives, comparison of efficiency of generation of TCR knockout in primary T-cells from donor 1 when using different volumes of sample containing guide4 yielded highest efficiency at 20  $\mu$ L volume (91.9%). The efficiency was 73.2% at 10  $\mu$ L and 78.2% at 15  $\mu$ L (**FIG. 16E**). Flow cytometry analysis was performed using anti-CD3-Alexa488 antibody at 168 hrs. Controls are shown in **FIG. 16E**, top panel.

[0382] In some alternatives, comparison of Cas9-mCherry expression levels at 24 hrs in primary T-cells from donor 2 when using different volumes of Cas9/guide sample showed a similar percentage of cells expressing Cas9-mCherry at 5  $\mu$ L (91%), 10  $\mu$ L (90.2%) and 20  $\mu$ L (90.8%) of sample volume (**FIG. 16F**).

[0383] In some alternatives, comparison of efficiency of generation of TCR knockout in primary T-cells from donor 2 when using different volumes of sample containing guide RNA guide4 yielded highest efficiency at 20  $\mu$ L volume (68.4%). The efficiency was 30.7% at 5  $\mu$ L and 38.4% at 10  $\mu$ L (**FIG. 16G**). Flow cytometry analysis was performed using anti-CD3-Alexa488 antibody at 168 hrs. Controls are shown in **FIG. 16G**, top panel.

[0384] In some alternatives, Cas9-mCherry expression at 24 hrs was comparable in Jurkat T-cells irrespective of the guide RNA sequence alternative used (**FIG. 16H**, bottom panel). Cas9-mCherry expression was lowest for guide1. Same MOI was used for all AAV guide RNAs. Controls are shown in **FIG. 16H**, top panel.

[0385] In some alternatives, comparison of the efficiency of generation of TCR knockout in Jurkat T-cells when using guide RNAs guide 1 – guide4 showed that guide4 (**FIG. 16A**) yielded the highest knockout efficiency (83.3%) (**FIG. 16I**, bottom panel). Flow cytometry analysis was performed using anti-CD3-Alexa488 antibody at 168 hrs. Controls are shown in **FIG. 16I**, top panel.

#### Example 17: CRISPR/Cas9 system using the TCR $\alpha$ CRISPR guide RNA guide4

[0386] In some alternatives, primary human CD4<sup>+</sup> T-cells were thawed from a frozen isolate, stimulated with CD3/CD28 Dynabeads (Life Technologies) in the presence of

cytokines (IL-2, IL-7 and IL-15) for 60 hours in antibiotic free media. Next, beads were removed and  $4.5 \times 10^5$  cells per condition were electroporated using a 10 $\mu$ L Neon tip ( $3 \times 10^5$  cells post electroporation) and AAV was added 3 hours post electroporation. Cas9 RNA was used at 1.5 $\mu$ g/sample (1 $\mu$ g post electroporation) and guide-specific AAV's were added at an MOI of  $1.33 \times 10^4$ /sample. Post electroporation, cells were plated in a 96 well plate in 200 $\mu$ L media with cytokines and left in a 30°C CO<sub>2</sub> incubator for 24 hours, after which cells were moved to a 37°C CO<sub>2</sub> incubator.

[0387] At 24 hours post electroporation, cells were checked for Cas9-mCherry expression and subsequently at 72, 96 and 168 hours for both mCherry and TCR-knockout with CD3-Alexa488 antibody (Biolegend) using BD LSRII. Voltages were kept same throughout the duration of the experiment.

[0388] In some alternatives, data showed that TCR $\alpha$  CRISPR guide RNA guide4 generated the highest TCR $\alpha$  knockout (**FIG. 16B - FIG. 16I**).

Example 18: Enhanced efficiency of CRISPR-mediated gene knockout in primary human T-cells

[0389] Translational application of the CRISPR/Cas9 programmable endonuclease system has been hindered by the need to transiently and simultaneously express Cas9 protein and guide RNA at sufficient levels to achieve high on-target nuclease activity in primary cells. In some alternatives, an mRNA/AAV split vector system that allows for highly efficient CRISPR-mediated gene editing in primary human T-cells is provided. This approach utilizes mRNA to express Cas9 in conjunction with adenoviral serotype 5 E4ORF6 and E1B55K proteins, the latter serving to render the T-cell permissive to AAV transduction for the purpose of guide RNA expression. In some alternatives, this approach is applied to disrupt the T-cell receptor  $\alpha$  subunit gene, a translationally relevant target, at efficiencies up to 60%, and demonstrate that the resulting edited T-cell population is otherwise phenotypically indistinguishable from the parental population. In some alternatives, this approach can be coupled to mRNA-based TREX2 exonuclease expression to achieve even higher editing efficiencies, illustrating the flexibility and potency of a split-vector approach. Transient expression of Ad5<sup>wt</sup> proteins increases AAV transduction in

human T-cells. Transient expression of Ad5<sup>wt</sup> proteins increases AAV transduction for both ssAAV6 and scAAV6. Transient expression of Ad5<sup>MRN-</sup> proteins increases CRISPR knockout efficiency in primary human T-cells.

Example 19: Increased rate of HDR with TALENs

[0390] In some alternatives, primary human CD4<sup>+</sup> T-cells were electroporated with 0.5µg of each half of CCR5 TALEN mRNA (**FIG. 32A**) or CD40L TALEN mRNA (**FIG. 32B**), without or with E4ORF6/E1B55K-H373A or without or with E1B55K-H354 mRNA (0.03µg each) on a Neon Transfection System (Life Technologies). Immediately following electroporation, cells were placed at 30°C for 24 hours and returned to 37°C for the duration of culture. Two hours following electroporation, cells were transduced with AAV6 containing donor template at 10% culture volume. Cells were analyzed for knock-in of the donor template (GFP<sup>+</sup>) at three weeks following electroporation/transduction on an LSRII flow cytometer (BD Biosciences).

[0391] In some alternatives, TALENs used in combination with the Ad5 mutants, increased gene targeting at two different loci. Thus, in some alternatives, TALENs used in combination with the Ad5 mutants, increased gene targeting at the CCR5 locus (**FIG. 32A**) and at the CD40L (**FIG. 32B**).

[0392] In some alternatives, the number of genes that can be targeted using TALENs ranges from 1-10. In some alternatives, the number of genes that can be targeted using TALENs is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or within a range defined by any two of the aforementioned numbers.

Example 20: Endonuclease-based genome editing

[0393] A system for editing at least one target gene in a cell and a method of using the system for genome editing are contemplated. The target gene is a gene of interest, which is edited by can be either gene disruption. The cell is a primary T-cell.

[0394] The system comprises a first nucleic acid sequence encoding one or more guide RNA and a second nucleic acid sequence encoding an endonuclease protein. The endonuclease can be any of the endonucleases disclosed herein and/or alternative variants and modifications of that are within the scope of the current disclosure. The second nucleic

acid is an mRNA and encodes any of the endonuclease protein. The second nucleic acid sequence encoding the endonuclease protein is codon optimized for expression in a eukaryotic cell. The one or more guide RNA is complimentary to the at least one target gene in a cell. The one or more guide RNA is provided in a vector. The vector can be a viral vector. The viral vector is an Adeno-associated virus (AAV) vector. The AAV vector can be a self-complementary vector, or a single stranded vector, or a combination of a self-complementary vector and a single stranded vector.

[0395] As many cell types possess a post-entry restriction on AAV vectors that renders AAV-mediated expression of transgenes, including guide RNAs, very inefficient, proteins that suppress the post-entry restriction on AAV vectors are provided on additional nucleic acid sequences. Thus, the system comprises a third nucleic acid sequence encoding a first adenoviral protein and a fourth nucleic acid sequence encoding a second adenoviral protein. The third nucleic acid and the fourth nucleic acid are mRNAs, which are codon optimized for expression in a eukaryotic cell. The nucleic acid sequences can either be introduced into the cell sequentially and in any order or be introduced into the cell simultaneously.

[0396] The first and second adenoviral proteins are from an AAV of serotype 5. The first adenoviral protein is a wild type E4ORF6, or an AXA mutant of E4ORF6. The second adenoviral protein is a wild type E1B55K, or an H373A mutant of E1B55K, or an H354 mutant of E1B55K, or an R240A mutant of E1B55K. While the mutant proteins are not as efficient as wild type proteins at suppressing at post-entry restriction on AAV vectors, they are relatively more efficient at enhancing gene targeting.

[0397] The first, second, third and fourth nucleic acid sequences are operably linked to regulatory elements that are operable in a eukaryotic cell. The first nucleic acid sequence can encode one or more guide RNA and each guide RNA is operably linked to a separate regulatory element. The first nucleic acid sequence encoding the guide RNA is transiently expressed in the cell. The one or more guide RNA sequences are complementary to the TCR $\alpha$  gene, the PD1 gene, the TIGIT gene, the Lag3 gene, and/or the Tim3 gene. The system also comprises nucleic acid sequences regions that bear homology to the gene of interest.

[0398] The system comprising the above-mentioned components is introduced into the primary T cell. These nucleic acid sequence regions that bear homology to the gene of interest direct the endonuclease-based system to be targeted to a specific gene. Targeting to the specific gene can result in a gene knockout, a gene knock-in, or both.

[0399] Depending on the nature of gene targeting approach (knockout or knock-in) the result can be determined by flow cytometry, or sequencing or both. For example, if the system is used for knocking out a gene of interest that encodes a cell surface-expressed protein, flow cytometry can be used to check for suppressed and/or lack of cell surface expression of the protein. Or, if the system is used for knocking out a gene of interest that encodes an intracellularly-expressed protein, flow cytometry can be used to check for suppressed and/or lack of intracellular expression of the protein. Or, if the system is used for knock-in, for example, knock-in of a dominant epitope of an antigen into a gene of interest that encodes a cell surface-expressed protein, flow cytometry can be used to check for cell surface expression of the dominant epitope. Or, if the system is used for knock-in, for example, knock-in of a dominant epitope of an antigen into a gene of interest that encodes an intracellularly-expressed protein, flow cytometry can be used to check for intracellular expression of the dominant epitope. In any of the above cases, the DNA sequencing of genomic DNA can also be used to confirm the desired gene targeting event. The number of genes that can be simultaneously targeted for knockout, knock-in or both can be 2 – 5.

[0400] The T-cells in which the gene of interest has been targeted are enriched by cell sorting or other cell enrichments methods. If the enriched cells are intended to be used for treating, ameliorating, and/or inhibiting a disease and/or a condition in a subject, the enriched cells are administered to the subject. For example, the subject may have a disease and/or a condition because the T-cells in the subject are “exhausted,” and therefore, are not effective at clearing one or more antigens from the disease and/or condition.

[0401] By targeting one or more “exhaustion” markers (e.g., PD1, TIGIT, Lag3 and Tim3), the “exhausted” condition of T-cells can be reversed. The targeted T-cells are administered to the subject (e.g., via the intravenous route). Follow-up testing is performed on the subject to assess the status of the targeted T-cells and their effect on the disease and/or condition. For example, blood is drawn from the subject at various intervals following administration of the targeted T-cells. Testing is performed to determine whether the

administered T-cells are activated, for example, by assessing their secretion of the cytokine (e.g. IL-2, TNF $\alpha$ ). Testing is also performed to determine the effect of administration of the targeted T-cells on the disease and/or condition.

#### Example 21: Materials and Methods

[0402] DNA constructs – Cas9 was obtained from Addgene (plasmid # 41815), PCR amplified and cloned into pWNY backbone (an in-house modified pUC57), pEVL200 and pEVL300 (linear mRNA vector with a 200 or 300 encoded polyA tail) with a T7 promoter and two Nuclear Localization Signals (NLS) – one each at the N-terminus and C-terminus, respectively. Cas9 was modified to remove *BsaI* sites to clone into the pEVL vector, without changing amino acid sequence. mCherry was linked to Cas9 with a T2A peptide at 3' end of Cas9. An mCherry only control containing a T7 promoter and a single NLS at the 5' end of mCherry was also generated in pWNY and pEVL200. E4ORF6 and E1B55K genes were gene synthesized (Integrated DNA Technologies, IDT) and cloned into pWNY downstream of a T7 promoter. E1B55K mutants were generated using site-directed mutagenesis (QuikChange II XL Site-Directed Mutagenesis Kit, Agilent)..

[0403] AAV constructs for single guide RNA (sgRNA) design, cloning and expression – Guides targeting the constant region of TCR $\alpha$ , PD-1, TIGIT, Lag3, Tim3, and CCR5 were designed using online CRISPR design tools (<http://crispr.mit.edu> and the Broad Institute's sgRNA designer - <http://www.broadinstitute.org/rnai/public/analysis-tools/sgrna-design>). Guides were then generated as gblocks by commercial DNA synthesis (Integrated DNA Technologies). The gblocks were cloned into scAAV6 or ssAAV6-GFP constructs using standard cloning techniques.

[0404] The gblocks were cloned into scAAV or ssAAV-GFP constructs with either a “GG” (T7 promoter requirement) or a “G” (U6 promoter) at the beginning of the guide, if a “G” was not already present at the start of the guide. Some guides with a U6 promoter had “GG” but the editing efficiency of the ones with “GG” or “G” was similar. Post ITR check, the constructs were used to generate AAV6.

[0405] In some alternatives, the guide targets used correspond to the following guide sequences: TCR $\alpha$  guide target: ACAAACTGTGCTAGACATG (SEQ ID NO: 16);

PD1 guide target: GCCCACGACACCAACCACCA (SEQ ID NO: 18); TIGIT guide target: TCTTCCCTAGGAATGATGAC (SEQ ID NO: 19); Lag3 guide target: GCGGTCCCTGAGGTGCACCG (SEQ ID NO: 20); Tim3 guide target: AGAAGTGGAATACAGAGCGG (SEQ ID NO: 21).

**[0406]** Production of Recombinant AAV6 vectors - AAV stocks were produced by triple transfection of AAV vector, serotype helper and Adenoviral helper (HGT1-Adeno) plasmids in HEK293T cells. Transfected cells were collected 48 hrs later, lysed by freeze-thaw, benzonase treated and purified over iodixanol density gradient. Titers of the viral stocks were determined by qPCR of AAV genomes and ranged from  $10^{10}$ - $10^{12}$ /ml.

**[0407]** mRNA production - DNA template was linearized with unique restriction enzymes and linearized plasmids were purified using the QiaQuick PCR purification kit (Qiagen). mRNA was transcribed in-vitro using commercial kits (mMessage mMachine T7 Ultra; Ambion or T7 mScript Standard RNA production system; CellScript) with slight modifications from the manufacturer's protocol. Briefly, the IVT reaction incubated for 2.5-3 hours, followed by DNase treatment for 1 hour. Poly(A) tailing, if required, was done for 1 hour and mRNA was purified using RNeasy (Qiagen).

**[0408]** Primary human T cell transfection by electroporation and transduction – T-cells were obtained from frozen PBMCs, using CD4+ or CD3+ isolation kits (Miltenyi Biotec). Briefly, PBMCs were thawed using drop-wise addition of cold DNase I Buffer: PBS, 5 mM MgCl<sub>2</sub>, 20 Kunitz Units/ml DNase I (EMD-Millipore), followed by centrifugation, and left to rest overnight in T cell media (RPMI, 20% FBS, 1% HEPES, 1% L-glutamine) supplemented with low-dose IL-15 (0.1ng/mL). T-cells were isolated the following day, according to the manufacturer's instructions, and purified T-cells were resuspended at  $1 \times 10^6$  live cells/ml in T cell growth media (culture media supplemented with IL-2 and IL-15; 5 and 1 ng/ml, respectively), and stimulated by using CD3/CD28 beads (Dyna Beads, Life Technologies) for 72 hrs at a 1:1 cell-bead ratio. Beads were then removed and cells were allowed to rest in T cell growth media for 0.5-2 hrs. Next, cells were electroporated with mRNA using either a Neon Transfection System (Figures 1, 2, 4) or MaxCyte GT (Figure 3) as follows: Cells were washed twice with PBS, resuspended in Neon Buffer T or MaxCyte Buffer at a density of  $4.5 \times 10^7$  cells/ml (Neon) or  $1.25 \times 10^8$  cells/ml (MaxCyte). After mixing, cells were electroporated (Neon conditions: 1400 V, 10



ms, 3 pulses, 10  $\mu$ l tip; MaxCyte conditions determined by the manufacturer for primary T-cells) and immediately dispensed into 200  $\mu$ L of pre-warmed T cell growth media in a 96-well plate. Cells were immediately incubated at 30°C, and AAV was added to the culture 2-4 hrs post electroporation, followed by continued 30°C incubation for 20 additional hrs. AAV donor was added as 10% of the final culture volume regardless of titer ( $\sim 1 \times 10^{4-5}$  MOI), unless specified otherwise. Subsequently, edited cells were cultured using standard conditions: 37°C and expanded in T cell growth media, replenished as needed to maintain a density of  $\sim 1 \times 10^6$  cells/ml every 2-3 days.

**[0409]** Flow cytometry and antibodies – Analysis of knock-out (TCR $\alpha$ , PD-1, TIGIT, Lag3, and Tim3) and HDR (BFP) was performed using the LSRII flow cytometer (BD Biosciences) and data was analyzed using FlowJo software (Treestar). All antibodies were from Biolegend, unless otherwise indicated. To assess knockout of surface markers, cells were labeled with fluorophore-conjugated antibodies, as follows: CD3-Alexa 488, CD3-PerCPCy5.5, or CD3-APC clone HIT3a; PD1-APC clone eh12.2H7; TIGIT-Alexa 700 clone 741182 (Novus Biologicals); Tim3-APC-Cy7 clone F38-2E2; and Lag3-FITC clone 3DS223H (eBioscience). CD4 or CD8 staining was done using CD4-BFP (clone OKT4) or CD8-BFP (RPA-T8). To upregulate surface expression of T cell exhaustion markers, T-cells were stimulated using CD3/CD28 beads for 48 hrs, 9-12 days following initial stimulation, except in the absence of TCR $\alpha$ , in which case PMA/ionomycin stimulation was used (see below). Cells were washed and acquired on LSRII by gating on live cells based on the forward and side scatter for downstream analysis.

**[0410]** Stimulation with PMA/ionomycin - Cells were plated at a density of  $1 \times 10^6$  in a 48 or 24 well plate. 10ng/mL PMA (Sigma) and 1 $\mu$ g/mL of ionomycin (Sigma) was added to the media for 3-4 hours, cells were washed 3-4 times with PBS with 2% FBS, and then re-plated with fresh media. Cells were allowed to recover for 48 hours before flow cytometry, or for 72 hours for karyotype analysis.

**[0411]** Karyotype analysis - Cells were grown in T-25 flasks at a density of  $1 \times 10^6$ - $1.5 \times 10^6$  per sample. Each sample was stimulated with PMA/ionomycin for 3-4 hrs, and then allowed to rest for 72 hrs in full media and cytokines. Karyotype analysis was done by the University of Washington Cytogenetics and Genomics Laboratory as Research

Testing. Standard G-banding (GTW stain) chromosome analysis was performed, on 20 cells per sample.

[0412] T7 Endonuclease I (T7EI) assay – The cleavage efficiency of Cas9 and sgRNA was estimated using the T7EI assay for both TCR $\alpha$  and CCR5 loci. Targeted genomic loci were amplified using either Accuprime Pfx or Hifi Platinum Taq DNA polymerase (Life Technologies), using the manufacturer's instructions. 400ng of the purified product (Qiaquick PCR clean-up kit, Qiagen) was denatured, subjected to T7EI (New England Biolabs) digestion for 30 mins at 37°C and analyzed on a 1-2% agarose gel (FIG. 2B).

[0413] Analysis of calcium signaling -  $5 \times 10^6$  cells were used per sample. Cells were washed in HBSS (with Ca<sup>2+</sup> and Mg<sup>2+</sup>) (ThermoFisher), loaded with 30 $\mu$ M Indo-1 AM (Molecular Probes, Life Technologies) in HBSS and incubated at 37 °C for 30 min, washed twice, and re-suspended in buffer. Baseline flow was obtained for 30sec, after which cells were stimulated with 200 $\mu$ g/mL PHA to stimulate T-cells, and data was collected for 5min.

[0414] Statistical analysis - Statistical analyses were performed with Prism 6 (GraphPad Software). Data is shown as mean +/- SEM unless otherwise noted. Tests of statistical significance were performed using an unpaired two-tailed Student's *t*-test with Welch's correction for unequal standard deviations when appropriate.

[0415] In some alternatives, implementation of CRISPR/Cas9 nuclease technology in primary human T-cells using an mRNA/AAV co-delivery method in which mRNA is used for Cas9 expression and an AAV vector is used for guide RNA expression and/or recombination template delivery is provided.

[0416] As AAV transduction manifested as an important limitation on efficacy during initial development of the mRNA/AAV co-delivery method, in some alternatives, mRNA-based co-expression of E4ORF6/E1B55K adenoviral helper proteins and a panel of mutants to determine whether a combination of biochemical activities could be identified that would disable post-entry restrictions on AAV-mediated gene expression while maintaining a cellular DNA repair environment conducive to efficient gene editing is evaluated.

[0417] In some alternatives, two of the mutants, E4ORF6/E1B55K H373A and H354, were identified as uniquely capable of supporting substantially enhanced efficiencies of both CRISPR-Cas9-mediated gene disruption and homology-directed gene targeting.

[0418] Adenoviral serotype 4 E4ORF6/E1B55K complexes enhance CRISPR-mediated gene targeting (but not gene disruption) in cultured cell models, an effect attributed to inhibition of DNA ligase IV activity and, as a consequence, reduced non-homologous end joining repair activity.

[0419] Thus, in some alternatives, the expression of adenoviral serotype 5 E4ORF6/E1B55K complexes with mRNA/AAV co-delivery might produce a synergistic effect on gene targeting efficiency through both inhibition of DNA ligase IV activity and relief of AAV post-entry transduction restrictions was contemplated.

[0420] In some alternatives, although transient expression of wild type E4ORF6/E1B55K complexes was highly efficacious at relieving restrictions on AAV-driven gene expression, it produced only modest increases in gene disruption or gene targeting efficiency in the primary human T-cell context. In contrast, in some alternatives, E4ORF6/E1B55K H373A or H354 mutants, which exhibited only a modest capacity to enhance AAV-driven gene expression, were observed to produce substantial enhancements in both gene disruption and gene targeting efficiency.

[0421] The H373A and H354 mutants' modest effect on AAV-driven gene expression (e.g. as in **FIG. 3**), which would be predicted to produce a correspondingly modest increase in both the level and duration of guide RNA expression, may in part explain their capacities to potentiate both gene disruption and gene targeting. Their collective residual biochemical activities may also allow an increased proportion of AAV genomes to remain available to participate in homology-directed repair, thus contributing to increased gene targeting efficiency.

[0422] However, two known biochemical activities are contemplated as central to these mutants' capacity to potentiate both gene disruption and gene targeting efficiency relative to the wild type E1B55K: 1) they preserve MRN-dependent DNA damage signaling (which promotes double strand break resolution by various forms of homology-directed DNA repair) while 2) limiting p53-dependent DNA damage signaling (which arrests cells in G1-phase in response to DNA double strand breaks). As a consequence, in some

alternatives, T-cells expressing these complexes would be predicted to permit a high fraction of Cas9-induced double strand breaks to transition to S-phase where they would be repaired by mutagenic alternative end joining in the absence of a recombination template, or by homology-directed repair in the case that a recombination template is provided.

[0423] In some alternatives, adenoviral serotype 5 E4ORF6/E1B55K H373A and H354 mutant “helper” proteins were identified as possessing the capacity to enhance the efficiency of Cas9-mediated gene editing in primary human T-cells. Collectively, in some alternatives, our results suggest that E4ORF6/E1B55K-H373A might be the best choice for an investigator interested in a general tool to enhance CRISPR/Cas9 gene editing, as it exhibited the most consistent activity across multiple types of gene editing applications.

[0424] The biochemical activities of these proteins suggest that their effects on gene editing efficiency are likely attributable to their promotion of S-phase repair of DNA double strand breaks. Thus, in some alternatives, they are likely to be generally applicable approaches to enhance homology-directed genome modification in primary human cells. In some alternatives, they are likely to be generally applicable as approaches to enhance homology-directed genome modification in primary human cells including with alternative nuclease platforms. In some alternatives, they are likely to be generally applicable approaches to enhance homology-directed genome modification in primary human cells including with alternative viral template delivery methods other than AAV.

[0425] Further, as accessory proteins from many human viruses can disable or modify various components of cellular DNA damage response and repair mechanisms, such proteins may represent a rich trove of biochemical activities for use as tools in human genome engineering.

[0426] Thus, in some alternatives, the use of accessory proteins from other human (and/or mammalian) viruses that disable and/or modify various components of cellular DNA damage response and/or repair mechanisms are contemplated in the CRISPR/Cas9 system provided herein. In some alternatives, such proteins are contemplated to represent a rich trove of biochemical activities for use as tools in human genome engineering.

[0427] The foregoing description and Examples detail certain alternatives of the invention. However, no matter how detailed the foregoing may appear in text, it will be appreciated that the invention may be practiced in many ways and the invention should be

construed in accordance with the appended claims and any equivalents thereof. While the present teachings have been described in terms of these exemplary alternatives, one of ordinary skill in the art will readily comprehend that numerous variations and modifications of these exemplary alternatives are possible without undue experimentation. All such variations and modifications are within the scope of the current teachings.

**[0428]** The foregoing examples are provided to better illustrate the disclosed teachings and are not intended to limit the scope of the teachings presented herein. All references cited herein, including patents, patent applications, papers, text books, and the like, and the references cited therein, to the extent that they are not already, are hereby incorporated by reference in their entirety.

**[0429]** The foregoing is considered to be sufficient to enable one of ordinary skill in the art to practice the invention. The foregoing description and examples detail certain preferred alternatives of the invention and describe the best mode contemplated by the inventors. In the event that one or more of the incorporated literature and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.

## WHAT IS CLAIMED IS:

1. A system for editing at least one target gene in a cell, the system comprising:
  - a first nucleic acid sequence, or a set of nucleic acid sequences, encoding one or more CRISPR guide RNAs, wherein the one or more CRISPR guide RNA is complementary to the at least one target gene in a cell and, wherein the first nucleic acid sequence, or the set of nucleic acid sequences, may be comprised in one or more vectors, but not required to be comprised in one or more vectors;
  - a Cas9 protein or a second nucleic acid sequence encoding a Cas9 protein;
  - a third nucleic acid sequence encoding a first adenoviral protein; and
  - a fourth nucleic acid sequence encoding a second adenoviral protein.
2. The system of Claim 1, wherein the cell is a eukaryotic cell.
3. The system of any of Claims 1-2, wherein the cell is a mammalian cell.
4. The system of any of Claims 1-3, wherein the cell is a human cell.
5. The system of any of Claims 1-4, wherein the cell is a primary cell.
6. The system of any of Claims 1-5, wherein the cell is not a transformed cell.
7. The system of any of Claims 1-6, wherein the cell is a primary lymphocyte, a CD34<sup>+</sup> stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.
8. The system of any of Claims 1-7, wherein the vector is a viral vector.
9. The system of Claim 8, wherein the viral vector is an Adeno-associated virus (AAV) vector.
10. The system of any of Claims 8-9, wherein the AAV vector is a self-complementary vector.
11. The system of any of Claims 8-9, wherein the AAV vector is a single stranded vector.
12. The system of any of Claims 8-9, wherein the AAV vector is a combination of a self-complementary vector and a single stranded vector.
13. The system of any of Claims 1-12, wherein the second nucleic acid encoding the Cas9 protein is an mRNA.

14. The system of any of Claims 1-13, wherein the second nucleic acid sequence encoding the Cas9 protein is codon optimized for expression in a eukaryotic cell, such as a human cell.

15. The system of any of Claims 1-14, wherein the Cas9 protein is from *S. pyogenes*.

16. The system of any of Claims 1-15, wherein the third nucleic acid encoding the first adenoviral protein is an mRNA.

17. The system of any of Claims 1-16, wherein the third nucleic acid encoding the first adenoviral protein is codon optimized for expression in a eukaryotic cell, such as a human cell.

18. The system of any of Claims 1-17, wherein the first adenoviral protein is from an AAV of serotype 5.

19. The system of any of Claims 1-18, wherein the first adenoviral protein is a wild type E4ORF6.

20. The system of Claim 19, wherein the sequence of the wild type E4ORF6 is set forth in SEQ ID NO: 3.

21. The system of any of Claims 1-18, the first adenoviral protein is a mutant E4ORF6.

22. The system of any of Claims 1-17 and 21, wherein the mutant E4ORF6 protein is an AXA mutant.

23. The system of Claim 22, wherein the sequence of the AXA mutant is set forth in SEQ ID NO: 23.

24. The system of any of Claims 1-15, wherein the fourth nucleic acid encoding the second adenoviral protein is an mRNA.

25. The system of any of Claims 1-15 and 24, wherein the fourth nucleic acid encoding the second adenoviral protein is codon optimized for expression in a eukaryotic cell, such as a human cell.

26. The system of any of Claims 1-15 and 25, wherein the second adenoviral protein is from an AAV of serotype 5.

27. The system of any of Claims 1-15 and 26, wherein the second adenoviral protein is a wild type E1B55K.

28. The system of Claim 27, wherein the sequence of the wild type E1B55K is set forth in SEQ ID NO: 1.

29. The system of any of Claims 1-15 and 26, wherein the second adenoviral protein is a mutant E1B55K.

30. The system of Claim 29, wherein the mutant E1B55K is an H373A mutant.

31. The system of Claim 30, wherein the sequence of the H373A mutant is set forth in SEQ ID NO: 2.

32. The system of Claim 29, wherein the mutant E1B55K is an H354 mutant.

33. The system of Claim 32, wherein the sequence of the H354 mutant is set forth in SEQ ID NO: 4.

34. The system of Claim 29, wherein the mutant E1B55K is an R240A mutant.

35. The system of Claim 34, wherein the sequence of R240A mutant is set forth in SEQ ID NO: 22.

36. The system of any of Claims 1-35, wherein the first, second, third and fourth nucleic acid sequences are operably linked to regulatory elements that are operable in a eukaryotic cell, such as a human cell.

37. The system of any of Claims 1-36, wherein the first nucleic acid sequence encoding one or more CRISPR guide RNA is operably linked to a regulatory element.

38. The system of any of Claims 1-37, wherein the first nucleic acid sequence encoding one or more CRISPR guide RNA is operably linked to a U6 promoter.

39. The system of any of claims 1-38, wherein when the first nucleic acid sequence encodes more than one CRISPR guide RNA, each guide RNA is operably linked to a separate regulatory element.

40. The system of any of Claims 1-39, wherein the first nucleic acid sequence encoding the CRISPR guide RNA is constitutively expressed.

41. The system of any of Claims 1-39, wherein the first nucleic acid sequence encoding the CRISPR guide RNA is transiently expressed.

42. The system of any of Claims 1-41, wherein the CRISPR guide RNA sequences for the TCR $\alpha$  gene are set forth in SEQ ID NO: 5, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17.



43. The system of any of Claims 1-42, wherein the CRISPR guide RNA sequence for the PD1 gene is set forth in SEQ ID NO: 18, for the TIGIT gene is set forth in SEQ ID NO: 19, for the Lag3 gene is set forth in SEQ ID NO: 20, and for the Tim3 gene is set forth in SEQ ID NO: 21.

44. The system of any of Claims 1-43, wherein the system can be used for gene knockout, gene knock-in, or both.

45. The system of Claim 1, wherein the first nucleic acid sequence, or the set of nucleic acid sequences, and the Cas9 protein or the second nucleic acid sequence encoding the Cas9 protein, are collectively replaced by a fifth nucleic sequence and a sixth nucleic acid sequence, wherein the fifth and sixth nucleic acid sequences comprise mRNAs encoding a left component and a right component of a TALEN nuclease, respectively.

46. A method for editing at least one target gene in a cell, the method comprising:

introducing into a cell a first nucleic acid sequence, or a set of nucleic acid sequences, encoding one or more CRISPR guide RNAs, wherein the one or more CRISPR guide RNA is complimentary to at least one target gene in the cell;

introducing into the cell a Cas9 protein or a second nucleic acid sequence encoding a Cas9 protein;

introducing into the cell a third nucleic acid sequence encoding a first adenoviral protein; and

introducing into the cell a fourth nucleic acid sequence encoding a second adenoviral protein.

47. The method of Claim 46, wherein the cell is a eukaryotic cell.

48. The method of any of Claims 46-47, wherein the cell is a mammalian cell.

49. The method of any of Claims 46-48, wherein the cell is a human cell.

50. The method of any of Claims 46-49, wherein the cell is a primary cell.

51. The method of any of Claims 46-50, wherein the cell is not a transformed cell.

52. The method of any of Claims 46-51, wherein the cell is a primary lymphocyte, a CD34<sup>+</sup> stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

53. The method of any of Claims 46-52, wherein the first nucleic acid sequence, or the set of nucleic acid sequences, encoding the one or more CRISPR guide RNAs, may be comprised in one or more vectors, but not required to be comprised in one or more vectors.

54. The method of Claim 53, wherein the viral vector is an Adeno-associated virus (AAV) vector.

55. The method of any of Claims 53-54, wherein the AAV vector is a self-complementary vector.

56. The method of any of Claims 53-54, wherein the AAV vector is a single stranded vector.

57. The method of any of Claims 53-54, wherein the AAV vector is a combination of a self-complementary vector and a single stranded vector.

58. The method of any of Claims 46-57, wherein the second, third and fourth nucleic acid sequences are mRNA.

59. The method of Claim of any of Claims 46-58, wherein the mRNAs are codon optimized for expression in a eukaryotic cell, such as a human.

60. The method of any of Claims 46-59, wherein the Cas9 protein is from *S. pyogenes*.

61. The method of any of Claims 46-60, wherein the first adenoviral protein is from an AAV of serotype 5.

62. The method of any of Claims 46-61, wherein the first adenoviral protein is a wild type E4ORF6.

63. The method of Claim 62, wherein the sequence of the wild type E4ORF6 is set forth in SEQ ID NO: 3.

64. The method of any of Claims 46-61, the first adenoviral protein is a mutant E4ORF6.

65. The method of Claim 46-61 and 64, wherein the mutant E4ORF6 protein is an AXA mutant.

66. The method of Claim 65, wherein the sequence of the AXA mutant is set forth in SEQ ID NO: 23.

67. The method of any of Claims 46-60, wherein the second adenoviral protein is from an AAV of serotype 5.

68. The method of any of Claims 46-60 and 67, wherein the second adenoviral protein is a wild type E1B55K.

69. The method of Claim 68, wherein the sequence of the wild type E1B55K is set forth in SEQ ID NO: 1.

70. The method of Claim 46-70 and 68, wherein the second adenoviral protein is a mutant E1B55K.

71. The method of Claim 70, wherein the mutant E1B55K is an H373A mutant.

72. The method of Claim 71, wherein the sequence of the H373A mutant is set forth in SEQ ID NO: 2.

73. The method of any of Claims 46-70 and 67, wherein the mutant E1B55K is an H354 mutant.

74. The method of Claim 73, wherein the sequence of the H354 mutant is set forth in SEQ ID NO: 4.

75. The method of any of Claims 46-70 and 67, wherein the mutant E1B55K is an R240A mutant.

76. The method of Claim 75, wherein the sequence of R240A mutant is set forth in SEQ ID NO: 22.

77. The method of any of Claims 46-76, wherein any one of the E4ORF6 variants can be used in combination with any one the E1B55K variants.

78. The method of any of Claims 46-77, wherein the number of genes that are simultaneously knocked out is 2 – 10.

79. The method of any of Claims 46-78, wherein the number of genes that are simultaneously knocked out is 2 – 5.

80. The method of any of Claims 46-79, wherein the dose of mRNA is 0.01 µg to 1 µg.

81. The method of any of Claims 46-80, wherein there is a 1.5 fold to 9 fold increase in the rate of mutations.

82. The method of any of Claims 46-81, wherein the CRISPR guide RNA sequences for the TCR $\alpha$  gene are set forth in SEQ ID NO: 5, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17.

83. The method of any of Claims 46-82, wherein the CRISPR guide RNA sequence for the PD1 gene is set forth in SEQ ID NO: 18, for the TIGIT gene is set forth in SEQ ID NO: 19, for the Lag3 gene is set forth in SEQ ID NO: 20, and for the Tim3 gene is set forth in SEQ ID NO: 21.

84. The method of any of Claims 46-83, wherein the first, second, third and fourth nucleic acid sequences are transiently introduced into the cell.

85. The method of any of Claims 46-84, wherein the first, second, third and fourth nucleic acid sequences are not permanently introduced into the cell.

86. The method of any of Claims 46-84, wherein introducing the first, second, third and fourth nucleic acid sequences into the cell does not transform the cell.

87. The system of any of Claims 1-45 wherein the target gene is a gene of interest.

88. The method of any of Claims 46-86, wherein the target gene is a gene of interest.

89. The system or method of any of the aforementioned claims, wherein the third nucleic acid sequence and fourth nucleic acid sequence are comprised in the AAV vector.

90. The method of any of Claims 46-86, wherein the second nucleic acid sequence is introduced into the cell first followed by the AAV vector comprising the first nucleic acid sequence, the second nucleic acid sequence, and the third nucleic acid sequence.

91. The method of any of Claims 46-86, wherein the AAV vector comprising the first nucleic acid sequence, the second nucleic acid sequence, and the third nucleic acid sequence is introduced into the cell first followed by second nucleic acid sequence.

92. The method of any of Claims 46-86, wherein the second nucleic acid sequence and the AAV vector comprising the first nucleic acid sequence, the second nucleic acid sequence, and the third nucleic acid sequence are co-delivered and introduced into the cell at the same time.

93. The method of any of Claims 46-92, wherein the system can be used for gene knockout, gene knock-in, or both.

94. The method of Claim 46, wherein the first nucleic acid sequence, or the set of nucleic acid sequences, and the Cas9 protein or the second nucleic acid sequence encoding the Cas9 protein, are collectively replaced by a fifth nucleic sequence and a sixth nucleic acid sequence, wherein the fifth and sixth nucleic acid sequences comprise mRNAs encoding a left component and a right component of a TALEN nuclease, respectively.

95. A method for editing at least one target gene in a cell, comprising:

introducing into a cell the system of any of Claims 1-45.

96. A method for treating, ameliorating, and/or inhibiting a disease and/or a condition in a subject, the method comprising:

providing to a subject having a disease and/or a condition the system of any one of Claims 1-45.

FIG. 1A




FIG. 1B




FIG. 1C









FIG. 1D



*FIG. 1E*

*FIG. 1E (Con'd)*


*FIG. 1E (Con'd)*

FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A






FIG. 3B




FIG. 3C




FIG. 3D




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5A




FIG. 5B






FIG. 5C





FIG. 6






FIG. 7A (Con'd)




FIG. 7B




FIG. 8A



FIG. 8B




FIG. 8C






FIG. 8D



FIG. 9

Cas9 + AAV.sgPD1.sgTCR.sgTIGIT.sgTim3.sgLag3




FIG. 9 (Con'd)

Cas9 + E4orf6 + E1b55k-H373A + AAV.sgPD1.sgTCR.sgTIGIT.sgTim3.sgLag3




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 11




FIG. 12A







FIG. 12A (Con'd)




C9,  
mC,  
HR,  
G4,  
Ad5

SSC

Pacific Blue

FIG. 12B






FIG. 13A




FIG. 13A (Con'd)




FIG. 13B




FIG. 14A








FIG. 15A




FIG. 15B




FIG. 15C




FIG. 16A

AACAAATGTGTCACAAAGTA (SEQ ID NO: 15)

ACAAAACTGTGCTAGACATG (SEQ ID NO: 16)

TGTGCTAGACATGAGGTCTA (SEQ ID NO: 17)

TCAAGAGCAACAGTGCTG (SEQ ID NO: 5)

FIG. 16B




FIG. 16C




FIG. 16D




FIG. 16E






FIG. 16F




FIG. 16G




FIG. 16H




FIG. 16I




FIG. 17

MERRNPSERGVPAGFSGHASVESGCETQESPATVVFPPGDNTDGGAAAAAGGSQAAAAGAE  
PMEPSRPGSGMNVVQVAELYPELRRILTITEDGQGLKGVKRERGACEATEEARNLAFSLMTRH  
RPECITFQQIKDNCANELDLLAQKYSIEQLTTYWLQPGDDFEEAIRVYAKVALRPDCKYKISKLVNIR  
NCCYISGNGAEEIDTEDRVAFRCMINMWPGLGMDGVVIMNVRFPGPNFSGTVFLANTNLI  
LHGVSFYGFNNTCVAWTDVRVRGCAFYCCWKGVVCRPKSRASIKKCLFERCTLGILSEGNSRVR  
HNVASDCGCFMLVKSVAVIKHNMVCGNCEDRASQMLTCSGDGNCHLLKTIHVASHSRKAWPVFE  
HNILTRCSLHLGNRRGVFLPYQC�LSHTKILLEPESMSKVNLNGLGVFDMTMKIWKVRLRYDETRRC  
RPCECGGKHIRNQPVMLDVTEELRPDHLVLACTRAEFGSDEDTD (SEQ ID NO: 1)

FIG. 18

MERRNPSERGVPAGFSGHASVESGCETQESPATVVRPPGDNTDGGAAAAAGGSQAAAAAGAEPEPESRPGSGMNVVQVAELYPELRRILTITEDGQGLGVKRERGACEATEEARNLAFSLMTRHRPECITFQQIKDNCANELDLAQKYSIEQLTTYWLQPGDDFEEAIRVYAKVALRPDCKYKISKLVNIRNCCYISGNGAEEIDTEDRVAFRCSMINMWPGVLGMDGVIMNVRFNFTGPNFSGTVFLANTNLILHGVSFYGFNNTCWEAWTDVVRGCAFYCCWKGVCRPKSRASIKKCLFERCTLGILSEGNSRVRHNVASDCGCFMLVKSVAVIKHNMVCGNCEDRASQMLTCSDBGNCHLLKTI~~A~~VASHSRKAWPVFEHNILTRCSLHLGNRRGVFLPYQC�LSHTKILLEPESMSKVNLNGLGVFDMTMKIWKVRLRYDETRTRCRPCECGGKHIRNQPMILDVTEELRPDHLVLACTRAEFGSDEDDTD (SEQ ID NO: 2)

FIG. 19

MTTSGVPFGMTLRPTSRRLSRRTYPYSRDRLPPEFETETRAILEDHPLLPECNTLTMHNVSYVRGLPC  
SVGFTLIQEWVVPWDMVLTREELVILRKCMHVCLCCANIDIMTSMMIHGYESWALHCHCSPGS  
LQCIAGGQVLASWFRMVVDGAMFNQRFIWIYREVVNYPKEVMFMSSVFMGRHLLIYLRWLW  
YDGHVGSVVPAMSGYSALHCGILNNIVLCCSYCADLSEIRVRCARRTRRLMLRAVRIIAEETTA  
MLYSCRTERRRQQFIRALLQHHRPILMHDYDSTPM (SEQ ID NO: 3)


FIG. 20

MERRNPSERGVPAGFSGHASVESGCETQESPATVVRPPGDNTDGGAAAAAGGSQAAAAAGAEPEPESRPGSGMNVVQVAELYPELRRILTITEDGQGLGVKRERGACEATEEARNLAFSLMTRHRPECITFQQIKDNCANELDLAQKYSIEQLTTYWLQPGDDFEEAIRVYAKVALRPDCKYKISKLVNIRNCCYISGNGAEEIDTEDRVAFRCSMINMWPGVLGMDGVIMNVRFNFTGPNFSGTVFLANTNLILHGVSFYGFNNTCWEAWTDVVRGCAFYCCWKGVCRPKSRASIKKCLFERCTLGILSEGNSRVRHNVASDCGCFMLVKSVAVIKHNMVCGNCEDRAGIPASQMLTCSDBGNCHLLKTIHVASHSRKAWPVFEHNILTRCSLHLGNRRGVFLPYQC�LSHTKILLEPESMSKVNLNGVFDMTMKIWKVRLRYDETRTRCRPCECGGKHIRNQPVMLDVTEELRPDHLVLACTRAEFGSDEDTD (SEQ ID NO: 4)




**FIG. 21**


TCRa CRISPR guide#4 generates the highest TCRa-KO (knockout)  
Day 1 mCherry (mRNA transfection)



Day 7 mCherry (mRNA transfection)




Day 7 TCR-KO



**FIG. 21 (Con'd)**


TCRa CRISPR guide#4 generates the highest TCRa-KO (knockout)

Day 1 mCherry (mRNA transfection)




mCherry

Day 7 mCherry (mRNA transfection)



mCherry


Day 7 TCR-KO




**FIG. 21 (Con'd)**

TCRa CRISPR guide#4 generates the highest TCRa-KO (knockout)

Day 1 mCherry (mRNA transfection)



Day 7 mCherry (mRNA transfection)



Day 7 TCR-KO




FIG. 22

MDKKYSIGLAIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRNICYLQEFSN  
EMAKVDDSSFFHRLSEESFLVEEDKKHERHPFIGNIVDEVAYHEKYPTIYHLRKKLVSDTDKADLRILYLALAHMIKFRGHFLIEGDLNP  
DNSDVKLFIQLVQTYNQLFEEENPINASGVDAKAILSARLSKRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKL  
QLSKDTYDDDLNLLAQIGDQYADFLAAKNLSDAILSDILRVNTEITKAPLSASMIKRYDEHHQDITLLKALVRQQQLPEKYKEIFF  
DQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFLKDNREK  
IEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEFVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSHLLYEYFTVYNELTK  
VKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLKKIHKDKDFLDNEENE  
DILEDIVLTLTFEDREMIEERLKTIAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDD  
SLTFKEDIQKAQVSGQDLSLHEHIANLAGSPAIAKKGILQTVKVVDDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRERMKRI  
EEGKELGSQILKEHPVENTQLQNEKLYLYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKNVLTNRSDKNRGKSDNV  
PSEEVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGSELDAKAGFIKRLQVETRQITKHVAQILDSRMNTKYDENDKLIREVKVI  
TLKSLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTAIIKKYPKLESEFVYGDYKVYDVVRKMIKSEQEIGKATAKYFFYSNIM  
NFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNVKTEVQTGGFSKESILPKRNSDKLIARKKDDWDPK  
KYGGFDSPTVAYSVLVVAKVEKGSKKLKSVKELLGITIMERSSEKKNPIDFLEAKGYKEVKKDLIILPKYSLFELENGRKRMLASAG  
ELQKGNELALPSKYVNFYLAISHYEKLKGPEDNEQQLFVEQHKHYLDEIEIQSEFSKRVILADANLDKVL SAYNKHHRDKPIREQA  
ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQTSITGLYETRIDLSQLGGD (SEQ ID NO: 6)

FIG. 23

ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAATAGCGTGGGCGGTGATCACTGATGAATATAAGGTTCCGTCTAAAAAGTTCAAGTTCTGGGAAATACAGACAGTATCAAAAAAATCTTATAGGGCTCTTTTATTTGACAGTGGAGACAGCGAAGCGACTCGTCTCAACGCGACAGCTCTGTAAGGTATACACGTCGGAAGAATC  
 GTATTGTTTACTACAGGAGATTTTTCAAATGAGATGGCGAAAGTAGATAGTTCTTTCATCGACTTGAAGAGTCTTTTGGTGAAGAACAGACAGCATGAACGTCATC  
 CTATTTTGGAAATATAGTAGAAGTTGCTTATCATGAGAAATATCAACTATCTATCATCTCGGAAAAAATTTGGTAGATTCTACTGATAAAGCGGATTTGCGCTTAATCTATTT  
 GGCCTAGCGCATATGATTAAAGTTTCGTGGTCAATTTTGAITGAGGGAGATTAAATCCCTGATAATAGTGATGTGGACAAACTATTATCCAGTTGGTACAAACCTACAATCAATTA  
 TTTGAAGAAAACCCCTATTAAACGCAAGTGGAGTAGATGTAAGCGATTCTTTCGACGATTGAGTAAATCAAGACGATTAGAAAAATCTCATTGCTCAGCTCCCGGTGAGAAGAA  
 AAATGGCTATTITGGGAATCTCATTTGCTTGTGATTGGTTGACCCCTAAATTTAAATCAAAATTTGATTGGCAGAAGATGCTAAATACAGCTTTCAAAAGATACCTTACGATGATG  
 ATTTAGATAATTTATTGGCGCAAATGGAGATCAATATGCTGATTGTTTGGCAGCTAAGAAATTTATCAGATGCTATTTACTTTTCAGATATCTTAAGAGTAAATACTGAAATAACT  
 AAGGCTCCCTATCAGCTTCAATGATTAAACGCTACGATGAACATCATCAAGACTTGACTCTTTTAAAGCTTTAGTTCGACAACTTCAGAAAAAGTATAAAGAAATCTTTTTTG  
 ATCAATCAAAAAACGGATATGAGGTTATATTGATGGGGAGCTAGCCAAAGAAATTTTAAATTTATCAACCAATTTTAGAAAAAATGGATGGTACTGAGGAAATATTGGTG  
 AAATAAATCGTGAAGATTGCTCGCAAGCAACGGACCTTTGACAAAGGCTCTATCCCATCAAAATTCACCTGGTGAGCTGCATGCTATTTGAGAAGACAAGAACTTTTAT  
 CCAATTTTAAAAAGACAATCGTGAGAAGATTGAAAAAATCTTGACTTTTGAATCTTATTTGTTGCTCAATTTGAGTGGTCAATTTGAGCGCTGGCAATAGTCTTTGATGGTGAAGTCTG  
 AAGAAACAATACCCCATGGAAATTTGAAGAAAGTTGCGATAAAGGTGCTTCAGCTCAATCATTTATTGAACGCTACAAAACTTTGATAAAAAATCTTCAAAATGAAAAAGTACTAC  
 CAAAAACATAGTTTCTTCAAAAAAATCGAAAAAGTTAACGAAATGACAAAGTCAAAATATGTTACTGAAGGAATCGGAAACCCAGCATTTCTTCAGGTGAACAGAAAGGCCA  
 TTGTTGATTACTCTTCAAAAAAATCGAAAAAGTTAACGAAATGACAAAGTCAAAATATGTTACTGAAGGAATCGGAAACCCAGCATTTCTTCAGGTGAACAGAAAGGCCA  
 TAATGCTTCATTAGGTACCTACCATGATTTGCTAAAAATTTTAAAGATAAAGATTTTGGATAATGAAGAAATGAAGATATCTTAGAGGATATTGTTTAAACATTGACCTTATTG  
 AAGATAGGAGATGATTGAGGAAAGACTTAAACATATGCTCACCTTTTATGATGATAAGGTGATAACAGCTTAAACGCTGCGGTTATCTGTTGAGGACGTTGCTCGAAAA  
 TTGATTAATGGTATTAGGATAAGCAATCTGGCAAAACAATATTAGATTTTGAATTCAGATGTTTTGCCAATCGCAATTTTATGACGCTGATCCATGATGATGTTGACATTAA  
 AAGAAGACATTCAAAAAGCACAAGTCTGGACAAGGCGATAGTTACATGAACATATTGCAAAATTTAGTGGTAGCCCTGCTATTAAGAAAGGTTATTTACAGACTGTAAAAAGTTG  
 TTGATGAATGGTCAAAGTAATGGGCGGCATAAGCCAGAAAAATATCGTTATTGAATGGCAGTGAAGAAATCAGACAACTCAAAAGGCCAGAAAAATTCGCGAGCGTATGAA  
 ACGAATCGAAGAAGGTATCAAGAAATTAGGAAGTCAGATTCTTAAAGAGCATCTGTTGAAAAATACTCAATGCAAAATGAAAAAGTCTATCTCTATTATCTCCAAATGGAAGAGA  
 CATGATGTGGACCAAGAATTAGATATTATCGTTTAAAGTGATTATGATGTCGATCACAATTGTTCCACAAAGTTTCTTAAAGACGATTCAATAGACAAATAAGGTTCTTAACGCGTTCT  
 GATAAAAAATCGTGGTAAATCGGATAACGTTCCAAGTGAAGAAGTAGTCAAAAAGATGAAGAACTATTGGAGACAACTTTGGTGAACCTCGCCAAATCAAGCATGGGCACAAATTTTGGATAGTCG  
 TTTAACGAAAGCTGAACGTGGAGGTTTGAGTGAACCTTGATAAGCTGGTTTATCAACGCGCAATGGTTGAACCTCGCCAAATCAAGCATGGGCACAAATTTTGGATAGTCG  
 CATGAATACTAAATACGATGAAAATGATAAATTTTCGAGAGGTTAAAGTAGTAACTTAAATCTAAATAGTTTCTGACTTCGCAAAAGATTTCCAATCTATAAAGTACGTGAG  
 ATTAACAATTACCATGATGCCATGATCGTATCTAAATGCCGCTGTTGGAAGTCTTTGATTAAAGAAATATCCAAACTTGAATCGGAGTTTGTCTATGGTGATTATAAAGTTTATG  
 ATGTTCTGTAATGATTGTAAGTCTGAGCAAGAAATAGGCAAAAGCAACCCGCAAAATATTTCTTTACTCTAATATCATGAACCTTCTCAAAACAGAAATACACTTGCATAATGGAGA  
 GATTTCGCAACCGCCCTTAATCGAACTAATGGGGAACCTGGAGAAATGTCTGGGATAAGGGCGAGATTGTCACAGCTGCGCAAGATTTGTCATGCCCAAGCAATATTG  
 TCAAGAAACAGAAAGTACAGACAGCGGATTCTCCAAGGAGTCAATTTTACCAAAAGAAATTCGAGCAAGCTTATGCTCTGTAAGAAAGTCTGGAATCCAAAGAAATATGTTGGT  
 TTTGATAGTCCACCGTAGCTTATTCAGTCTTAGTGTGTAAGGTGAAAAAGGAAATCGAAGAAATGTAAGTCTTAAAGTCTAGGATCAACAATTATGGAAGAAAG  
 TTCCTTTGAAAAAATCCGATTGACTTTTGAAGCTAAAGGATATAGGAAGTTAAAGAACTTAATCAATTAACCTACCTAAATAGTCTTTTGGTGTAGAAAAACGGTCTGTAAA  
 CGGATGCTGGTAGTGGCGGAGAAATACAAAAAGGAAATGAGTGGCTCTGCCAAGCAAAATATGTAATTTTATTTAGCTAGTCAATTAAGAAATTTGAAGGTTGAAGGTTAGTCCAGA  
 AGATAACGAACAAAAACAATTTGTTGGAGCAGCATGAAGCATATTAGATGAGATTATTGAGCAAAATCAGTGAATTTTAAAGCGTGTATTAGCAGATGCCAATTTAGATAA  
 AGTTCTTAGTGATATAACAAACATAGAGACAAACCAATACGTGAACAGCAAAAAATATTATTCATTATTACGTTGACGAATCTTGGAGTCCCGCTGCTTTTAAATATTGAT  
 ACAACAATTGATCGTAAACGATATACGCTACAAAAAGAAAGTTTAGATGCCACTCTTATCCATCAATCCCATGCTGTTGATGAGTCAGCTAGGAGGTT  
 ACTGA (SEQ ID NO: 7)

FIG. 24

ATGACAAGAAGTACTCATTGGGCTCGTATCGGCACAACAGCGTCGGCTGGGCCGTCATTACGGACGAGTACAAGGTCCGAGCAAAAAATTCAAAGTCTGGGCAATA  
CCGATCGCCAGCATAAAGAAGAACCTCATTGGGCCCTCTGTTGACTCCGGGAGAGCGCGCAAGCCACGGGCTCAAAAGAACAGCAGCGGCAGATATACCCGCAG  
AAAGAAATCGGATCTGCTACCTGCAGGAGATCTTTAGTAATGAGATGGTAAGTGGATGACTCTTTCTCCATAGGTGAGGAGTCTTTTGGTGGAGGAGATAAAAAAGC  
ACGAGCGCCACCAATCTTTGGCAATATCGTGGACGAGGTGGGTACCATGAAAGTACCAACCATATATCATCTGAGGAAGAAGCTTAGACAGTACTGATAAGGCTGA  
CTTGCGTTGATCTATCTCGCTGGGCATATGATCAAAATTCGGGACACTTCTCATCGAGGGGACCTGAACCCAGACAACGCGATGTCGACAAACTCTTTATCCAACT  
GGTTCAGACTTACAATCAGCTTTCGAAGAGAACCAGATCAACGCTCCGGAGTTGACGCCAAAGCAATCTGAGCGTAGGCTGTCAAATCCCGCGGCTCGAAAACTCA  
TCGACAGCTCCCTGGGAGAGAAAGACGGCTGTTGGTAATCTTACGCCCTGCTACTCGGCTGACCCCAACTTAAATCTAACTCGACCTGGCCGAAGATGCCAAG  
CTTCAACTGAGCAAGACACCTACGATGATCTGACAAATCTGCTGGCCAGATCGGCGACCATGAGCGCTAGTATGATCAAGCGCTATGATGAGCACCAAGACTTGACTTTGCTGAAGGCCCTTG  
GCTGAGTGATATCTCGAGTGAACACGGAGATCACCAAGCTCCGCTGAGCGCTAGTATGATCAAGCGCTATGATGAGCACCAAGACTTGACTTTGCTGAAGGCCCTTG  
TCAGACAGCAACTGCTGAGAAGTACAAGGAAATTTCTTCGATCAGTCTAAAAATGGCTACGCCGATACATTGACGGGGAGCAAGCCAGGAGAAATTTACAAATTTAT  
AAGCCCATCTTGAAAAAATGGACGGCACCGAGAGCTGCTGTAAGCTTAAACAGAGAAGATCTGTTCGCAACAGCGCACTTCGACAATGGAAGCATCCCCACAG  
TTCACTGGGCGAACTGCAGCTATCTCAGGCGGCAAGAGGATTTCTACCCCTTTTGAAGATAACAGGGGAAAGATTGAGAAAAATCCTCACATTCGGATACCTACTATG  
TAGGCCCTCGCCCGGAAATTCAGATTCGCTGGATGACTCGCAATCAGAAAGAGACATCACTCCTGGAACCTCGAGGAAGTCGTGGATAAGGGGCTCTGCCCCA  
GTCCTTCATCGAAAGGATGACTAACTTTGATAAAAAATCTGCTAACGAAAGGTCTTCTTAAACACTCTCTGCTGTAAGTACTTACAGTCTTACAGGCTCACCAAGGT  
CAAAATACGTACAGAGGGATGAGAAAGCCAGCATTCCTGCTGGAGAGCAAGAAAGCTATCTGGAACCTCTCTTCAAGACGAAACCGGAAAGTACCGTGAAACAGCTC  
AAAGAAGACTATTTCAAAAGATTGAATGTTTCGACTCTGTTGAAATCAGCGGAGTGAGGATCGCTTCAACGCATCCTCGGAACTATCACGATCTCTGAAAAATCATTA  
AGACAAGGACTTCTGGAATGAGGAGAACGAGGACATTTGAGGACATTTCTCACCCCTTACGTTGTTGAAGATAGGGAGATGATTGAAGAACGCTTGAAAACTTAC  
GCTCATCTTCGACGACAAGTCAATGAACACAGCTCAAGAGGCGCCGATATACAGGATGGGGCGGCTGTCAGGAAACTGATCAATGGGATCGAGACAAGCAGAGTGGA  
AAGACAATCTCGATTCTTAAGTCCGATGGATTGCCAACCGGAATTCATGCACTGATCCATGATGACTCTCTCACCTTTAAGGAGGACATCCAGAAAGCACAAGTTCT  
GGCCAGGGGACAGTCTTCAGGACACATCGCTAATCTTGCAGGTAGCCAGCTATCAAAAAGGGAATCTGCAAGACCGTTAAGGTCGTGGATGAACCTGCTCAAAAGTATG  
GAAGGCATAAGCCCGAGATAATCGTTATCGAGATGGCCGAGAGAACCAACTACCCAGAGGACAGAAAGCAAGTACGAGAAAGGATGAAGAGGATTGAAGAGGGTATA  
AAAGAACTGGGGTCCCAATCCTTAAGGAACACCCAGTTGAAACACCCAGCTTCAGAAATGAGAAGCTCTACCTGACTACCTGCAGAACGGCAGGACATGTACGTGGATC  
AGGAACTGGACATCAATCGGCTCTCCGACTACGACGTGGCTATCGTCCCCAGTCTTTCTCAAAGATGATTCTTAATAAAGTGTGACAAGATCCGATAAAGCTA  
GAGGGAAGAGTGATAACGTCGCCCTCAGAAGAAGTTGTCAAGAAAAATGAAAAATTAATGGCGGCGAGCTGTGAACGCCAACTGATCACACAACGGAAGTTCGATAATCTGAC  
TAAGGCTGAACGAGGTGGCCTGCTGAGTTGGATAAAGCCGGCTTCATCAAAAGGCGAGCTTGTGAGACACGCCAGATCACCAAGCAGCTGGCCCAAAATTCGATTACGC  
ATGAACACCAAGTACGATGAAATGACAAACTGATTCGAGAGGTGAAAGTTATTACTGAACTAAGCTGAGTCAAGCTTTCAGAAAGGACTTCAGTTTATAAGGTGAG  
AGAGATCAACAAATACCACCATGCGCATGATGCCTACTGTAATGCAAGTGGTAGGCACTGCACCTATCAAAAAATATCCAAAGCTTGAATCTGAAATTTGTTACGGAGACTATA  
AGTGTACGATGTTAGGAAATGATCGCAAAAGTCTGAGCAGGAAATAGGCAAGGCCACCGCTAAGTACTCTTTACAGCAATATTAATGAAATTTTCAAGACCGGAGATTACACT  
GGCCAAATGGAGAGATTCGGAAGCGACCACTTATCGAAACAAACGGAGAAACAGGAGAAATCGTGTGGACAAGGTAGGATTCGGACAGTCCGGAAGGTCTCTGTCCAT  
GCCGAGGTGAACATCGTTAAAAAGACCGGATTCAGAGTACAGACCGGAGGCTTCTCAAGGAAAGTATCTCCCGAAAAAGGAACAGCGCAAGCTGATCGCACGCAAAAAAGATTG  
GGACCCCAAGAAATACGGCGGATTCGATTCTCTACAGTGCCTACAGTGTACTGTTGGCCAAAGTGGAGAAAGGAAAGTCTAAAAAACTCAAAAGCTCAAGGAACTG  
CTGGGCATCAATCATGGAGCGATCAAGCTTCGAAAAAACCCTATCGACTTCTCGAGGCGAAAGGATATAAAGAGGTCAAAAAAGACCTCATCATTAAGCTTCCCAAGTA  
CTCTCTTTGAGCTTGAACGGCCGAAACGAATGCTCGTAGTGGGGGAGCTGCAGAAAGGTAAACGAGTACGAGCTGCCCTCTAAATACGTTAATTTCTGTATCTGG  
CCAGCCATATGAAAGCTCAAAGGGTCTCCGAGATAATGAGCAGAAAGCAGCTGTTCTGGGAACAACAACACTACCTTGTATGAGATCATCGAGCAAAATTAAGCGAAT  
CTCCAAAAGAGATGATCCTCGCCGACGCTAACCTCGATAAGGTGCTTTCTGCTTACAATAAGCACAGGGATAAGCCCATCAGGAGCAGGAGCAAAAAACATTATCCACTTGTTA  
CTCTGACCAACTTGGGCGCCTGACGCTTCAAGTACTTCGACACCACTAGACAGAAAGCGGTACACCTCTACAAAGGAGGTCTCTGGACGCCACACTGATTCATCAGTCA  
ATTACGGGGCTCTATGAACAAGAAATCGACCTCTCTCAGCTCGGTGGAGACTAA (SEQ ID NO: 8)

FIG. 25

ATGAGCGACCTGGTGTGGGCTGGACATCGGCATCGGCAGCGTGGGCGTGGGCATCCTGAACAAGGTGACCGGCGAGATCATCACAAAGAACAGTCGTCATCTTCCCTGCT  
 GCTCAGGCTGAGAACAACTGGTGGCGCGCACCAACCGCCAGGGTGGCGGCTTGGTGGCGCAAGAACGACCGGGCGGTGGCGCTGAACCGCCTGTTTCGAGGAGAGCGGC  
 CTGATACCGACTTACCAAGATCAGCATCAACCTGAACCCCTACCAAGTGGCGTGAAGGGCCTACCGACGAGCTGAGCAACGAGGAGCTGTTTCATCGCCCTGAAGAACA  
 TGGTGAAGCACCGCGCATCAGCTACCTGGACGACGACGACGCGCAACAGCAGCGTGGGCGACTACGCCAGATCGTGAAGGAGAACAGCAAGCAGCTGGAGACC  
 AAGACCCCGGCGAGATCCAGCTGGAGCGCTACAGACCTACGGCCAGCTGGCGGGGACTTACCGTGGAGAAAGGACGGCAAGAACCCGCTGATCAACGTTTCCCC  
 ACCAGCGCTACCGCAGCGAGGCCCTGGCATCCTGCAGACCCAGCAGGAGTTCAACCCCGAGATCACCGGCGGAGACCTTGAACAACCTTTCGGCATCTTCGATCGGCAAGTGA  
 GCAAGTACTACCAAGCGCCCGCAACGAGAGCGCGACCGACTACGGCCGAGGTTCAACCTGCTGAACGACTGAACAACCTGACCGTGGCAACCTTTCGGCATCTTCGATCGGCAAGTGA  
 CCTTCTACCCGACGAGTTCCGGCGCGCAAGGCCAGCTACACCGCCAGGAGTTCAACCTGCTGAACGACTGAACAACCTGACCGTGGCAACCTTTCGGCATCTTCGATCGGCAAGTGA  
 CAAGGAGCAGAAACAGATCACTACGTGAAGAACGAGAGGCCATGGGCCCGCCAAAGCTTCAAGTACATCGCCAAGCTGCTGAGCTGCGACGTGGACGTGGCCGACAT  
 CAAGGCTACCGCATCGACAAGAGCGCAAGGCCGAGATCCACACTTCGAGGCTACCGCAAGATGAAGACCTGGAGACCTTGGACATCGAGCAGATGGACCCGCGAGA  
 CCTGGACAAGCTGGCTACCTGAACACCGAGCGGAGGGCATCCAGAGGCCCTGGAGCACGAGTTGCGGACGCGAGCTTCCCGAGCTGATCCCGAGCTGACGACCAAGCAGGTGGAC  
 GAGCTGGTCAGTTCGCAAGGCCAACAGCAGCATCTTCGGCAAGGGTGGCAACTTCAGCGTGAAGCTGATGGAGCTGATCCCGAGCTGACCGGAGGATCTACAACCCCTG  
 GAGCAGATGACCATCTGACCCGCTGGCAAGCAGAAAGACACAGCAGCAACAAGTACATCGAGAAAGCTGCTGACGAGAACTGCTGACCGGAGGATCTACAACCCCTG  
 GTGGCAAGAGCGTGGCCAGGCCATCAAGATCGTGAACCGCGCATCAAGGAGTACGGGACTTCGACAACATCGTGTGAGATGGCCCGGAGACCAACAGGAGCGA  
 CGAGAAAGGCCATCCAGAAGATCCAGAAGGCCAACAAAGACGAGAGCGGCCCATGCTGAAGCGCCCAACAGTACACGGCAAGGCCGAGCTCCAGCACTGATCAACAACAG  
 TGTTCACGGCCACAAGCAGCTGGCCACCAAGATCCGCTTGCCACAGCAGCGGCGAGCGCTGCTGTACCCGGCAAGACCATCAGCATCCAGCACTGATCAACAACAG  
 CAACAGTTCGAGGTGGACCATCTGCCCCTGAGCATACCTTCGACGACAGCTGGCCAAAGGTGCTGTACCCGGCAAGACCATCAGCATCCAGCACTGATCAACAACAG  
 CCCCTACAGGCCCTGGACAGATGGACGACGCTGGAGCTTCGGGAGCTGAAGGCCCTCGTGCGGAGAGCAAGACCCCTGAGCAACAAGAAAGGAGTACCTGCTGAC  
 CGAGGAGACATCAGCAAGTTCGACGTGCGCAAGAACTTCAGAGCGCAACCTGTTGAGACCCGCTACGCCAGCGCGTGGTGAACCGCCTGCAGGAGCACTTCCG  
 CGCCACAAGATCGACACCAAGTGAGCGTGGTGGCGGGCCAGTTCACAGCGCAGCTGCGCGCCACTGGGGCATCGAAGACCCCGACACTACCAACCAACCGCGT  
 GGACGCCCTGATCATTGGGCTTAGCCAGCTGAACCTGTGGAAGAACGAGAACACCCCTGGTGAAGTACAGCGAGGACCACTGACATCGAGACCGGCGAGCT  
 GATCAGCGACGAGTACAAGGAGCGTGTCAAGGCCCTTACAGCCCTACCAAGCAAGGAGTTCGAGGACAGCATCCTGTTTCAGTACCAGGT  
 GGACAGCAAGTTCAACCGCAAGATCAGCGACGCCACCATCTACGCCCGCCAGGCCAAGTGGGCAAGGACAAAGGCCGAGACCTACGTGCTGGGCAAGATCAAGG  
 ACATCTACCCAGGACGCTACGACGCTTCAAGAGATCAAGAAGGACAGCAAGTTCCTGATGTACCGCCAGCAACCCCAAGCTTCGAGAAGGTGATCGAGCC  
 CATCTGGAGAACTACCCCAACAGCAGATCAACGATAAAGGCAAGGAGTCCCTGCAACCCCTTCTGAAGTACAAGGAGGACGACCGGTACATCCGCAAGTACAGCAA  
 GAAGGCAACGGCCCGAGATCAAGAGCTGAAGTACTACGACAGCAAGCTGGGCAACCATCGACATCACCCCAAGGACGCAACAACAAAGGTGCTGCAGAGCG  
 TGAGCCCTGGCGCGCAGCTGACTTCAACAAGACCCCGGCAAGTACGAGATCTGGGCTGAAGTACCGGACCTGCAAGTGAAGGGACCGGACCTACAAGAT  
 CAGCCAGGAGAAGTACAACGACATCAAGAAGAGGGCGTGGACGCGACAGCGAGTTCAAGTTCACCTGTACAAGAACGACCTTCTGCTGTGAAGGACCCGAG  
 CCAAGGACCAACAGCTGTTCGCTTCTGAGCCGACCATGCCCAAGCAGAGCACTACGTGGAGCTGAAGCCCTACGACAAGCAGAAAGTTCGAGGGCGGCGAGGCCCTGA  
 TCAAGGTGCTGGGCAACGTGGCCAAACAGCGGCCAGTGGCAAGAGGGCTGGCAAGATCAGCATCTACAAGGTGCGCACCGCAGCTGCTGGGCAACACGACATC  
 ATCAAGAACGAGGGCGACAAGCCCAAGCTGGACTTCTAA (SEQ ID NO: 9)

[illegible]



ATGGCCGCTTCAAGCCCAACCCCATCAACTACATCTGGGCTGGACATCGCCAGCGTGGGCTGGCCCATGTTGGAGATCGACGAGGACGAGAACCCCATCTGCC  
TGATCGACCTGGGTGCGCGTGTTCGAGCGCGCTGAGGTGCCAAGACTGGTGACAGTCTGGCTATGGCTGCCGGCTTGCTCGTCTGTTCCGGCGCTTACTCGCCCGCGC  
GCTACCGCTTCTGCGCTCTGCCGCTCTGAAGCGCGAGGGTGTGTCGAGGCTGCCGACTTCGACGAGAAGCGCTGATCAAGAGCTGCCAACACTCTTTGGCAGC  
TGCGCGCTGCGCTCTGGACCGCAAGCTGACTCCTCTGGAGTGGAGCGCGTGTCTGCACTGATCAAGCACCGCGGCTACTGAGCCAGCGCAAGAACGAGGGCGAGA  
CCGCCGACAAGAGCTGGGTGCTGCTGAAGGGCGTGGCCGACAACGCCACGCCCTGCAGACTGGTGACTTCGCACTCTGCTGAGCTGGCCCTGAACAAGTTTCGAGAA  
GGAGAGCGGCCACATCCGCAACACGCGCGGCACTACAGCCACACCTTCAGCCGCAAGGACCTGCAGGCGGAGCTGATCTGCTGTTTCGAGAAGCAGAAGGAGTTTCGGCAA  
CCCCACGTAGCGGGGCTGAAGGAGGGCATCGAGACCTGCTGATGACCCAGCGCCCGCTGAGCGGCGACGCCGTGCGAAGAGATGCTGGGCCACTGCACCTTCGA  
GCCAGCGAGCCCAAGGCCCAAGAACACTACCCGCGAGCGTTCATCTGGCTGACCAAGCTGAACAACCTGCGCATCTGGAGCAGGCGAGCGGCCCTGAC  
GACACGAGCGGCCACCTGATGACGAGCCCTACGCAAGCAAGCTGACTACGCCAGGCCCGCAAGCTGTGGTCTGGAGGACACCGCTTCTTCAAGGGCTGC  
GCTACGGCAAGGACAACGCCGAGCCAGCCCTGATGGAGATGAAGGCTACCAGCCATCAGCCGCGCCCTGGAAAGGAGGCTGAAGGACAAGAGTCTCTTG  
AACTGAGCCCCGAGCTGCAGGACGAGATGGCACCGCTTCAGGACCCAGGACATCACCGCCCTGAAGGACCGCATCAGGCCGAGATCTCTGGAG  
GCCCTGTGAAGCACATCAGTTTCGAAAGTTCTGCAGATCAGCTGAAGGCCCTGCGCGCATCTGCCCTGATGGAGCAGGCAAGCGCTACGACGAGGCTGCGCC  
AGATCTACGGGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCTCTATCCCGCGCAGAGATCCGCAACCCCTGGTCTGGCGCCTGAGCCAGGC  
CCGCAAGGTGATCAACGGCGTGTGGCGCTACGGAGCCCCCGCATCCACATCGAGACCGCCGAGGTGGCAAGACTTCAAGGACCGCAAGGAGATCGAGAA  
GCGCCAGGAGGAACCGCAAGGACCGGAGAGGCCGCCCAAGTTCCGCGAGTACTTCCCAACTTCGTGGCGAGCCCAAGAGCAAGAGATCTCTGAAGCTGCGCT  
GTACGAGCAGCAGCAGGCAAGTGCCTGTACAGCGGCAAGGAGATCAACCTGGCGCTGAACGAGAAGGCTACGTGGAGATCGACCAACCGCTGCCCTCAGCCGAC  
CTGGGACGACAGCTTCAACAACAGGTGCTGGTGTGGGACGCGAGAACCAAGGCAACGAGCCCTACGAGTACTTCAACGGCAAGGACAAAGCGCGAGTG  
GCAGGAGTTCAAGGCCGCGTGGAGACCAAGCGCTTCCCGCGACGCAAGAGCAGCGCATCTGCTGCAGAAAGTTTCGACGAGGACGGCTTCAAGGAGCGCAACCTGAACGA  
CACCCGCTACGTGAACCGCTTCTGTGCCAGTCGTCGCGACCGCATGCGCTGACCGGCAAGGCAAGCGCGTTCGCCAGCAACGGCCAGATCACCAACCTGCTG  
CGCGGCTTCTGGGGCTCGCAAGGTGCGCGCGAGAACGACCGCACCGCTGGAGCCGTGGTGGTCTGCAGACCGTGGCCATGCAGCAAGATCACCCCG  
TTCGTGCGCTACAAGGAGATGAACGCCCTTCGACGGTAAACCATCGACAAGGAGACCGCGAGGTGCTGCACCAAGAACCCACTTCCCAGCCCTGGGAGTCTTCGCC  
AGGAGGTGATGATCCGCGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGCGCACACCCCGAGAAAGCTGCGCACCTGCTGGCCGAGAAGCTGAGCAGCGCC  
CTGAGGCCGTGCACGAGTACGTGACTCTGTTGCTGAGCCGCGCCCCAACCGCAAGATGAGCGGTGAGGGTACATGGAGACCGTGAAGAGCGCCAAAGCGCTGAGCG  
AGGGCGTGAGCGTGTGCGCTGCCGTGACCCAGCTGAAGTGAAGGACCTGGAGAAGATGGTGAACCGGAGCGGCAACCGCATGTAAGGCGCTGAAGGCCCGC  
CTGGAGGCCCAAGAGGACGACCCCGCAAGGCCCTTCGCGGAGCCCTTACAAGTACGACAAGCCCGCAACCGCATCCAGCAGGTGAAGGCCGTGCGGTGGAGCAGGTG  
CAGAAGACCGCGTGTGGTGGCGCAACCAACAGCGCATCGCCGACACGCCACCATGTTGCGCTGGACGTGTTTCGAGAAGGGCGACAAGTACTACCTGTTGCCCATCTAC  
AGCTGGCAGGTGGCAAGGGCATCTGCCGACCGCGCGTGTGTCAGGGCAAGGACGAGGAGTGGCAGTGTGTCAGACGAGCTTCAACTTCAAGTTTCAAGCTGCAC  
CCCAACGACTGTTGGAGTGTATCAACAAGAGGCCGATGTTCCGCTACTTCGCCAGTGCACCGCGCACCGCAACATCAACATCCGCATCCACGACCTGGACCA  
AGATCGGCAAGAACGGCATCTGGAGGGCATCGGCGTGAAGACCGCCTGAGCTTCAGAAAGTACCAGATCGACGAGTCCGCCCTGCCGCTGAAGA  
AGGCCCTCTGTGCGCTAA (SEQ ID NO: 11)

[illegible]

FIG. 29

ATGAAGAGGAGATCAAGGACTACTTCTGGGCTGGACGTGGGACCGGACCGGTGGGCTGGGCTGACCGACACGACTACAAGCTGCTGAAGGCCAACCGCAAGGAC  
CTGTGGGGCATGCGTCTTCGAGACTGTGAGACCGCGAGGTGGCGGTGACCGCGTGTGCGCGGCGCATCGAGCGCAAGAGCGCATCAAGTGTGTCAG  
GAGCTGTTACGACGAGATCGCAAGACCGAGAGGCTTCTTCAGCGCATGAAGGAGAGCCCTTCTACGCCGAGGACAAGCATCTCTGAGGAGAAACACCCCTGTTCA  
ACGACAAGGACTTCGCCGACAAAGACCTACCAAGGCTACCCACCATCAACACCTGATCAAGGCTGGATCGAGAAACAAGGTGAAGCCCGACCTCTGCTGTACCTG  
GCCTGCCACAATCATCAAGAAAGCGCGCTTCTGTTTCGAGGGGACTTCGACAGCGAGAACCTGACACCAAGCTGACCGCATCCAGGCTGTTGAGTACCTGCGCGAGG  
ACATGGAGGTGGACATCGACGCCGACAGCCAGAAGGTGAAGGAGATCTGAAGGACAGCAGCCTGAAGAAACAGCGAGAAAGCAGAGCCGCTGAAACAAGATCTGGGCTG  
AAGCCGAGCAAGACAGAAAGGCCATCACCAACTGATCAGCGGCAACAAGATCAACTTCGCGACCTGTACGACAACCCCGACCTGAAGGACGCGCGAGAAAGACAGC  
ATCAGTTTCAGCAAGGACGACTTCGACGCCCTGAGCGACGACTGCGGCGACAGCTTCGAGCTGCTGAAGGCCAAGGCCGCTTACCAAGCTGAAGAACGTGATCAAGAACGCACTTCCC  
TGAGCAAGGTGATCGGCGACGAGCAGTACCTGAGCTTCGCCAAGGTGAAGATCTACGAGAAAGCACAAGACCGACCTACAGCGGCTACGTGGGCTGTGCAAGACCAAGAGCAAGAGCTGATCAACAACAA  
CAAGGACTACAAGAGGTGTCGGCTACAACAAGAACGAGAAACAACAATACAGCGGCTACGTGGGCTGTGCAAGACCAAGAGCAAGAGCTGATCAACAACAA  
CAGCGTGAACCGAGGACTTCTACAAGTTCTGAAGACCATCTGAGCGCAAGAGCGAGATCAAGGAGGTGAACGACATCTGACCGGATCGAGACCGGACCTTCTCTG  
CCCAAGCAGATCAGCAAGAGCAACGCCGAGATCCCTACCAAGTCCGCAAGATGGAGCTGGAGAAAGATCCTGAGCAACCGCGAGAGCACTTCAGCTTCTCTGAAGCAGAAG  
GACGAGAAGGCTGAGCCACAGCGAGAAGATCATGCTGCTGACCTCAAGATCCCCTACTACATCGGCCCATCAACGACAACCAAGAAAGTCTTCCCCGACCGCTG  
CTGGTGGTGAAGAGGAGAGAGCCCGAGGCAAGACCCCTGGAATCTTCGACCACATCGACAAGGAGAAAGACCGCGAGGCTTCAACACCTGACATCATCGACGGCAAG  
CCTTGCACATACCTGGTGGGAGAGCTGCTGCCAAGAGCAGCTGTACAGCGAGTACACCGTGTGAACGAGATCAACAACCTGACATCATCGACGGCAAG  
AACATCTCGACATCAAGCTGAAGCAGAAGATCTACGAGGACCTGTTCAAGAAAGTACAAGAAAGATCACCCAGAAGCAGATCAGCACCTTCATCAAGCAGCAGGGCATCTGCA  
ACAAGACCGACGAGGTGATCATCTGGGATCGACAAGGAGTGCAACGAGCTGAAGAGTACATCGAGCTGAAGAACTCTTCGGCAAGCAGGTGGACGAGATCAGCA  
CCAAGAACATGCTGAGGAGATCATCCGCTGGGCCACCATCTACGACGAGGCGAGGCAAGACCATCTGAAAGCAACAGATCAAGGCCGAGTACGGCAAGTACTGCAAGC  
ACGAGCAGATCAAGAAAGTCTGAACCTGAAGTTCAGCGGCTGGGCGCTGAGCGCAAGTTCCTGGAGACCGTGACCGAGAGATCAAGAGAGTCAAGAGAGTCAAGAGGACGCGGA  
ACATCATACCGCCATCGCGAGACCCAGAACACCTGATGAGCTGTGAGCAGCGAGTTCACCTTCACCGAGAACTCAAGAAAGTCAAGAGAGTCAAGAGAGTCAAGAGAGTCAAGAG  
GAAGCAGTTACGCTACGAGGCTGGAAGCCCTGTTCTGAGCCCGAGCTGTGAAGAGATGCTGTGGCAGACCTGAGAGTGGTGAAGGAGTCAAGAGAGTCAAGAGAGTCAAGAGAG  
GCTCCTCTAAGAACTTTCATCGAGATGGCAAGGGCGGAGCTGAGCTGCTCGACCAAGACCCGCTGAAGATCTCTGAGGACCTGTACAACAACTGTACAACAACTGCAAGAACG  
ACGCCGACGATTACGAGCGAGATCAAGGACTGAGCGGCAAGATCGAAGACGAGGACAACCTGCGCTCGCGACGCAAGCTGACCTACTACCCAGCTGACACCCAGCTGGGA  
AGTGATGTACTCGGCAAGCCCATCGAGATCGGCCACGTGTTCCACACGACACTACGACATCGACCATCTACCCCGAGAGCAAGATCAAGAGACGACAGCATCAGCAA  
CCGCGTGTGTGTCAGCAGCTGCAACAAGAAACAAGGAGGACAAGTACCCTGAAAGCGAGATCCAGAGCAAGCAGCGGCTCTGGAATCTCTGCAAGCGCAACAA  
CTTCATCAGCTGGAGAAGTGAACCGCTGACCCGCGCAACCCCATACGACGACGAGACCGCAAGTTCATCGCCCGCAAGCTGAGAGTCTGCAAGCTACCAAG  
GTGGCCGCAAGGTGTCGAGAAGATGTTCCCGAGACCAAGATCGTGTACAGCAAGGCGGAGACCGTGAGCATGTTCCGCAACAAGTTCGACATCGTGAAGTCCCGGAG  
ATCAACGACTTCACCCGCGCACGCGCTACTCAAGGTGTCGACTACGAGTGAAGCGCAACAACATCACCGCTGGGAGAGGGCAAGACCATCATCACCTGAAAGGAGCGCAAA  
CCCCAAGATCGCCACACCTACAACCTGAGGCTGCAAGGAGGCGAGCTGTTCAACGACCATCATGAAGAGGCTGGGAGAGGGCCCTGGCCAGTGAAGGAGATG  
CTGAAGCGCAACACCCCATCAGCAAGTACGCGGCTACAACAAGGTGAGCGCCCTACTACACCTGATCGAGTACGAGGAGAAAGGCAACAAGATCCGCAAGCTGGAGACC  
GGCCCTTCAGCAACATCAGCAATCCAGAAAGGACCGAGCTGTAAGAGTACCTGACCGACCTGCTGGGCAAGAGGAGTCAAGATCTGTGCCCCAAGATCAAGA  
ATCCCTGTACCTGGTGAAGGACATCCAGAAAGGACCGAGCTGTAAGAGTACCTGACCGACCTGCTGCTGCGCCCGCTGCACTTCTGCTGAGCAACAACAGAGTGTG  
TCAACAGCTGCTGAAGATCAACGGCTTCCCTGCCACATCACCGGCAAGACCAACGACAGCTTCTGCTGCGCCCGCTGCACTTCTGCTGAGCAACAACAGAGTGTG  
TACTTCAAGAAGATCATCCGTTTCAGCGAGATCCGACGCGCGGAGAGATCGGCAAGACCATCAGCCCTACGAGGACCTGAGCTTCGCGAGCTACATCAAGGAGAAC  
TGTGAAGAAGACCAAGACGAGATCGGCGAGAAAGGATTCAGACCTGCTGCAAGAAAGAACCTGGAGATCTACGACATGCTGTGACCAAGCAAGGACCA  
TCTACAAGAAAGCGCCCAACAGCGCCACCATCGACCTGCTGTAAGGGCAAGGAGAGTTCAAGAGCTGATCATCGAAGACCAAGTTCGAGGTGCTGGAGATCTGTAA  
GCTGTTACGCGCCACCCGCAACGTGAGCGACCTGACGACATCGCGGCGAGCAAGTACGCGGCTGGCCAAAGATCGGCAACAAGATCAGCAGCTGGACAACATGCACTCT  
GATCTACCAGAGCATCACCGGCTCTTCGAGAAGCGCATCGACCTGCTGAAGGTGTAA (SEQ ID NO: 13)

[illegible]

FIG. 31

GCCCACGACACCAACCACCA (SEQ ID NO: 18)

TCTTCCCTAGGAATGATGAC (SEQ ID NO: 19)

GCGGTCCTGAGGTGCACCG (SEQ ID NO: 20)

AGAAGTGAATACAGAGCGG (SEQ ID NO: 21)

FIG. 32A




FIG. 32B




FIG. 33

ATGGAGAGAAGGAATCCTAGTGAGAGGGAGTGCCCGCGGGTTTTCTGGTCACGCCTCCGTGGAATCCGGATGTGAGAC  
TCAGGAGTCCCCCGCACCGTGGTGTTCGCGCCACAGGAGACAACTGACGTGGCGCGGCTGCTGCAGGTGGA  
AGCCAAAGCCCGCTGTGGGCCGAGCCGATGGAACCCGAATCCAGACCCGGTCCCTCTGGCATGAACGTTGTGTCAGGT  
CGCAGAACTCTACCCCGAACTCCGCAGGATCTTGACAATCACGGAGGACGGCCAGGGCCTCAAGGGAGTGAAGAGAGAG  
AGAGGGGCTTGTGAGGCCACTGAGGAAGCTCGCAATCTGGCGTTTTTCATTGATGACAAGGCACAGGCCGGGAATGCATTAC  
ATTCCAACAGATTAAAGGACAACTGCGCAACGAGCTCGATCTCTGGCCCCAGAAAGTATAGCATCGAGCAGCTGACAACTAT  
TGCTGCAGCCCGGACGATTTTGAAGAGGCCATCCGCGTGTACGCAAAAGGTGGCCCTGCGACCTGACTGCAATATAAG  
ATTTCCAAACTGTTAAACATCCGGAATTGTTGTATATTAGTGAAATGGCGCAGAAAGTGAGATTGACACAGAGGATCGAG  
TCGCTTTCGGGTGCTCTATGATCAACATGTGGCCCGTGTGCTCGGCATGGATGGCTAGTCATTATGAATGTGGCTTTCACC  
GGACCTAATTTAGCGGAACCGTCTTCTGGCAACACTAATCTGATCCTGCATGGAGTTTCTTCTATGGATTAAATAACACC  
TGTGTTGAAGCTTGGACCGACGTGCGGGTTAGAGGGTGTGCTTTTATTGCTGTGAAAGGCGTCGTGTGTAGACCCAAA  
AGTAGAGCTTCTATCAAGAAATGCCTGTTTCGAGAGGTGTACTCTGGGCATTCTCAGTGAAGTAATAGCAGGGTCAGGCATA  
ACGTGGCCTCAGATTGCGGATGTTTATGTTGTTAAATCCGTGGCTGTGATCAAGCACAAACATGGTGTGTGGCAATTGTGA  
GGACCGGGCATCTCAAATGCTGACATGTTCCGATGGCAACTGTACCTGCTCAAACAATTACCGTTGCGAGCCATTCTCGG  
AAGGCCTGGCCAGTTTTTCGAGCATAACATCCTGACGCGCTGTAGTCTCCACCTGGGTAAACAGACGGGGCTTTTCCTGCCAT  
ATCAGTGTAACCTGTCACATAACCAAGATACTCCTGGAAACCCAGAACTATGAGTAAAGTGAACCTGAATGGTGTATTCGATATG  
ACCATGAAGATATGGAAAGTCTCCGCTATGACGAAACTAGGACTAGGTGTAGGCCCTGCGAGTGTGGCGGCAAGCATATC  
CGCAACCAACCCGTGATGCTGGACGTGACCGAGGAGCTGCGCCCCGATCACCTGGTGTGCTGGCCTGCACCAGAGCAGAATT  
CGGGAGCTCAGACGAAGACACTGATTAA (SEQ ID NO: 22)



FIG. 34

ATGGGCACTAGTGGGTACCTTTGGCATGACCCCTCCGCCCACTCGGTCAAGGCTCTCCGGAGAACTCCTTACTCTC  
GCGATAGGCTTCCTCCGTTGAAACCGAAACACGGGCAACCATTCCTGGAAGATCATCCACTGCTGCCAGAGTGTAATACCCCT  
GACGATGCATAACGTTTCTTACGTCCGGGTCTGCCCTGTCCGTGGGTTTACTCTGATCCAGGAGTGGTCTGTCCTTGG  
GATATGGTCTCACACGCGAGGAGCTGGTGATCCTGAGAAAGTGATGCACTGTCTGTGTTGGCAAACATCGACATTAT  
GACCAGTATGATGATTATGATACGAGAGCTGGCGCTTCACTGCCACTGCTCATCCCTGGCAGCCTGCAGTGATTGCA  
GGGGGCCAGGTGCTCGCTTCCTGGTTTAGAATGGTAGTGGATGGCGCCATGTTTAATCAGAGATTCAATTTGGTATCGGGAG  
GTTGTGAACATAACATGCCAAAGGAAGTCATGTTTATGAGCAGCGTTCATGCGGGGCGGCATCTGATATATCTGAGAC  
TGTGGTACGACGGTACGTGGGCTCTGTGCTGCAATGTCTCGGATACAGCGCCCTGCACTGTGGGATCCTCAATAAT  
ATAGTCGTCTTGTGTGCTCTTATTGCGCAGATCTCAGTGAGATAAGAGTCAGGTGCTGTGCAAGACGGACCGCAAGGGCG  
ATGCTCCGGCGCGTCATCATTGCCGAGGAGACAACCTGCCATGCTTTACAGCTGTAGAACAGAGCGCAGACGCCAGCAG  
TTTATCAGAGCCCTGCTGCAGCACCAACCGCCCCATACTCATGCTACTACGACAGTACGCCCAATGTAA (SEQ ID NO: 23)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/032153

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 48/00; C12N 15/64; C12N 15/85 (2016.01)

CPC - A61K 48/00; A61K 48/0066; C12N 15/8509; C12N 15/907; C12N 2750/14143 (2016.05)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC - A61K 48/00; C12N 15/64; C12N 15/85

CPC - A61K 48/00; A61K 48/0066; C12N 15/8509; C12N 15/907; C12N 2750/14143

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC - 424/93.71; 424/93.7; 435/369; 435/455; 435/254.11 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Orbit, Google Patents, Google Scholar

Search terms used: mammalian genome editing crispr/cas9 talen adenovirus gene replacement "guide RNA" nuclease inassignee: childrens

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2015/0110762 A1 (SANGAMO BIOSCIENCES, INC.) 23 April 2015 (23.04.2015) entire document	1-3, 45-48, 94
A	GAJ et al. "ZFN, TALEN, and CRISPR/Cas-Based Methods for Genome Engineering," Trends in Biotechnology, 31 July 2013 (31.07.2013), Vol. 31, Pgs. 397-405. entire document	1-3, 45-48, 94
A	US 2014/0273226 A1 (SYSTEM BIOSCIENCES, LLC) 18 September 2014 (18.09.2014) entire document	1-3, 45-48, 94
A	WO 2015/031775 A1 (TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION) 05 March 2015 (05.03.2015) entire document	1-3, 45-48, 94

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

27 July 2016

Date of mailing of the international search report

19 AUG 2016

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, VA 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/032153

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 4-44, 49-93, 95, 96  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.